Orthofix Medical (OFIX) 10-K 31 Mar 14 2013 FY Annual report Financial data

Document_and_Entity_Informatio

Document and Entity Information (USD $)	12 Months Ended
In Millions, except Share data, unless otherwise specified	Dec. 31, 2013	Mar. 24, 2014	Jun. 28, 2013
Document And Entity Information [Abstract]	'	'	'
Document Type	'10-K	'	'
Amendment Flag	'false	'	'
Document Period End Date	31-Dec-13	'	'
Document Fiscal Year Focus	'2013	'	'
Document Fiscal Period Focus	'FY	'	'
Trading Symbol	'OFIX	'	'
Entity Registrant Name	'ORTHOFIX INTERNATIONAL N V	'	'
Entity Central Index Key	'0000884624	'	'
Current Fiscal Year End Date	'--12-31	'	'
Entity Well-known Seasoned Issuer	'No	'	'
Entity Current Reporting Status	'Yes	'	'
Entity Voluntary Filers	'No	'	'
Entity Filer Category	'Accelerated Filer	'	'
Entity Common Stock, Shares Outstanding	'	18,187,194	'
Entity Public Float	'	'	$497.50

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Dec. 31, 2011	Dec. 31, 2010
In Thousands, unless otherwise specified
Current assets:	'	'	'	'	'	'	'	'	'	'
Cash and cash equivalents	$30,486	'	'	'	$31,055	'	'	'	$33,207	$13,561
Restricted cash	23,761	'	'	'	21,314	'	'	'	'	'
Trade accounts receivable, less allowances of $11,969 and $13,543 at December 31, 2013 and 2012, respectively	75,567	'	'	'	107,312	'	'	'	'	'
Inventories	90,577	'	'	'	83,373	'	'	'	'	'
Deferred income taxes	33,947	'	'	'	33,450	'	'	'	'	'
Prepaid expenses and other current assets	25,906	'	'	'	34,079	'	'	'	'	'
Total current assets	280,244	'	'	'	310,583	'	'	'	'	'
Property, plant and equipment, net	54,606	'	'	'	53,835	'	'	'	'	'
Patents and other intangible assets, net	9,046	'	'	'	7,290	'	'	'	'	'
Goodwill	53,565	'	72,758	'	74,388	'	'	'	73,094	'
Deferred income taxes	18,336	'	'	'	18,881	'	'	'	'	'
Other long-term assets	7,385	'	'	'	7,920	'	'	'	'	'
Total assets	423,182	430,058	459,450	475,758	472,897	539,566	530,395	694,106	'	'
Current liabilities:	'	'	'	'	'	'	'	'	'	'
Bank borrowings	'	'	'	'	16	'	'	'	'	'
Trade accounts payable	20,674	'	'	'	22,575	'	'	'	'	'
Other current liabilities	46,146	'	'	'	39,594	'	'	'	'	'
Total current liabilities	66,820	'	'	'	62,185	'	'	'	'	'
Long-term debt	20,000	'	'	'	20,000	'	'	'	'	'
Deferred income taxes	13,132	'	'	'	11,456	'	'	'	'	'
Other long-term liabilities	12,736	'	'	'	11,424	'	'	'	'	'
Total liabilities	112,688	111,001	114,223	102,366	105,065	193,599	205,196	381,734	'	'
Contingencies (Note 17)	'	'	'	'	'	'	'	'	'	'
Shareholders' equity	'	'	'	'	'	'	'	'	'	'
Common shares $0.10 par value; 50,000,000 shares authorized; 18,102,335 and 19,339,329 issued and outstanding as of December 31, 2013 and 2012, respectively	1,810	'	'	'	1,934	'	'	'	'	'
Additional paid-in capital	216,653	'	'	'	246,306	'	'	'	'	'
Retained earnings	89,332	'	'	'	114,847	'	'	'	'	'
Accumulated other comprehensive income	2,699	'	'	'	4,745	'	'	'	'	'
Total shareholders' equity	310,494	319,057	345,227	373,392	367,832	345,967	325,199	312,372	292,074	'
Total liabilities and shareholder's equity	$423,182	$430,058	$459,450	$475,758	$472,897	$539,566	$530,395	$694,106	'	'

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parenthetical) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, except Share data, unless otherwise specified
Statement Of Financial Position [Abstract]	'	'
Trade accounts receivable, allowances	$11,969	$13,543
Common shares, par value	$0.10	$0.10
Common shares, authorized	50,000,000	50,000,000
Common shares, issued	18,102,335	19,339,329
Common shares, outstanding	18,102,335	19,339,329

Consolidated_Statements_of_Ope

Consolidated Statements of Operations and Comprehensive Income (Loss) (USD $)

3 Months Ended

6 Months Ended

12 Months Ended

In Thousands, except Share data, unless otherwise specified

Dec. 31, 2013

Sep. 30, 2013

Jun. 30, 2013

Mar. 31, 2013

Dec. 31, 2012

Sep. 30, 2012

Jun. 30, 2012

Mar. 31, 2012

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Income Statement [Abstract]

'

'

'

'

'

'

'

'

'

'

'

'

Product sales

'

'

'

'

'

'

'

'

'

$352,796

$401,039

$405,147

Marketing service fees

'

'

'

'

'

'

'

'

'

47,738

46,542

36,824

Net sales

106,143

92,738

98,280

103,373

117,365

107,857

113,423

108,936

'

400,534

447,581

441,971

Cost of sales

32,517

23,920

20,246

25,617

24,944

24,384

27,547

21,378

'

102,300

98,253

95,527

Gross profit

73,626

68,818

78,034

77,756

92,421

83,473

85,876

87,558

'

298,234

349,328

346,444

Operating expenses

'

'

'

'

'

'

'

'

'

'

'

'

Sales and marketing

'

'

'

'

'

'

'

'

'

176,581

187,131

193,511

General and administrative

'

'

'

'

'

'

'

'

'

65,147

53,391

64,481

Research and development

'

'

'

'

'

'

'

'

'

26,768

28,577

22,861

Amortization of intangible assets

'

'

'

'

'

'

'

'

'

2,687

2,298

2,550

Costs related to the accounting review and restatement

'

'

'

'

'

'

'

'

'

12,945

'

'

Impairment of goodwill

'

'

'

'

'

'

'

'

19,193

19,193

'

'

Charges related to U.S. Government resolutions (Note 17)

'

'

'

'

'

'

'

'

'

'

1,295

57,141

Total operating expenses

80,004

84,418

69,230

69,669

66,808

64,668

71,578

69,638

'

303,321

272,692

340,544

Operating (loss) income

6,378

-15,600

8,804

8,087

25,613

18,805

14,298

17,920

'

-5,087

76,636

5,900

Other income and (expense)

'

'

'

'

'

'

'

'

'

'

'

'

Interest expense, net

'

'

'

'

'

'

'

'

'

-1,925

-4,743

-5,541

Other income (expense)

'

'

'

'

'

'

'

'

'

2,220

-1,705

-2,412

Total other income (expense)

'

'

'

'

'

'

'

'

'

295

-6,448

-7,953

(Loss) income before income taxes

'

'

'

'

'

'

'

'

'

-4,792

70,188

-2,053

Income tax expense

'

'

'

'

'

'

'

'

'

-10,116

-25,138

-14,165

Net (loss) income from continuing operations

-8,564

-18,084

4,130

7,610

16,009

10,574

9,870

8,597

'

-14,908

45,050

-16,218

Discontinued operations (Note 16)

'

'

'

'

'

'

'

'

'

'

'

'

Gain on sale of Breg, Inc., net of tax

'

'

'

'

'

'

'

'

'

'

1,345

'

Loss from discontinued operations

'

'

'

'

'

'

'

'

'

-15,510

-2,994

-2,705

Income tax benefit (expense)

'

'

'

'

'

'

'

'

'

4,903

-563

813

Net loss from discontinued operations

'

'

'

'

'

'

'

'

'

-10,607

-2,212

-1,892

Net (loss) income

'

'

'

'

'

'

'

'

'

-25,515

42,838

-18,110

Net income (loss) per common share-basic:

'

'

'

'

'

'

'

'

'

'

'

'

Net (loss) income from continuing operations

($0.47)

($1)

$0.22

$0.39

$0.83

$0.55

$0.52

$0.46

'

($0.80)

$2.37

($0.89)

Net loss from discontinued operations

'

'

'

'

'

'

'

'

'

($0.57)

($0.12)

($0.10)

Net (loss) income per common share-basic

($0.43)

($1.10)

($0.12)

$0.23

$1.10

$0.26

$0.38

$0.50

'

($1.37)

$2.25

($0.99)

Net income (loss) per common share-diluted:

'

'

'

'

'

'

'

'

'

'

'

'

Net (loss) income from continuing operations

($0.47)

($1)

$0.21

$0.39

$0.81

$0.54

$0.51

$0.45

'

($0.80)

$2.32

($0.89)

Net loss from discontinued operations

'

'

'

'

'

'

'

'

'

($0.57)

($0.11)

($0.10)

Net (loss) income per common share-diluted:

($0.43)

($1.10)

($0.12)

$0.23

$1.07

$0.25

$0.37

$0.49

'

($1.37)

$2.21

($0.99)

Weighted average number of common shares:

'

'

'

'

'

'

'

'

'

'

'

'

Basic

'

'

'

'

'

'

'

'

'

18,697,228

18,977,263

18,219,343

Diluted

'

'

'

'

'

'

'

'

'

18,697,228

19,390,413

18,219,343

Other comprehensive income (loss), before tax:

'

'

'

'

'

'

'

'

'

'

'

'

Translation adjustment

'

'

'

'

'

'

'

'

'

-1,768

768

-2,279

Unrealized gain (loss) on derivative instrument

'

'

'

'

'

'

'

'

'

-442

416

-693

Other comprehensive income (loss), before tax

'

'

'

'

'

'

'

'

'

-2,210

1,184

-2,972

Income tax related to components of other comprehensive income

164

'

'

'

-153

'

'

'

164

164

-153

256

Other comprehensive income (loss), net of tax

'

'

'

'

'

'

'

'

'

-2,046

1,031

-2,716

Comprehensive (loss) income

'

'

'

'

'

'

'

'

'

($27,561)

$43,869

($20,826)

Consolidated_Statements_of_Cha

Consolidated Statements of Changes in Shareholders' Equity (USD $)	Total	Common Shares [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Accumulated Other Comprehensive Income [Member]
In Thousands, except Share data
Balance, Amount at Dec. 31, 2010	$293,918	$1,772	$195,597	$90,119	$6,430
Balance, Shares at Dec. 31, 2010	'	17,726,645	'	'	'
Net income	-18,110	'	'	-18,110	'
Unrealized gain (loss) on derivative instrument net of tax benefit	-437	'	'	'	-437
Translation adjustment	-2,279	'	'	'	-2,279
Purchase of minority interest	-517	'	-517	'	'
Tax benefit on exercise of stock options	1,737	'	1,737	'	'
Reclassification for tax benefit on exercise of stock options	-8,999	'	-8,999	'	'
Share-based compensation expense	6,648	'	6,648	'	'
Common shares issued	20,113	74	20,039	'	'
Common shares issued, Shares	'	738,799	'	'	'
Balance, Amount at Dec. 31, 2011	292,074	1,846	214,505	72,009	3,714
Balance, Shares at Dec. 31, 2011	'	18,465,444	'	'	'
Net income	42,838	'	'	42,838	'
Unrealized gain (loss) on derivative instrument net of tax benefit	263	'	'	'	263
Translation adjustment	768	'	'	'	768
Share-based compensation expense	6,303	'	6,303	'	'
Common shares issued	25,586	88	25,498	'	'
Common shares issued, Shares	'	873,885	'	'	'
Balance, Amount at Dec. 31, 2012	367,832	1,934	246,306	'	4,745
Balance, Shares at Dec. 31, 2012	19,339,329	19,339,329	'	'	'
Net income	-25,515	'	'	-25,515	'
Unrealized gain (loss) on derivative instrument net of tax benefit	-278	'	'	'	-278
Translation adjustment	-1,768	'	'	'	-1,768
Share-based compensation expense	6,267	'	6,267	'	'
Common shares issued	3,450	20	3,430	'	'
Common shares issued, Shares	'	200,584	'	'	'
Retirement of repurchased common stock	-39,494	-144	-39,350	'	'
Retirement of repurchased common stock, Shares	'	-1,437,578	'	'	'
Balance, Amount at Dec. 31, 2013	$310,494	$1,810	$216,653	$89,332	$2,699
Balance, Shares at Dec. 31, 2013	18,102,335	18,102,335	'	'	'

Consolidated_Statements_of_Cha1

Consolidated Statements of Changes in Shareholders' Equity (Parenthetical) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Statement Of Stockholders Equity [Abstract]	'	'	'
Unrealized gain (loss) on derivative instrument, tax (benefit)	($164)	$153	($256)

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Cash flows from operating activities:	'	'	'
Net (loss) income	($25,515)	$42,838	($18,110)
Adjustments to reconcile net (loss) income to net cash provided by operating activities:	'	'	'
Depreciation and amortization	22,659	20,580	23,017
Amortization of debt costs	720	1,737	1,239
Provision for doubtful accounts	6,003	10,572	12,936
Deferred income taxes	-1,986	-1,252	-52
Share-based compensation	6,267	6,303	6,648
Impairment of goodwill	19,193	'	'
Gain on sale of Breg, Inc., net of tax	'	-1,345	'
Excess income tax benefit on employee stock-based awards	-82	-1,020	-1,737
Income tax benefit (expense) on employee stock-based awards	795	2,910	'
Other	4,442	4,136	4,491
Changes in operating assets and liabilities, net of effect of dispositions:	'	'	'
Trade accounts receivable	25,747	-18,438	293
Inventories	-6,626	-2,495	-12,624
Escrow receivable	'	41,537	-32,562
Prepaid expenses and other current assets	6,791	-15,577	2,829
Trade accounts payable	-2,280	4,575	2,322
Charges related to U.S. Government resolutions	'	-83,178	87,825
Other current liabilities	8,018	-5,729	2,695
Other long-term assets	4,296	3,416	-17,307
Other long-term liabilities	-1,561	616	2,878
Net cash provided by operating activities	66,881	10,186	64,781
Cash flows from investing activities:	'	'	'
Capital expenditures for property, plant and equipment	-24,787	-27,994	-24,965
Capital expenditures for intangible assets	-4,891	-780	-793
Payment made in connection with acquisition	'	'	-5,250
Net proceeds from sale of Breg Inc.	'	153,773	'
Net cash (used in) provided by investing activities	-29,678	124,999	-31,008
Cash flows from financing activities:	'	'	'
Net proceeds from issuance of common shares	3,450	25,586	20,113
Payment of refinancing fees and debt issuance costs	'	'	-758
Repayments of long-term debt	-16	-188,695	-7,500
Repayment of bank borrowings, net	'	-1,297	-2,561
Changes in restricted cash	-2,375	25,799	-24,178
Purchase of common stock	-39,494	'	'
Cash payment for purchase of minority interest in subsidiary	'	'	-517
Excess income tax benefit on employee stock-based awards	82	1,020	1,737
Net cash used in financing activities	-38,353	-137,587	-13,664
Effect of exchange rate changes on cash	581	250	-463
Net (decrease) increase in cash and cash equivalents	-569	-2,152	19,646
Cash and cash equivalents at the beginning of the year	31,055	33,207	13,561
Cash and cash equivalents at the end of the year	30,486	31,055	33,207
Cash paid during the year for:	'	'	'
Interest	2,046	4,569	17,088
Income taxes	$8,773	$18,268	$26,227

Summary_of_significant_account

Summary of significant accounting policies	12 Months Ended
	Dec. 31, 2013
Accounting Policies [Abstract]	'
Summary of significant accounting policies	'
	1	Summary of significant accounting policies
		(a)	Basis of consolidation
	The consolidated financial statements include the financial statements of the Company and its wholly owned and majority-owned subsidiaries and entities over which the Company has control.
	All intercompany accounts, transactions and profits are eliminated in the consolidated financial statements on a continuing operations basis unless otherwise noted.
		(b)	Reclassifications
	The Company has reclassified certain line items to conform to the current year presentation. The reclassifications have no effect on previously reported net earnings or shareholders’ equity.
		(c)	Use of estimates in preparation of financial statements
	The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. On an ongoing basis, we evaluate our estimates, including those related to the recoverability and useful lives of long-lived assets and the adequacy of the allowance for doubtful accounts and inventory obsolescence, and income taxes. We base our estimates on historical experience, future expectations and on other relevant assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates.
		(d)	Foreign currency translation
	The financial statements for operations outside the United States are generally maintained in their local currency. All foreign currency denominated balance sheet accounts, except shareholders’ equity, are translated to U.S. dollars at year end exchange rates and revenue and expense items are translated at weighted average rates of exchange prevailing during the year. Gains and losses resulting from the translation of foreign currency are recorded in the accumulated other comprehensive income component of shareholders’ equity. Transactional foreign currency gains and (losses), including those generated from intercompany operations, are included in other expense, net and were $0.7 million loss, $0.5 million loss and $1.6 million loss for the years ended December 31, 2013, 2012 and 2011, respectively.
		(e)	Cash and cash equivalents
	The Company considers all highly liquid investments with an original maturity of three months or less at the date of purchase to be cash equivalents.
		(f)	Restricted cash
	Restricted cash consists of cash held at certain subsidiaries, the distribution or transfer of which to Orthofix International N.V. (the “Parent”) or other subsidiaries that are not parties to the credit facility described in Note 9 is restricted. The senior secured credit facility restricts the Parent and subsidiaries that are not parties to the facility from access to cash held by Orthofix Holdings, Inc. and its subsidiaries. All credit party subsidiaries have access to this cash for operational and debt repayment purposes.
		(g)	Market risk
	In the ordinary course of business, the Company is exposed to the impact of changes in interest rates and foreign currency fluctuations. The Company’s objective is to limit the impact of such movements on earnings and cash flows. In order to achieve this objective, the Company seeks to balance its non-U.S. dollar denominated income and expenditures. During 2013, 2012 and 2011, the Company made use of a foreign currency swap agreement to manage cash flow exposure generated from foreign currency fluctuations.
	The Company generally does not require collateral on trade receivables.
		(h)	Inventories
	Inventories are valued at the lower of cost or estimated net realizable value, after provision for excess, obsolete or impaired items which is reviewed and updated on a periodic basis by management. For inventory procured or produced, whether internally or through contract manufacturing arrangements, at our manufacturing facility in Italy, cost is determined on a weighted-average basis, which approximates the first-in, first-out (“FIFO”) method, due to the high turn-over rate of inventory at this location. For inventory procured or produced, whether internally or through contract manufacturing arrangements, at our manufacturing facility in Texas, standard costs, which approximates actual cost on the FIFO method, is used to value inventory. Standard costs are reviewed annually by management, or more often in the event circumstances indicate a change in cost has occurred. The valuation of work-in-process, finished products, field inventory and consignment inventory includes the cost of materials, labor and other production costs. Field inventory represents immediately saleable finished products inventory that is in the possession of the Company’s direct sales representatives. Consignment inventory represents immediately saleable finished products located at third party customers, such as distributors and hospitals.
		(i)	Long-lived assets, including intangibles
	Property, plant and equipment is stated at cost less accumulated depreciation. Costs include all expenditures necessary to place the asset in service, including freight and sales and use taxes. Plant and equipment also includes instrumentation held by customers and is generally used to facilitate the implantation of the Company’s products, the associated cost and accumulated depreciation as of December 31, 2013 was $54.9 million and ($33.7 million), respectively. Depreciation is computed on a straight-line basis over the useful lives of the assets. Depreciation of leasehold improvements is computed over the shorter of the lease term or the useful life of the asset. The useful lives are as follows:
			Years
	Buildings			25 to 33
	Plant equipment and instrumentation			2 to 10
	Furniture and fixtures			4 to 8
	Expenditures for maintenance and repairs and minor renewals and improvements, which do not extend the lives of the respective assets, are expensed as incurred. All other expenditures for renewals and improvements are capitalized. The assets and related accumulated depreciation are adjusted for property retirements and disposals, with the resulting gain or loss included in operations. Fully depreciated assets remain in the accounts until retired from service.
	Patents and other intangible assets are recorded at cost, or when acquired as a part of a business combination at estimated fair value. These assets primarily include patents and other technology agreements (“developed technologies”) and trademarks. Identifiable intangible assets which are considered definite lived are amortized over their useful lives using a method of amortization that reflects the pattern in which the economic benefit of the intangible assets is consumed. The Company’s weighted average amortization period for developed technologies is 11 years.
	Intangible and long-lived assets with definite lives, such as developed technologies, are tested for impairment if any adverse conditions exist or change in circumstances have occurred that would indicate impairment or a change in the remaining useful life. If an impairment indicator exists, the Company tests the intangible asset for recoverability. For purposes of the recoverability test, the Company groups its intangible assets with other assets and liabilities at the lowest level of identifiable cash flows if the intangible asset does not generate cash flows independent of other assets and liabilities. If the carrying value of the intangible asset (asset group) exceeds the undiscounted cash flows expected to result from the use and eventual disposition of the intangible asset (asset group), the Company will write the carrying value down to the fair value in the period identified.
	The Company generally calculates fair value of indefinite-lived intangible assets as the present value of estimated future cash flows. In determining the estimated future cash flows associated with intangible assets, the Company uses estimates and assumptions about future revenue contributions, cost structures and remaining useful lives of the asset (asset group). The use of alternative assumptions, including estimated cash flows, discount rates, and alternative estimated remaining useful lives could result in different calculations of impairment.
		(j)	Goodwill
	The Company tests goodwill at least annually for impairment. The Company tests more frequently if indicators are present or changes in circumstances suggest that impairment may exist. These indicators include, among others, declines in sales, earnings or cash flows, or the development of a material adverse change in the business climate. The Company assesses goodwill for impairment at the reporting unit level, which is defined as an operating segment or one level below an operating segment, referred to as a component. The Company has identified four reporting units, which are consistent with the Company’s reporting segments: BioStim, Biologics, Extremity Fixation, and Spine Fixation.
	In order to calculate the respective carrying values, the Company initially recorded goodwill based on the purchase price allocation performed at the time of acquisition. Corporate assets and liabilities that directly relate to a reporting unit’s operations are ascribed directly to that reporting unit. Corporate assets and liabilities that are not directly related to a specific reporting unit, but from which the reporting unit benefits, are allocated based on the respective contribution measure of each reporting unit. Effective July 1, 2013, the Company re-aligned its reporting units and consequently reallocated the carrying value of goodwill from its previous reporting units to its new reporting units based on the relative fair value of each new reporting unit to total enterprise value at July 1, 2013.
	As a result of the Company’s change in reportable segments, the Company allocated goodwill to each reportable segment, and subsequently evaluated each reportable segment for possible impairment of goodwill, as there were indicators of impairment when completing a qualitative analysis. The result of this analysis was a full impairment of the goodwill allocated to our Extremity Fixation and our Spine Fixation reportable units, totaling $19.2 million.
	The Company’s annual goodwill impairment analysis, which was performed qualitatively during the fourth quarter of 2013, did not result in any additional impairment charge.
		(k)	Derivative instruments
	The Company manages its exposure to fluctuating cash flows resulting from changes in interest rates and foreign exchange within the consolidated financial statements according to its hedging policy. Under the policy, the Company may engage in non-leveraged transactions involving various financial derivative instruments to manage exposed positions. The policy requires the Company to formally document the relationship between the hedging instrument and hedged item, as well as its risk-management objective and strategy for undertaking the hedge transaction. For instruments designated as a cash flow hedge, the Company formally assesses (both at the hedge’s inception and on an ongoing basis) whether the derivative that is used in the hedging transaction has been effective in offsetting changes in the cash flows of the hedged item and whether such derivative may be expected to remain effective in future periods. If it is determined that a derivative is not (or has ceased to be) effective as a hedge, the Company will discontinue the related hedge accounting prospectively. Such a determination would be made when (1) the derivative is no longer effective in offsetting changes in the cash flows of the hedged item; (2) the derivative expires or is sold, terminated or exercised; or (3) management determines that designating the derivative as a hedging instrument is no longer appropriate. Ineffective portions of changes in the fair value of cash flow hedges are recognized in earnings.
	The Company records all derivatives as either assets or liabilities on the balance sheet at their respective fair values. For a cash flow hedge, the effective portion of the derivative’s change in fair value (i.e. gains or losses) is initially reported as a component of other comprehensive income, net of related taxes, and subsequently reclassified into net earnings when the hedged exposure is no longer effective.
	The Company utilizes a cross currency swap to manage its foreign currency exposure related to a portion of the Company’s intercompany receivable of a U.S. dollar functional currency subsidiary that is denominated in Euro. The cross currency swap has been accounted for as a cash flow hedge in accordance with ASC Topic 815, Derivatives and Hedging.
		(l)	Accumulated other comprehensive income
	Accumulated other comprehensive income is comprised of foreign currency translation adjustments and the effective portion of the gain (loss) on the Company’s cross-currency swap, which is designated and accounted for as a cash flow hedge (see Note 10). The components of and changes in accumulated other comprehensive income are as follows:
	(U.S. Dollars in thousands)		Foreign Currency			Fair Value of			Accumulated Other
			Translation			Cross-			Comprehensive
			Adjustments			Currency Swaps			Income
	Balance at December 31, 2011 (Restated)		$	3,846		$	(132	)	$	3,714
	Unrealized gain on cross-currency swaps, net of taxes of $153			—			263			263
	Foreign currency translation adjustment (1)			768			—			768
	Balance at December 31, 2012 (Restated)			4,614			131			4,745
	Unrealized loss on cross-currency swaps, net of tax benefit of $164			—			(278	)		(278	)
	Foreign currency translation adjustment (1)			(1,768	)		—			(1,768	)
	Balance at December 31, 2013		$	2,846		$	(147	)	$	2,699
	-1	As the cash generally remains permanently invested in the non U.S. dollar denominated foreign subsidiaries, no deferred taxes are recognized on the related foreign currency translation adjustment.
		(m)	Revenue recognition and accounts receivable
	Commercial revenue is related to the sale of the Company’s implant products, generally representing hospital customers. Revenues are recognized when these products have been utilized and a confirming purchase order has been received from the hospital.
	Revenue is derived from third-party payors, including commercial insurance carriers, health maintenance organizations, preferred provider organizations and governmental payors such as Medicare, in connection with the sale of our stimulation products. Revenue is recognized when the stimulation product is placed on or implanted in and accepted by the patient. Amounts paid by these third-party payors are generally based on fixed or allowable reimbursement rates. These revenues are recorded at the expected or pre-authorized reimbursement rates, net of any contractual allowances or adjustments. Certain billings are subject to review by the third-party payors and may be subject to adjustment.
	For distributor revenue, which is related primarily to implant products, the Company recognizes revenue either on a sell-in or sell-through basis depending on the specific circumstances of the distributor. In some cases the Company recognizes distributor revenue as title and risk of loss passes at either shipment from the Company’s facilities or receipt at the distributor’s facility, assuming all other revenue recognition criteria has been achieved (the “sell-in method”). Based on the results of the Independent Review, the Company determined in some cases the revenue recognition criteria for distributor sales were not satisfied at the time of shipment or receipt; specifically, the existence of extra-contractual terms or arrangements caused the Company not to meet the fixed or determinable criteria for revenue recognition in some cases, and in others collectability had not been established. In situations where we are unable to satisfy the requirements to recognize revenue on the sell-in method, we recognize revenue relating to distributor arrangements once the product is delivered to the end customer (the “sell-through method”). Because the Company does not have reliable information about when its distributors sell the product through to end customers, the Company uses cash collection from distributors as a basis for revenue recognition under the sell-through method. Although in many cases the Company is legally entitled to the accounts receivable at the time of shipment, the Company has not recognized accounts receivables or any corresponding deferred revenues associated with distributor transactions for which revenue is recognized on the sell-through method. Effective April 1, 2013, all distributor revenue is recognized on the sell-through basis.
	For distributors on the sell-in method prior to April 1, 2013, cost of sales is recognized upon shipment. For sell-through distributors, whose revenue is recognized upon cash receipt, the Company considers whether to match the related cost of sales expense with revenue or to recognize expense upon shipment. In making this assessment, the Company considers the financially viability of its distributors based on their creditworthiness to determine if collectability of amounts sufficient to realize the costs of the products shipped is reasonably assured at the time of shipment to these distributors. In instances where the distributor is determined to be financially viable, the Company defers the costs of sales until the revenue is recognized.
	Biologics revenue is primarily related to a collaborative arrangement with MTF. In 2008, the Company entered into a collaborative arrangement with MTF to develop and commercialize Trinity Evolution ®, a stem cell-based bone growth biologic matrix. With the development process completed in 2009, the Company and MTF operated under the terms of a separate commercialization agreement. Under the terms of the 10-year agreement, MTF sourced the tissue, processed it to create the bone growth matrix, packaged and delivered it to the customer in accordance with orders received from the Company. The Company has exclusive global marketing rights for Trinity Evolution ® and receives marketing fees from MTF based on total sales. These marketing fees are recorded on a net basis within net sales and were $47.7 million, $46.5 million and $36.8 million in 2013, 2012 and 2011, respectively. On January 10, 2012, the Company announced that it had reached an agreement with MTF to both co-develop and commercialize a new technology for use in bone grafting applications and to expand MTF’s Trinity Evolution ® processing capacity. The amendment amends the term of the existing agreement until the later of (i) 15 years after the date that certain development milestones were achieved under the existing agreement (which occurred during 2010) or (ii) the date that certain licensing arrangements between the Company and NuVasive, Inc. expire. MTF is considered the primary obligor in these arrangements and therefore the Company recognizes these marketing service fees on a net basis upon shipment of the product to the customer.
	Revenues exclude any value added or other local taxes, intercompany sales and trade discounts. Shipping and handling costs are included in cost of sales.
	The process for estimating the ultimate collection of accounts receivable involves significant assumptions and judgments. Historical collection and payor reimbursement experience is an integral part of the estimation process related to reserves for doubtful accounts and the establishment of contractual allowances. Accounts receivable are analyzed on a quarterly basis to assess the adequacy of both reserves for doubtful accounts and contractual allowances. Revisions in allowances for doubtful accounts estimates are recorded as an adjustment to bad debt expense within sales and marketing expenses, and contractual allowances are recorded as an adjustment to revenue. These estimates are periodically tested against actual collection experience.
		(n)	Sale of accounts receivable
	The Company will generally sell receivables from certain Italian hospitals each year. The estimated related fee for 2013 and 2012 was $0.8 million and $0.6 million, respectively, which is recorded as interest expense. Trade accounts receivables sold without recourse are removed from the balance sheet at the time of sale.
		(o)	Share-based compensation
	The fair value of service-based stock options are determined using the Black-Scholes valuation model. Such value is recognized as expense over the service period net of estimated forfeitures.
The fair value of market-based stock options are determined at the date of the grant using the Monte Carlo valuation methodology. Such value is recognized as expense over the requisite service period adjusted for estimated forfeitures for each separately vesting tranche of the award. The Monte Carlo methodology that we use to estimate the fair value of market-based options incorporates into the valuation the possibility that the market condition may not be satisfied.
The expected term of options granted is estimated based on a number of factors, including the vesting and expiration terms of the award, historical employee exercise behavior for both options that are currently outstanding and options that have been exercised or are expired, the historical volatility of the Company’s common stock and an employee’s average length of service. The risk-free interest rate is determined based upon a constant U.S. Treasury security rate with a contractual life that approximates the expected term of the option award. Management estimates expected volatility based on the historical volatility of the Company’s stock. The compensation expense recognized for all equity-based awards is net of estimated forfeitures. Forfeitures are estimated based on an analysis of actual option forfeitures.
	(p)	Advertising costs
The Company expenses all advertising costs as incurred. Advertising expense included in sales and marketing expense for the years ended December 31, 2013, 2012 and 2011 was $0.2 million, $0.3 million and $0.5 million, respectively.
	(q)	Research and development costs
Expenditures related to the collaborative arrangement with MTF are expensed based on the terms of the related agreement. Milestone payments made to MTF in 2013 and 2012 totaled $2.5 million and $3.0 million, respectively. There were no milestone payments made to MTF in 2011. Expenditures for other research and development are expensed as incurred.
	(r)	Income taxes
The Company is subject to income taxes in both the U.S. and foreign jurisdictions, and uses estimates in determining the provision for income taxes. The Company accounts for income taxes using the asset and liability method for accounting and reporting for income taxes. Under this method, deferred tax assets and liabilities are recognized based on temporary differences between the financial reporting and income tax basis of assets and liabilities using statutory rates. This process requires that the Company project the current tax liability and estimate the deferred tax assets and liabilities, including net operating loss and tax credit carry forwards. In assessing the need for a valuation allowance, the Company has considered the recent operating results, future taxable income projections and all prudent and feasible tax planning strategies.
The Company accounts for uncertain tax positions in accordance with ASC 740, Income Taxes, which contains a two-step approach to recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position taken or expected to be taken in a tax return by determining if the weight of available evidence indicates that it is more likely than not that, on an evaluation of the technical merits, the tax position will be sustained on audit, including resolution of any related appeals or litigation processes. The second step is to measure the tax benefit as the largest amount that is more than 50% likely to be realized upon ultimate settlement. The Company reevaluates income tax positions periodically to consider factors such as changes in facts or circumstances, changes in or interpretations of tax law, effectively settled issues under audit, and new audit activity. Such a change in recognition or measurement would result in recognition of a tax benefit or an additional charge to the tax provision.
The Company includes imputed interest and any applicable penalties related to tax issues as part of income tax expense in our consolidated financial statements.
	(s)	Net income (loss) per common share
Net income (loss) per common share—basic is computed using the weighted average number of common shares outstanding during each of the respective years. Net income (loss) per common share—diluted is computed using the weighted average number of common and common equivalent shares outstanding during each of the respective years using the “treasury stock” method, if dilutive. Common equivalent shares represent the dilutive effect of the assumed exercise of outstanding share options (see Note 20). The only differences between basic and diluted shares result from the assumed exercise of certain outstanding share options.
	(t)	Financial instruments and concentration of credit risk
Financial instruments that could subject the Company to a concentration of credit risk consist primarily of cash and cash equivalents and accounts receivable. Generally, the cash is held at large financial institutions and our cash equivalents consist of highly liquid money market funds. The Company performs ongoing credit evaluations of the customers, generally does not require collateral and maintain a reserve for potential credit losses. The Company believes that a concentration of credit risk related to the accounts receivable is limited because the customers are geographically dispersed and the end users are diversified across several industries.
Net sales to our customers and distributors based in Europe were approximately $52 million in 2013 which results in a substantial portion of our trade accounts receivable balance as of December 31, 2013. It is at least reasonably possible that changes in global economic conditions and/or local operating and economic conditions in the regions these distributors operate, or other factors, could affect the future realization of these accounts receivable balances.
	(u)	Recently issued accounting standards
In July 2013, the Financial Accounting Standards Board (“FASB”), issued Accounting Standards Update (“ASU”) No. 2013-11, Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, A Similar Tax Loss, or a Tax Credit Carryforward Exists. The authoritative guidance concludes that, under certain circumstances, unrecognized tax benefits should be presented in the financial statements as a reduction to a deferred tax asset for a net operating loss carryforward, a similar tax loss, or a tax credit carryforward. We adopted this guidance early, as permitted, for the fiscal year ended December 31, 2013. The adoption of this guidance did not have a material effect on our consolidated financial statements.
In February 2013, the FASB issued ASU No. 2013-02, Comprehensive Income (Topic 220): Reporting of Amounts Reclassified Out of Accumulated Other Comprehensive Income. The standard requires presentation (either in a single note or parenthetically on the face of the financial statements) of the effect of significant amounts reclassified from each component of accumulated other comprehensive income based on its source and the income statement line items affected by the reclassification. If a component is not required to be reclassified to net income in its entirety, a cross reference to the related footnote for additional information is required. The amendments are effective prospectively for reporting periods beginning after December 15, 2013. The adoption of this guidance did not have a material effect on our consolidated financial statements.
On June 16, 2011, the FASB issued ASU No. 2011-05, Presentation of Comprehensive Income. This ASU eliminates the current option to present other comprehensive income and its components in the statement of changes in shareholders’ equity and increases the prominence of other comprehensive income in the statements by providing an alternative to present the components of net income and comprehensive income as either one continuous or two separate but consecutive financial statements. Companies are also required to present reclassification adjustments for items that are reclassified from other comprehensive income to net income within these statements. This standard is to be applied retrospectively and is effective for fiscal years beginning after December 15, 2011 with early adoption permitted. The Company adopted this ASU as of March 31, 2012 and it did not have a material impact on the Company’s consolidated financial statements.

Restatement_of_the_Consolidate

Restatement of the Consolidated Financial Statements	12 Months Ended
	Dec. 31, 2013
Text Block [Abstract]	'
Restatement of the Consolidated Financial Statements	'
	2	Restatement of the Consolidated Financial Statements
	Background
	In July 2013, the Audit Committee (the “Audit Committee”) of the Company’s Board of Directors (the “Board”) commenced an independent review with the assistance of outside professionals into whether the Company had properly recognized revenue under U.S. generally accepted accounting principles (“GAAP”) in connection with certain revenue that had been recorded in 2012 and 2011 (the “Independent Review”). In conjunction with the Independent Review, the Company concluded that errors existed in the Company’s previously issued financial statements for the fiscal years ended December 31, 2012 and 2011, the interim quarterly period ended March 31, 2013, and certain other prior periods.
	In reaching these conclusions, the Company considered information obtained in the Independent Review, including emails, data and interviews with current and former employees that indicated (i) the existence of extra-contractual terms or arrangements at the onset of the sale and concessions agreed to subsequent to the initial sale, such as extended payment terms and return and exchange rights for sales to distributors with respect to certain transactions, (ii) that at the time of some sales collection was not reasonably assured, and (iii) that certain amounts previously characterized as commissions were paid to related parties of the applicable customer.
	The Company assessed the information derived from the Independent Review in making determinations with respect to accounting adjustments reflected in the restated consolidated financial statements contained in the Amendments and in its Annual Report on Form 10-K for the fiscal year ended December 31, 2013, and such determinations are consistent with the findings of the Independent Review. In addition to the matters that were the subject of the Independent Review, certain other adjustments identified by management, including revisions to inventory reserves and royalties, were made to the consolidated financial statements in connection with the restatement.
	The correction of these errors had the following impact: decreased net sales by $14.7 million and $28.2 million for the years ended December 31, 2012 and 2011, respectively; and decreased net income from continuing operations by $8.9 million and $14.5 million for the years ended December 31, 2012 and 2011, respectively. The following include descriptions of the significant adjustments to the Company’s financial position and results of operations from the previously reported consolidated financial statements.
	Distributor Revenue Recognition
	The Company has determined that it previously recognized revenue with respect to certain distributor relationships before all revenue recognition criteria were met. Specifically, the Company has determined that a fixed or determinable sales price did not exist, and/or collection was not reasonably assured, with respect to certain transactions where revenue had previously been recognized at the time of shipment. Specifically, the Company’s review revealed arrangements, or extra-contractual terms, with certain of the Company’s distributors regarding extended payment terms, return or exchange rights, and contingent payment obligations for sales to such distributors with respect to certain transactions. There were also concessions being made subsequent to the shipment of inventory to the distributors and the related revenue recognition. Based on the results of this review, it was determined that these arrangements were not appropriately evaluated under the appropriate revenue recognition criteria applicable under GAAP. Distributor sales represented approximately 11 – 13% of the Company’s net sales (prior to the restatement) of approximately $462 million and $470 million for the years ended December 31, 2012 and 2011, respectively.
	The Company previously recognized distributor revenue as title and risk of loss passed at either shipment from the Company’s facilities or receipt at the distributor’s facility, assuming all other revenue recognition criteria had been achieved (the “sell-in method”). Based on review of all facts and circumstances related to the arrangements described above, the Company determined that in many instances the revenue recognition criteria under the sell-in method were not satisfied at the time of shipment or receipt; specifically, the existence of extra-contractual terms or arrangements caused the Company not to meet the fixed or determinable criteria for revenue recognition in some cases, and in others collectability had not been established. In situations where the Company is unable to reasonably estimate the effects of these extra-contractual terms, it is precluded from recognizing revenue relating to distributor arrangements until the product is delivered to the end customer. This method is commonly referred to as the “sell-through” revenue recognition method because the vendor does not recognize revenue until the transaction consideration is fixed or determinable, which coincides with the selling of the product through the distribution channel to the end customer. Because the Company does not have reliable information about when its distributors sell the product through to end customers, the Company will use cash collection from distributors as a basis for revenue recognition under the sell-through method. Although in many cases the Company is legally entitled to the accounts receivable at the time of shipment, since the revenue recognition criteria has not been met, the Company has not recognized accounts receivables or any corresponding deferred revenues associated with these transactions.
	As part of the review, the Company also considered the accounting treatment for the related cost of sales when distributor revenue is recognized on a sell-through basis. Previously, cost of sales were recognized upon shipment; however, the Company believes the matching of the recognition of costs of sales with revenue is preferred and therefore considered if such costs should be deferred until revenue is recognized on a sell-through basis. In making this assessment, the Company considered the financial viability of its distributors based on their creditworthiness to determine if collectability of amounts sufficient to realize the costs of the products shipped was reasonably assured at the time of shipment to these distributors. In instances where the distributor was determined to be financially viable, the Company determined that costs of sales should be deferred until the revenue is recognized. For those distributors where the Company has concluded that collectability was not reasonably assured, the Company has expensed the related cost of sales upon shipment.
	Based on the results of the Independent Review, the Company determined that all distributor transactions should be transitioned to the sell-through method of accounting as of the dates described below:
		•		For distributor transactions within the Company’s Orthopedics division, the Company has determined that sell-through accounting should be applied within the Brazil subsidiary for all prior periods given the frequency with which the Company conducted business under extra-contractual and undocumented terms, as well as the Company’s inability to fully access underlying transactional and other information that would be necessary to evaluate transactions under a sell-in basis. For distributor transactions within the division outside the Brazil subsidiary, there were also sales to four distributors that did not meet the fixed or determinable or collectability revenue recognition criteria and therefore, such sales were adjusted to sell-through accounting in the restatement.
		•		For distributor transactions within the Company’s U.S. Spine division, the Company has determined that sell-through accounting should be applied beginning January 1, 2011. Following its consideration of the information provided from the Independent Review, the Company believes that January 1, 2011 is the date extra-contractual terms became pervasive in the Company’s U.S. business, and it is unaware of circumstances existing prior to that date that would require it to broadly apply sell-through accounting to all distributor transactions within the U.S. Spine division. Additionally, there were sales in 2012 and 2011 for which revenue was previously recognized that did not meet the fixed or determinable criteria and the product associated with such sales was subsequently returned in 2013 (i) under the terms of negotiated agreements whereby the Company terminated its relationships with two distributors and (ii) by an additional distributor who returned certain product sold pursuant to a contingent sales arrangement. Such sales represented approximately $3.3 million and $4.1 million for the years ended December 31, 2012 and 2011, respectively. Due to the return of the product, no revenue will be recognized for these transactions.
		•		The Company has determined that stimulation products sold to distributors within the Company’s U.S. Spine division during 2012 did not meet the fixed or determinable (and in some cases, collectability) revenue recognition criterion at the time of shipment. Therefore, the Company has determined that sell-through accounting should be applied for these sales. Management also determined that many of these distributors (or affiliates thereof) received commission payments as part of the sales transactions, which the Company previously recorded as sales and marketing expense. The Company has recorded adjustments in the restatement to net these commission expenses against revenue, as they represented product discounts.
		•		The Company has determined that it will prospectively apply sell-through accounting for all remaining distributor arrangements (which entails arrangements within the Company’s Orthopedics division outside the Brazil subsidiary) beginning April 1, 2013, the earliest date for which financial statements had not previously been issued by the Company at the time of the determination. Although the Independent Review did not provide information to indicate extra-contractual terms or that historical revenue recognition was inappropriate in these remaining instances, the Company believes the information from the Independent Review indicating that the Company has a history of extra-contractual arrangements for distributor transactions, as described above, provides additional information which should be considered in reassessing the application of sell-through accounting on a prospective basis, particularly given that the Company believes that there is a higher risk associated with distributor arrangements generally.
	The effect of adjustments made to the Company’s previously filed consolidated statements of operations as a result of these matters are shown in the tables below. These adjustments also had the following effects on the Company’s previously filed consolidated balance sheets:
		•		Accounts receivable decreased as of December 31, 2012 by $41.3 million related to the de-recognition of receivables for which revenue has been deferred and will now be recognized on a sell-through basis, based on cash collections.
		•		Inventory increased as of December 31, 2012 by $11.0 million to recognize the costs of inventory shipments to distributors determined to be financially viable as discussed previously.
	Inventory Reserves
	The Company also identified material errors in inventory reserves. One error related to the Company recording an increase of $1.2 million to the Company’s excess and obsolete reserve in the second quarter of 2012 related to a product within the Spine business that was subsequently reversed by the Company in the fourth quarter of 2012. During the Company’s review, it was determined that removing the reserve in the fourth quarter of 2012 was not correct; therefore the reserve has been reinstated.
	The Company has also determined that certain inconsistencies existed with respect to how the Company previously computed and recorded inventory reserves. As a result, the Company has reviewed the methodologies used to compute and record inventory reserves and determined that errors in the application of GAAP existed in prior periods, which required adjustment in these financial statements. Based on this review, the Company has determined that it previously made reductions to previously recorded reserves based on changes in forecasted demand, which it believes was contrary to guidance set forth in ASC Topic 330, Inventory (specifically ASC 330-10-35-14), which states that a write-down of inventory to the lower-of-cost-or-market value at the close of a fiscal year creates a new cost basis that subsequently should not be marked up based on changes in underlying circumstances. The restated consolidated financial statements contain several adjustments to reflect recomputed inventory reserves in each of the relevant periods.
	These adjustments resulted in a decrease to inventory (due to an increase in reserves) as of December 31, 2012, by $14.8 million.
	Royalties
	The Company also reviewed the accounting for royalties and determined there were royalties classified as sales and marketing expense; however, such royalties were based on sales of products and were paid to doctors who consulted on development of those products. Given these amounts are attributable to the cost of producing the Company’s products, the Company determined they are correctly classified as cost of goods sold.
	Other Adjustments
	In addition to the adjustments recorded to address the Company’s errors in accounting for distributor revenue recognition, inventory reserves, and royalties, the Company has identified other errors that are generally not material, individually or in the aggregate, but have been recorded in connection with the restatement.
	Included in Other Adjustments are adjustments to reclassify interest expense from continuing operations to discontinued operations of $3.9 million for the year ended December 31, 2011. The reclassification was necessary as the Company used a portion of the proceeds from the sale of Breg, Inc. to repay in full the remaining $87.5 million balance on the Term Loan Facility and pay down $57.5 million of amounts outstanding under the Revolving Credit Facility.
	There were no material impacts to the statements of cash flows for the items above other than to increase operating cash flows and decrease financing cash flows for $1 million for the year ended December 31, 2012. The results of the adjustments to the Company’s previously filed consolidated statements of operations detailed above are summarized in the tables below. The tax effect of the adjustments is estimated based on the Company’s effective tax rate.
			Year Ended December 31, 2012
						Adjustments by Category
	(U.S. Dollars, in thousands)		Previously			Distributor			Inventory			Royalties			Other			Total			Restated
			Reported			Revenue			Reserves									Adjustments
	Net sales		$	462,320		$	(14,777	)	$	—		$	—		$	38		$	(14,739	)	$	447,581
	Cost of sales			86,492			(2,032	)		5,647			8,190			(44	)		11,761			98,253
	Gross profit			375,828			(12,745	)		(5,647	)		(8,190	)		82			(26,500	)		349,328
	Operating expenses
	Sales and marketing			200,343			(6,629	)		—			(8,190	)		1,607			(13,212	)		187,131
	General and administrative			53,827			(2	)		—			—			(434	)		(436	)		53,391
	Research and development			28,577			—			—			—			—			—			28,577
	Amortization of intangible assets			2,098			—			—			—			200			200			2,298
	Charges related to U.S. Government resolutions			1,973			—			—			—			(678	)		(678	)		1,295
				286,818			(6,631	)		—			(8,190	)		695			(14,126	)		272,692
	Operating income			89,010			(6,114	)		(5,647	)		—			(613	)		(12,374	)		76,636
	Other income and (expense)			(6,282	)		—			—			—			(166	)		(166	)		(6,448	)
	Income before income taxes			82,728			(6,114	)		(5,647	)		—			(779	)		(12,540	)		70,188
	Income tax expense			(28,792	)		1,782			1,645			—			227			3,654			(25,138	)
	Net income from continuing operations		$	53,936		$	(4,332	)	$	(4,002	)	$	—		$	(552	)	$	(8,886	)	$	45,050
			Year Ended December 31, 2011
						Adjustments by Category
	(U.S. Dollars, in thousands)		Previously			Distributor			Inventory			Royalties			Other			Total			Restated
			Reported			Revenue			Reserves									Adjustments
	Net sales		$	470,121		$	(29,135	)	$	—		$	—		$	985		$	(28,150	)	$	441,971
	Cost of sales			92,619			(8,289	)		3,377			7,713			107			2,908			95,527
	Gross profit			377,502			(20,846	)		(3,377	)		(7,713	)		878			(31,058	)		346,444
	Operating expenses
	Sales and marketing			200,145			(1,216	)		—			(7,713	)		2,295			(6,634	)		193,511
	General and administrative			64,374			—			—			—			107			107			64,481
	Research and development			22,861			—			—			—			—			—			22,861
	Amortization of intangible assets			2,350			—			—			—			200			200			2,550
	Charges related to U.S. Government resolutions			56,463			—			—			—			678			678			57,141
				346,193			(1,216	)		—			(7,713	)		3,280			(5,649	)		340,544
	Operating income			31,309			(19,630	)		(3,377	)		—			(2,402	)		(25,409	)		5,900
	Other income and (expense)			(11,868	)		—			—			—			3,915			3,915			(7,953	)
Income (loss) before income taxes			19,441			(19,630	)		(3,377	)		—			1,513			(21,494	)		(2,053	)
Income tax expense			(21,181	)		6,408			1,102			—			(494	)		7,016			(14,165	)
Net loss from continuing operations		$	(1,740	)	$	(13,222	)	$	(2,275	)	$	—		$	1,019		$	(14,478	)	$	(16,218	)
The effects of the restatements on the Company’s consolidated balance sheet as of December 31, 2012 are as follows:
		As of December 31, 2012
(U.S. Dollars, in thousands except share and per share data)		Previously			Adjustments			Restated
		Reported
Assets
Current assets:
Cash and cash equivalents		$	31,055		$	—		$	31,055
Restricted cash			21,314			—			21,314
Trade accounts receivable, less allowances of $13,543			150,316			(43,004	)		107,312
Inventories			88,744			(5,371	)		83,373
Deferred income taxes			16,959			16,491			33,450
Prepaid expenses and other current assets			32,056			2,023			34,079
Total current assets			340,444			(29,861	)		310,583
Property, plant and equipment, net			51,362			2,473			53,835
Patents and other intangible assets, net			6,880			410			7,290
Goodwill			74,388			—			74,388
Deferred income taxes			19,904			(1,023	)		18,881
Other long-term assets			11,303			(3,383	)		7,920
Total assets		$	504,281		$	(31,384	)	$	472,897
Liabilities and shareholders’ equity
Current liabilities:
Bank borrowings		$	16		$	—		$	16
Trade accounts payable			21,812			763			22,575
Other current liabilities			46,969			(7,375	)		39,594
Total current liabilities			68,797			(6,612	)		62,185
Long-term debt			20,000			—			20,000
Deferred income taxes			11,456			—			11,456
Other long-term liabilities			4,930			6,494			11,424
Total liabilities			105,183			(118	)		105,065
Contingencies (Note 17)
Shareholders’ equity
Common shares $0.10 par value; 50,000,000 shares authorized; 19,339,329 issued and outstanding			1,934			—			1,934
Additional paid-in capital			246,111			195			246,306
Retained earnings			148,549			(33,702	)		114,847
Accumulated other comprehensive income			2,504			2,241			4,745
Total shareholders’ equity			399,098			(31,266	)		367,832
Total liabilities and shareholders’ equity		$	504,281		$	(31,384	)	$	472,897
The effects of the restatements on the Company’s consolidated statement of operations and comprehensive income for the year ended December 31, 2012 are as follows:
		Year Ended December 31, 2012
(U.S. Dollars, in thousands, except share and per share data)		Previously			Adjustments			Restated
		Reported
Product sales		$	415,850			(14,811	)	$	401,039
Marketing service fees			46,470			72			46,542
Net sales			462,320			(14,739	)		447,581
Cost of sales			86,492			11,761			98,253
Gross profit			375,828			(26,500	)		349,328
Operating expenses
Sales and marketing			200,343			(13,212	)		187,131
General and administrative			53,827			(436	)		53,391
Research and development			28,577			—			28,577
Amortization of intangible assets			2,098			200			2,298
Charges related to U.S. Government resolutions (Note 17)			1,973			(678	)		1,295
			286,818			(14,126	)		272,692
Operating income			89,010			(12,374	)		76,636
Other income and (expense)
Interest expense, net			(4,577	)		(166	)		(4,743	)
Other expense			(1,705	)		—			(1,705	)
			(6,282	)		(166	)		(6,448	)
Income before income taxes			82,728			(12,540	)		70,188
Income tax expense			(28,792	)		3,654			(25,138	)
Net income from continuing operations			53,936			(8,886	)		45,050
Discontinued operations (Note 16)
Gain on sale of Breg, Inc.,			1,345			—			1,345
Loss from discontinued operations			(4,012	)		1,018			(2,994	)
Income tax benefit (expense)			26			(589	)		(563	)
Net loss from discontinued operations			(2,641	)		429			(2,212	)
Net income		$	51,295			(8,457	)	$	42,838
Net income (loss) per common share—basic:
Net income from continuing operations		$	2.84			(0.47	)	$	2.37
Net loss from discontinued operations			(0.14	)		0.02			(0.12	)
Net income per common share—basic		$	2.7			(0.45	)	$	2.25
Net income (loss) per common share—diluted:
Net income from continuing operations		$	2.78			(0.46	)	$	2.32
Net loss from discontinued operations			(0.14	)		0.03			(0.11	)
Net income per common share—diluted:		$	2.64			(0.43	)	$	2.21
Weighted average number of common shares:
Basic			18,977,263			—			18,977,263
Diluted			19,390,413			—			19,390,413
Other comprehensive income, before tax:
Translation adjustment		$	480			288		$	768
Unrealized gain on derivative instrument			416			—			416
Other comprehensive income, before tax			896			288			1,184
Income tax expense related to components of other comprehensive income			(153	)		—			(153	)
Other comprehensive income, net of tax			743			288			1,031
Comprehensive income		$	52,038			(8,169	)	$	43,869
The effects of the restatements on the Company’s consolidated statement of operations and comprehensive loss for the year ended December 31, 2011 are as follows:
		Year Ended December 31, 2011
(U.S. Dollars, in thousands, except share and per share data)		Previously			Adjustments			Restated
		Reported
Product sales		$	432,975			(27,828	)	$	405,147
Marketing service fees			37,146			(322	)		36,824
Net sales			470,121			(28,150	)		441,971
Cost of sales			92,619			2,908			95,527
Gross profit			377,502			(31,058	)		346,444
Operating expenses
Sales and marketing			200,145			(6,634	)		193,511
General and administrative			64,374			107			64,481
Research and development			22,861			—			22,861
Amortization of intangible assets			2,350			200			2,550
Charges related to U.S. Government resolutions (Note 17)			56,463			678			57,141
			346,193			(5,649	)		340,544
Operating income			31,309			(25,409	)		5,900
Other income and (expense)
Interest expense, net			(9,456	)		3,915			(5,541	)
Other expense			(2,412	)		—			(2,412	)
			(11,868	)		3,915			(7,953	)
Income (loss) before income taxes			19,441			(21,494	)		(2,053	)
Income tax expense			(21,181	)		7,016			(14,165	)
Net loss from continuing operations			(1,740	)		(14,478	)		(16,218	)
Discontinued operations (Note 16)
Gain on sale of Breg, Inc.			—			—			—
Income (loss) from discontinued operations			1,263			(3,968	)		(2,705	)
Income tax (expense) benefit			(596	)		1,409			813
Net income (loss) from discontinued operations			667			(2,559	)		(1,892	)
Net loss		$	(1,073	)		(17,037	)	$	(18,110	)
Net income (loss) per common share—basic:
Net loss from continuing operations		$	(0.10	)		(0.79	)	$	(0.89	)
Net income (loss) from discontinued operations			0.04			(0.14	)		(0.10	)
Net loss per common share—basic		$	(0.06	)		(0.93	)	$	(0.99	)
Net income (loss) per common share—diluted:
Net loss from continuing operations		$	(0.10	)		(0.79	)	$	(0.89	)
Net income (loss) from discontinued operations			0.04			(0.14	)		(0.10	)
Net loss per common share—diluted:		$	(0.06	)		(0.93	)	$	(0.99	)
Weighted average number of common shares:
Basic			18,219,343			—			18,219,343
Diluted			18,219,343			—			18,219,343
Other comprehensive loss, before tax:
Translation adjustment		$	(3,192	)		913		$	(2,279	)
Unrealized loss on derivative instrument			(693	)		—			(693	)
Other comprehensive loss, before tax			(3,885	)		913			(2,972	)
Income tax benefit related to components of other comprehensive income			256			—			256
Other comprehensive loss, net of tax			(3,629	)		913			(2,716	)
Comprehensive loss		$	(4,702	)		(16,124	)	$	(20,826	)

Inventories

Inventories	12 Months Ended
	Dec. 31, 2013
Inventory Disclosure [Abstract]	'
Inventories	'
	3	Inventories
			December 31,
	(U.S. Dollars in thousands)		2013		2012
					(Restated)
	Raw materials		$	6,499	$	7,623
	Work-in-process			6,606		7,886
	Finished products			31,342		28,308
	Field inventory			34,932		22,629
	Consignment inventory			3,916		6,155
	Deferred cost of sales			7,282		10,772
			$	90,577	$	83,373
	Field inventory represents immediately saleable finished products that are in the possession of the Company’s direct sales representatives. Consignment inventory represents immediately saleable finished products located at third party customers, such as distributors and hospitals. Deferred cost of sales result from transactions where the Company has shipped product or performed services for which all revenue recognition criteria have not yet been met. Once all revenue recognition criteria have been met, revenue previously recorded as deferred and associated cost of sales are recognized.

Property_plant_and_equipment

Property, plant and equipment	12 Months Ended
	Dec. 31, 2013
Property Plant And Equipment [Abstract]	'
Property, plant and equipment	'
	4	Property, plant and equipment
			December 31,
	(U.S. Dollars in thousands)		2013			2012
						(Restated)
	Cost
	Buildings		$	4,075		$	3,911
	Plant, equipment and instrumentation			131,572			120,982
	Furniture and fixtures			5,872			5,567
				141,519			130,460
	Accumulated depreciation			(86,913	)		(76,625	)
			$	54,606		$	53,835
	Depreciation expense for the years ended December 31, 2013, 2012 and 2011 was $20.0 million, $15.8 million and $14.3 million, respectively.

Patents_and_other_intangible_a

Patents and other intangible assets	12 Months Ended
	Dec. 31, 2013
Goodwill And Intangible Assets Disclosure [Abstract]	'
Patents and other intangible assets	'
	5	Patents and other intangible assets
			December 31,
	(U.S. Dollars in thousands)		2013			2012
						(Restated)
	Cost
	Patents		$	42,568		$	38,905
	Trademarks—definite lived			620			657
				43,188			39,562
	Accumulated amortization
	Patents			(33,688	)		(31,845	)
	Trademarks—definite lived			(454	)		(427	)
				(34,142	)		(32,272	)
	Patents and other intangible assets, net		$	9,046		$	7,290
	Amortization expense for intangible assets is estimated to be approximately $2.1 million, $1.8 million, $1.7 million, $1.4 million, $0.5 million and $1.5 million for the periods ending December 31, 2014, 2015, 2016, 2017, 2018 and 2019 and thereafter, respectively.

Goodwill

Goodwill	12 Months Ended
	Dec. 31, 2013
Goodwill And Intangible Assets Disclosure [Abstract]	'
Goodwill	'
	6	Goodwill
	The following table presents the changes in the net carrying value of goodwill by reportable segment as well as the reallocation as of July 1, 2013 in conjunction with our change in reportable segments. (See Note 1 “Summary of significant accounting policies”):
	(U.S. Dollars in thousands)		Spine			Orthopedics			BioStim		Biologics		Extremity			Spine Fixation			Total
													Fixation
	At December 31, 2011		$	41,419		$	31,675		$	—	$	—	$	—		$	—		$	73,094
	Foreign currency			145			1,149			—		—		—			—			1,294
	At December 31, 2012			41,564			32,824			—		—		—			—			74,388
	Foreign currency			(163	)		(1,467	)		—		—		—			—			(1,630	)
	At June 30, 2013			41,401			31,357			—		—		—			—			72,758
	Reallocation at July 1, 2013			(41,401	)		(31,357	)		42,678		10,887		9,825			9,368			—
	Impairment			—			—			—		—		(9,825	)		(9,368	)		(19,193	)
	At December 31, 2013		$	—		$	—		$	42,678	$	10,887	$	—		$	—		$	53,565
	Goodwill Impairment
	The Company tests goodwill at least annually for impairment. The Company tests more frequently if indicators are present or changes in circumstances suggest that impairment may exist. These indicators include, among others, declines in sales, earnings or cash flows, or the development of a material adverse change in the business climate. The Company assesses goodwill for impairment at the reporting unit level, which is defined as an operating segment or one level below an operating segment, referred to as a reporting unit.
	In order to calculate the respective carrying values, the Company initially recorded goodwill based on the purchase price allocation performed at the time of acquisition. Corporate assets and liabilities that directly relate to a reporting unit’s operations are ascribed directly to that reporting unit. Corporate assets and liabilities that are not directly related to a specific reporting unit, but from which the reporting unit benefits, are allocated based on the respective contribution measure of each reporting unit. Effective July 1, 2013, the Company re-aligned its segments, and consequently reallocated the carrying value of goodwill to its new reporting units, determined to be the Company’s segments (i.e., BioStim, Biologics, Spine Fixation, and Extremity Fixation), based on the relative fair value of each new reporting unit to total enterprise value at July 1, 2013.
	In the first quarter of 2012, ASU 2011-08, “Testing of Goodwill for Impairment” became effective. ASU 2011-08 allows entities testing goodwill for impairment the option of performing a qualitative assessment before calculating the fair value of a reporting unit (i.e. the first step of the goodwill impairment test). If entities determine, on the basis of qualitative factors, that the fair value of the reporting unit is more likely than not greater than the carrying amount, a quantitative calculation would not be needed.
	As a result of the Company’s change in reportable segments, the Company re-allocated goodwill to each reporting unit. We estimated the fair value of each reporting unit using a weighting of fair values derived from an income approach, a cost approach, and a market approach (all Level 3 fair value measurements). Under the income approach, we calculated the fair value of each reporting unit based on the present value of its estimated future cash flows. Cash flow projections are based on our estimates of revenue growth rates and operating margins, taking into consideration industry and market conditions. The discount rate used was based on the weighted average cost of capital adjusted for the risks associated with the reporting unit and the projected cash flows. The cost approach involves methods of determining a Company’s value by analyzing the market value of a Company’s assets. The market approach estimates fair value based on market multiples of revenue and earnings of comparable publicly traded companies that have similar operating and investment characteristics as our reporting units.
	Upon estimating the fair value of the reporting units, we determined it was less than its carrying value for two of our reporting units, Extremity Fixation and Spine Fixation. As a result, we performed step two of the impairment analysis and allocated the fair value of these reporting units to the estimated fair values of each of the assets and liabilities of the reporting units (including identifiable intangible assets) with the excess fair value being the implied goodwill. Estimating the fair value of certain assets and liabilities requires significant judgment about future cash flows. The implied fair value of the reporting unit’s goodwill was less than its carrying value, which we recorded as a full impairment loss of goodwill for our Spine Fixation and Extremity Fixation reporting units, totaling $19.2 million, during the third quarter of 2013. The Company’s annual goodwill impairment analysis, which was performed qualitatively during the fourth quarter of 2013, did not result in any additional impairment charge.

Bank_borrowings

Bank borrowings	12 Months Ended
	Dec. 31, 2013
Debt Disclosure [Abstract]	'
Bank borrowings	'
	7	Bank borrowings
	Borrowings under the line of credit consist of borrowings in Euros used to fund international operations. The borrowings under such facility were zero and $.01 million at December 31, 2013 and 2012, respectively. The weighted average interest rate on borrowings under lines of credit as of December 31, 2013 and 2012 was 3.70%.
	The Company had an unused available line of credit of €5.8 million ($8.0 million) and €5.8 million ($7.6 million) at December 31, 2013 and 2012, respectively, in its Italian line of credit. This line of credit provides the Company the option to borrow amounts in Italy at rates which are determined at the time of borrowing. This line of credit is unsecured.

Other_current_liabilities

Other current liabilities	12 Months Ended
	Dec. 31, 2013
Payables And Accruals [Abstract]	'
Other current liabilities	'
	8	Other current liabilities
			December 31,
	(U.S. Dollars in thousands)		2013		2012
					(Restated)
	Accrued expenses		$	16,016	$	9,089
	Salaries, bonuses, commissions and related taxes payable			16,598		17,915
	Accrued legal expenses			10,292		8,496
	Other payables			3,240		4,094
			$	46,146	$	39,594

Longterm_debt

Long-term debt	12 Months Ended
	Dec. 31, 2013
Debt Disclosure [Abstract]	'
Long-term debt	'
	9	Long-term debt
	On August 30, 2010, the Company’s wholly owned U.S. holding company, Orthofix Holdings, Inc. (“Orthofix Holdings”) entered into a Credit Agreement (the “Credit Agreement”) with certain domestic direct and indirect subsidiaries of the Company (the “Guarantors”), JPMorgan Chase Bank, N.A., as Administrative Agent, RBS Citizens, N.A., as Syndication Agent, and certain lender parties thereto.
	The Credit Agreement provides for a five year, $200 million secured revolving credit facility (the “Revolving Credit Facility”), and a five year, $100 million secured term loan facility (the “Term Loan Facility”, and together with the Revolving Credit Facility, the “Credit Facilities”). Orthofix Holdings has the ability to increase the amount of the Credit Facilities by an aggregate amount of up to $50 million upon satisfaction of certain conditions.
	In May 2012, the Company used a portion of the proceeds from the sale of Breg, Inc. (“Breg”) (see Note 16) to repay in full the remaining $87.5 million balance on the Term Loan Facility and pay down $57.5 million of amounts outstanding under the Revolving Credit Facility. This use of proceeds was required by the lenders’ consent dated April 23, 2012 to the Credit Agreement. As a result of the sale of Breg, Breg ceased to be a subsidiary of the Company and, therefore, Breg was released as a credit party under the Credit Agreement. Additionally, the Company paid $20 million in June and $20 million in September 2012 to reduce amounts outstanding under the Revolving Credit Facility. As a result, at December 31, 2012, the Term Loan Facility had been repaid in full and there was $20 million outstanding under the Revolving Credit Facility both at December 31, 2013 and 2012. Borrowings under the Credit Facilities bear interest at a floating rate, which is, at Orthofix Holdings’ option, either the London Inter-Bank Offered Rate (“LIBOR”) plus an applicable margin or a base rate (as defined in the Credit Agreement) plus an applicable margin (in each case subject to adjustment based on financial ratios). Such applicable margin will be up to 3.25% for LIBOR borrowings and up to 2.25% for base rate borrowings depending upon a measurement of the consolidated leverage ratio with respect to the immediately preceding four fiscal quarters. As of December 31, 2013 and 2012, the entire Revolving Credit Facility was at the LIBOR rate plus a margin of 2.50%. The effective interest rate on the Credit Facilities as of December 31, 2013 and 2012 was 2.7%.
	Outstanding principal on the Revolving Credit Facility is due on August 30, 2015.
	Borrowings under the Revolving Credit Facility, which may be made in the future, will be used for working capital, capital expenditures and other general corporate purposes of Orthofix Holdings and its subsidiaries. The Guarantors have guaranteed repayment of Orthofix Holdings’ obligations under the Credit Agreement. The obligations of Orthofix Holdings and each of the Guarantors with respect to the Credit Facilities are secured by a pledge of substantially all of the assets of Orthofix Holdings and each of the Guarantors.
	The Credit Agreement, as amended, requires Orthofix Holdings and the Company to comply with coverage ratios on a consolidated basis and contains affirmative and negative covenants, including limitations on additional debt, liens, investments and acquisitions. The Credit Agreement, as amended, also includes events of default customary for facilities of this type. Upon the occurrence of an event of default, all outstanding loans may be accelerated and/or the lenders’ commitments terminated. The Company was in compliance with the affirmative and negative covenants at December 31, 2012 and there were no events of default.
	On August 14, 2013, the Company and certain required lender parties to the Credit Agreement entered into a Limited Waiver (the “Limited Waiver”). Under the Limited Waiver, the lenders under the Credit Agreement (the “Lenders”) collectively waived requirements under the Credit Agreement that the Company deliver quarterly financial statements with respect to the fiscal quarters ending on June 30, 2013 and September 30, 2013, and related financial covenant certificates, until the earlier of (i) March 31, 2014 or (ii) the date that is one day after such financial statements are publicly filed or released. In addition, the Limited Waiver provided that the restatement of the Company’s financial statements for any period ending on or before March 31, 2013 will not constitute a default or event or default provided that within one business day after the public release or filing of such restated financial statements, the Company delivers corrected financial statements and compliance certificates with respect to such restated periods and immediately pay any additional interest and other fees that would have been owed had applicable interest and fees originally been calculated based on the restated financial statements. The Company was in compliance with the affirmative and negative covenants at December 31, 2013 and there were no events of default.
	Certain subsidiaries of the Company have restrictions on their ability to pay dividends or make intercompany loan advances pursuant to the Company’s Credit Facilities. The net assets of Orthofix Holdings and its subsidiaries are restricted for distributions to the parent company. Domestic subsidiaries of the Company, as parties to the credit agreement, have access to these net assets for operational purposes.
	The amount of restricted net assets of Orthofix Holdings and its subsidiaries as of December 31, 2013 and 2012 is $192.0 million and $213.4 million, respectively. In addition, the Credit Agreement restricts the Company and subsidiaries that are not parties to the Credit Facilities from access to cash held by Orthofix Holdings, Inc. and its subsidiaries. All of the Company’s subsidiaries that are parties to the Credit Agreement have access to this cash for operational and debt repayment purposes. The amount of restricted cash of the Company as of December 31, 2013 and 2012 was $23.8 million and $21.3 million, respectively.
	In conjunction with obtaining the Credit Facilities and the Credit Agreement, as amended, the Company incurred debt issuance costs of $5 million which includes $0.8 million of costs related to the May 2011 amendment. These costs are being amortized using the effective interest method over the life of the Credit Facilities. In conjunction with the Term Loan Facility repayment in May 2012, the Company wrote off $0.8 million of the related debt issuance costs. As of December 31, 2013 and 2012, debt issuance costs, net of accumulated amortization, related to the Credit Agreement were $1.1 million and $1.8 million, respectively.

Derivative_instruments

Derivative instruments	12 Months Ended
	Dec. 31, 2013
Derivative Instruments And Hedging Activities Disclosure [Abstract]	'
Derivative instruments	'
	10	Derivative instruments
	The tables below disclose the types of derivative instruments the Company owns, the classifications and fair values of these instruments within the balance sheet, and the amount of gain (loss) recognized in other comprehensive income (loss) (“OCI”) or net income (loss).
	(U.S. Dollars in thousands)		Fair value: favorable			Balance sheet location
			(unfavorable)
	As of December 31, 2013
	Cross-currency swap		$	(1,036	)	Other long-term liabilities
	As of December 31, 2012
	Cross-currency swap		$	305		Other long-term assets
			For the year ended
			December 31,
	(U.S. Dollars in thousands)		2013			2012		2011
	Cross-currency swap gain (loss) recorded in other comprehensive income (loss), net of taxes		$	(278	)	$	263	$	(437	)
	Cross-currency swap
	On September 30, 2010, the Company entered into a cross-currency swap agreement (the “replacement swap agreement”) with JPMorgan Chase Bank and Royal Bank of Scotland PLC (the “counterparties”) to manage its cash flows related to foreign currency exposure for a portion of the Company’s intercompany receivable of a U.S. dollar functional currency subsidiary that is denominated in Euro.
	Under the terms of the swap agreement, the Company pays Euros based on a €28.7 million notional value and a fixed rate of 5.00% and receives U.S. dollars based on a notional value of $39 million and a fixed rate of 4.635%. The expiration date is December 30, 2016, the date upon which the underlying intercompany debt, to which the swap agreement applies, matures. The swap agreement is designated as a cash flow hedge and therefore the Company recognized an unrealized gain (loss) on the change in fair value, net of tax, within other comprehensive income.

Fair_value_measurements

Fair value measurements	12 Months Ended
	Dec. 31, 2013
Fair Value Disclosures [Abstract]	'
Fair value measurements	'
	11	Fair value measurements
	Fair value is defined as the price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Non-financial assets and liabilities of the Company measured at fair value include any long-lived assets or equity method investments that are impaired in a currently reported period. The authoritative guidance also describes three levels of inputs that may be used to measure fair value:
	Level 1 —		quoted prices in active markets for identical assets and liabilities
	Level 2 —		observable inputs other than quoted prices in active markets for identical assets and liabilities
	Level 3 —		unobservable inputs in which there is little or no market data available, which require the reporting entity to develop its own assumptions
	As of December 31, 2013, the Company’s financial instruments included cash equivalents, restricted cash, accounts receivable, short-term bank borrowings, accounts payable, long-term secured debt, and a cross-currency derivative contract. Cash equivalents consist of short-term, highly liquid, income-producing investments, all of which have original maturities of 90 days or less, including money market funds. The carrying value of restricted cash, accounts receivable, short-term bank borrowings and accounts payable approximate fair value due to the short-term maturities of these instruments. The Company’s credit facilities carry a floating rate of interest, and therefore, the carrying value is considered to approximate the fair value.
	The Company’s cross-currency derivative instrument is the only financial instrument recorded at fair value on a recurring basis. This instrument consists of an over-the-counter contract, which is not traded on a public exchange. The fair value of the swap contract is determined based on inputs that are readily available in public markets or can be derived from information available in publicly quoted markets. Therefore, the Company has categorized the swap contract as a Level 2 derivative financial instrument. The Company also considers counterparty credit risk and its own credit risk in its determination of all estimated fair values. The Company has consistently applied these valuation techniques in all periods presented.
	The fair value of the Company’s financial assets and liabilities on a recurring basis were as follows:
	(U.S. Dollars in thousands)		Balance			Level 1			Level 2			Level 3
			December 31,
			2013
	Assets
	Deferred compensation plan		$	3,361		$	3,361		$	—		$	—
	Total		$	3,361		$	3,361		$	—		$	—
	Liabilities
	Deferred compensation plan		$	(2,506	)	$	(2,506	)	$	—		$	—
	Cash Flow Hedges
	Cross-currency hedge			(1,036	)		—			(1,036	)		—
	Total		$	(3,542	)	$	(2,506	)	$	(1,036	)	$	—
	(U.S. Dollars in thousands)		Balance			Level 1			Level 2			Level 3
			December 31,
			2012
	Assets
	Deferred compensation plan		$	3,305		$	3,305		$	—		$	—
	Cash flow hedges
	Cross-currency hedge			305			—			305			—
	Total		$	3,610		$	3,305		$	305		$	—
	Liabilities
	Deferred compensation plan		$	(2,320	)	$	(2,320	)	$	—		$	—
	Cash flow hedges
	Cross-currency hedge			—			—			—			—
	Total		$	(2,320	)	$	(2,320	)	$	—		$	—

Commitments

Commitments	12 Months Ended
	Dec. 31, 2013
Commitments And Contingencies Disclosure [Abstract]	'
Commitments	'
	12	Commitments
	Leases
	The Company has entered into operating leases for facilities and equipment. These leases are non-cancellable and typically do not contain renewal options. Certain leases contain rent escalation clauses for which the Company recognizes the expense on a straight-line basis. Rent expense under the Company’s operating leases for the years ended December 31, 2013, 2012 and 2011 was approximately $3.4 million, $4.1 million and $4.8 million, respectively. Future minimum lease payments under operating leases, net of amounts to be received under sub-leases, as of December 31, 2013 are as follows:
	(U.S. Dollars in thousands)
	2014		$	4,342
	2015			4,107
	2016			3,713
	2017			2,974
	2018			2,846
	Thereafter			3,049
	Total		$	21,031

Business_segment_information

Business segment information	12 Months Ended
	Dec. 31, 2013
Segment Reporting [Abstract]	'
Business segment information	'
	13	Business segment information
	On July 1, 2013, we began certain organizational and executive leadership changes to align with how our Chief Operating Decision Maker (the “CODM”) reviews performance and makes decisions in managing the Company. We manage our business by our four strategic business units (“SBUs”), which are comprised of BioStim, Biologics, Extremity Fixation, and Spine Fixation supported by Corporate activities. These SBUs represent the segments for which our CODM reviews financial information and makes resource allocation decisions among business units. The primary metric used by the Chief Operating Decision Maker in managing the Company is contribution margin, which is defined as gross profit less sales and marketing expense. The Company neither discretely allocates assets, other than goodwill, to its operating segments nor evaluates the operating segments using discrete asset information. Accordingly, our segment information has been prepared based on our four SBUs reporting segments. These four segments are discussed below.
	BioStim
	The BioStim SBU manufactures, distributes, and provides support services for a portfolio of market leading devices for enhancing bone fusion that utilize Orthofix’s patented pulsed electromagnetic (PEMF) technology. These Food and Drug Administration-approved Class 3 medical devices are indicated as an adjunctive treatment to enhance fusion success in cervical and lumbar spine fusion as well as a therapeutic treatment for non-healing fractures outside of the spine (non-unions). The PEMF technology is supported by a strong clinical background on mechanism of action in the scientific literature and current research and clinical studies are underway to identify potential new clinical indications.
	Biologics
	The Biologics SBU provides a portfolio of regenerative products that allow physicians to successfully treat a variety of spinal and orthopedic conditions. This SBU specializes in the marketing of the Company’s regeneration tissue forms. Biologics distributes its tissues through a network of distributors, sales, representatives and affiliates to market to hospitals, doctors, and other healthcare providers, primarily in the U.S. Our partnership with MTF allows us to exclusively market our Trinity Evolution® and Trinity Elite® tissue forms for musculoskeletal defects to enhance bony fusion.
	Extremity Fixation
	The Extremity Fixation SBU offers products that allow physicians to successfully treat a variety of orthopedic conditions unrelated to the spine. This SBU specializes in the design, development, and marketing of the Company’s orthopedic products used in fracture repair, deformity correction and bone reconstruction. Extremity Fixation distributes its products through a network of distributors, sales representatives, and affiliates. This SBU uses both distributors and direct sales representatives to sell orthopedics products to hospitals, doctors, and other health providers, globally.
	Spine Fixation
	The Spine Fixation SBU specializes in the design, development and marketing of a portfolio of implant products used in surgical procedures of the spine. Spine Fixation distributes its products through a network of distributors and affiliates. This SBU uses distributors and direct sales representatives to sell spine products to hospitals, doctors and other healthcare providers, globally.
	Corporate
	Corporate activities are comprised of the operating expenses of Orthofix International N.V. and its holding company subsidiaries, along with activities not necessarily identifiable within the four SBUs.
	External Net Sales by SBU:
	The table below presents external net sales for continuing operations by SBU reporting segment. Net sales include product sales and marketing service fees.
			External Net Sales by SBU
			Year ended December 31,
	(U.S. Dollars in thousands)		2013						2012						2011
			Net Sales			Percent of			Net Sales			Percent of			Net Sales		Percent of
						Total Net						Total Net					Total Net
						Sales						Sales					Sales
									(Restated)			(Restated)			(Restated)		(Restated)
	BioStim		$	147,910			37	%	$	181,959			41	%	$	188,136		43	%
	Biologics			53,769			13	%		53,730			12	%		42,919		10	%
	Extremity Fixation			103,385			26	%		112,009			25	%		119,521		27	%
	Spine Fixation			95,470			24	%		99,883			22	%		91,395		20	%
	Total Net Sales		$	400,534			100	%	$	447,581			100	%	$	441,971		100	%
	The table below presents net margin, defined as gross profit less sales and marketing expenses from continuing operations by SBU reporting segment:
	Net Margin by SBU		Year Ended December 31,
	(U.S. Dollars in thousands)		2013			2012			2011
						(Restated)			(Restated)
	Net Margin
	BioStim		$	64,930		$	86,654		$	93,056
	Biologics			24,532			23,559			18,979
	Extremity Fixation			26,389			34,337			29,530
	Spine Fixation			7,245			19,142			13,068
	Corporate			(1,443	)		(1,495	)		(1,700	)
	Total net margin		$	121,653		$	162,197		$	152,933
	General & administrative			65,147			53,391			64,481
	Research and development			26,768			28,577			22,861
	Amortization of intangible assets			2,687			2,298			2,550
	Costs related to the accounting review and restatement			12,945			—			—
	Impairment of goodwill			19,193			—			—
	Charges related to U.S. Government resolutions			—			1,295			57,141
	Operating (loss) income		$	(5,087	)	$	76,636		$	5,900
	The following table presents depreciation and amortization for continuing operations by SBU reporting segment:
			Depreciation and amortization by SBU
			Year Ended December 31,
	(U.S. Dollars in thousands)		2013			2012			2011
						(Restated)			(Restated)
	BioStim		$	1,946		$	1,584		$	2,033
	Biologics			628			543			415
	Extremity Fixation			7,195			5,196			5,148
	Spine Fixation			12,794			10,752			9,211
	Corporate			96			70			53
	Total		$	22,659		$	18,145		$	16,860
	Geographical information
	The following geographic data includes net sales by geographic destination:
	(U.S. Dollars in thousands)		2013			2012			2011
						(Restated)			(Restated)
	U.S.		$	295,857		$	334,624		$	328,585
	International:
	U.K.			10,002			8,431			8,206
	Italy			16,755			18,742			17,447
Brazil			26,786			31,166			34,424
Other			51,134			54,618			53,309
Total international			104,677			112,957			113,386
Total net sales		$	400,534		$	447,581		$	441,971
Analysis of property, plant and equipment by geographic area:
(U.S. Dollars in thousands)		2013			2012
					(Restated)
U.S.		$	39,858		$	39,554
Italy			7,813			7,617
U.K.			1,871			1,402
Brazil			3,210			3,421
Others			1,854			1,841
Total		$	54,606		$	53,835

Income_taxes

Income taxes	12 Months Ended
	Dec. 31, 2013
Income Tax Disclosure [Abstract]	'
Income taxes	'
	14	Income taxes
	The provision for (benefit from) income taxes on continuing operations in the accompanying consolidated statements of operations consists of the following:
			Year Ended
			December 31,
	(US$ in thousands)		2013			2012			2011
						(Restated)			(Restated)
	U.S.
	Current		$	2,914		$	17,897		$	25,148
	Deferred			5,716			1,788			(12,657	)
	Total U.S			8,630			19,685			12,491
	Non-U.S.
	Current			2,355			4,609			2,735
	Deferred			(869	)		844			(1,061	)
				1,486			5,453			1,674
	Total tax expense		$	10,116		$	25,138		$	14,165
	The tax effects of the significant temporary differences, which comprise the deferred tax assets and liabilities and assets, are as follows:
	(US$ in thousands)		2013			2012
						(Restated)
	Intangible assets and goodwill		$	4,978		$	5,346
	Inventories and related reserves			14,678			14,020
	Deferred revenue and cost of sales			9,669			11,682
	Other accruals and reserves			3,200			3,868
	Accrued compensation			3,880			3,817
	Allowance for doubtful accounts			4,429			3,718
	Accrued interest			17,775			18,229
	Net operating loss carryforwards			34,215			27,231
	Other, net			621			539
				93,445			88,450
	Valuation allowance			(31,472	)		(26,361	)
	Deferred tax asset		$	61,973		$	62,089
	Withholding taxes			(13,132	)		(11,456	)
	Property, plant and equipment			(9,690	)		(9,758	)
	Deferred tax liability			(22,822	)		(21,214	)
	Net deferred tax assets		$	39,151		$	40,875
	The valuation allowance as of December 31, 2013 and 2012 was $31.5 million and $26.4 million, respectively. The net increase in the valuation allowance of $5.1 million during the year principally relates to certain current period foreign losses not benefitted and certain state net operating losses and tax credits. The valuation allowance is attributable to net operating loss carryforwards and certain temporary differences in certain foreign jurisdictions, the benefit for which is dependent upon the generation of future taxable income in those foreign jurisdictions. In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income and tax planning strategies in making this assessment. Based upon the level of historical taxable income and projections for future taxable income over the periods in which the deferred tax assets are deductible, management believes it is more likely than not the Company will realize the benefits of these temporary differences, net of the existing valuation allowances at December 31, 2013.
	The Company has state net operating loss carryforwards of approximately $22.8 million, a portion of which began to expire in 2013. The Company has net operating losses of foreign taxing jurisdictions of approximately $121.7 million. The majority of the foreign losses relates to the Company’s Netherlands operations, a portion of which began to expire in 2013. The Company has provided a valuation allowance against a significant portion of these state and foreign net operating loss carryforwards since it does not believe that this deferred tax asset can be realized prior to expiration.
	The rate reconciliation for continuing operations presented below is based on the U.S. federal income tax rate, rather than the parent company’s country of domicile tax rate. Management believes, given the large proportion of taxable income earned in the United States, such disclosure is more meaningful.
	(U.S. Dollars in thousands, except percentages)		2013						2012						2011
			Amount			Percent			Amount			Percent			Amount			Percent
									(Restated)			(Restated)			(Restated)			(Restated)
	Statutory U.S. federal income tax rate		$	(1,677	)		35	%	$	24,565			35	%	$	(719	)		35	%
	State taxes, net			2,744			(57.3	)		1,708			2.4			1,896			(92.4	)
	Foreign rate differential			(626	)		13.1			(3,115	)		(4.4	)		1,585			(77.2	)
	Valuation allowance—foreign losses			3,913			(81.7	)		6,183			8.8			4,882			(237.8	)
	SRL intangible			(2,288	)		47.8			(2,214	)		(3.2	)		(2,421	)		117.9
	Goodwill impairment			6,452			(134.7	)		—			—			—			—
	Domestic manufacturing deduction			(233	)		4.9			(1,694	)		(2.4	)		(1,703	)		82.9
	Withholding taxes			1,679			(35.0	)		1,679			2.4			1,676			(81.6	)
	Settlement of U.S. Government resolutions			—			—			(1,260	)		(1.8	)		9,520			(463.7	)
	Other items, net			152			(3.2	)		(714	)		(1.0	)		(551	)		26.9
	Income tax expense/effective rate		$	10,116			(211.1	)%	$	25,138			35.8	%	$	14,165			(690.0	)%
	The income tax expense and effective tax rate for the year ended 2013 reflects a disproportionate ratio to the $25.1 million of income tax expense and effective tax rate of 35.8% for the year ended 2012. The principal factors affecting the Company’s effective tax rate was the company’s mix of earnings amongst various tax jurisdictions, state taxes, and the impairment of $19.2 million in non-deductable goodwill. For the years ended 2012 and 2011, the Company did not record tax benefit on certain expenses associated with the Company’s estimate of the charges related to U.S. Government resolutions.
	On January 2, 2013, the American Taxpayer Relief Act of 2012 (“Act”) was enacted. The Act provides tax relief for businesses by reinstating certain tax benefits and credits retroactively to January 1, 2012. There are several provisions of the Act that impact the Company, most notably the extension of the Research and Development credit. Income tax accounting rules require tax law changes to be recognized in the period of enactment; as such, the Company recognized a tax benefit of $0.3 million in its provision for income taxes in the first quarter of 2013.
	The Company’s unrecognized tax benefit was $0.7 million and $1.2 million for the years ended December 31, 2013 and 2012, respectively. The Company recognizes potential accrued interest and penalties related to unrecognized tax benefits in income tax expense. The Company had approximately $0.5 million and $0.8 million accrued for payment of interest and penalties as of December 31, 2013 and 2012, respectively.
	The entire amount of unrecognized tax benefits, including interest, would favorably impact the Company’s effective tax rate if recognized. As of December 31, 2013, the Company does not expect the amount of unrecognized tax benefits to change significantly over the next twelve months.
	A reconciliation of the gross unrecognized tax benefits (excluding interest and penalties) for the years ended December 31, 2013 and December 31, 2012 follows:
	(US$ in thousands)		2013			2012
						(Restated)
	Balance as of January 1,		$	1,189		$	610
	Additions for current year tax positions			183			793
	Decreases for prior year tax positions			(12	)		(106	)
	Settlements of prior year tax positions			(560	)		—
	Expiration of statutes			(77	)		(108	)
Balance as of December 31,		$	723		$	1,189
The Company files a consolidated income tax return in the U.S. federal jurisdiction, the U.K., Italy and numerous consolidated and separate income tax returns in many state and other foreign jurisdictions. The statute of limitations with respect to federal tax authorities is closed for years prior to December 31, 2010. The statute of limitations for the various state tax filings is closed in most instances for the years prior to December 31, 2009. The statute of limitations with respect to the major foreign tax filing jurisdictions is closed for years prior to December 31, 2008.
The Company’s intention is to reinvest the total amount of its unremitted foreign earnings (residing outside Curaçao) in the local jurisdiction, to the extent they are generated and available, or to repatriate the earnings only when tax-effective. As an entity incorporated in Curaçao, “foreign subsidiaries” refer to both U.S. and non-U.S. subsidiaries. Furthermore, only income sourced in the U.S. is subject to U.S. income tax. Unremitted foreign earnings increased from $292.0 million at December 31, 2012 to $345.2 million at December 31, 2013. The $345.2 million at December 31, 2013 includes $354.8 million in U.S subsidiaries. It is not practicable to determine the amounts of net additional income tax that may be payable if such earnings were repatriated. The Company does not anticipate any impact on income tax liabilities since earnings are permanently reinvested for both U.S and non-U.S. subsidiaries.
Total cash and cash equivalents at December 31, 2013 were $54.2 million, of which $23.7 million is restricted under the senior secured credit agreement for use in the U.S. and is therefore classified as restricted cash on the balance sheet. The Company’s U.S. business generates sufficient cash flow and has borrowing capacity in the United States to fund its U.S. operations. Cash and cash equivalents of $30.5 million at December 31, 2013 was held by non-U.S. subsidiaries and is permanently reinvested for use in non-U.S. operations.

Related_parties

Related parties	12 Months Ended
	Dec. 31, 2013
Related Party Transactions [Abstract]	'
Related parties	'
	15	Related parties
	In 2011, we sold $0.5 million in products to OrthoPro, Inc. and Superior Medical Equipment, who were independent distributors for Breg, Inc., and were owned by the son of a former board member.

Sale_of_Breg_and_Disposition_o

Sale of Breg and Disposition of Sports Medicine SBU	12 Months Ended
	Dec. 31, 2013
Discontinued Operations And Disposal Groups [Abstract]	'
Sale of Breg and Disposition of Sports Medicine SBU	'
	16	Sale of Breg and Disposition of Sports Medicine SBU
	On April 23, 2012, the Company’s subsidiary Orthofix Holdings and Breg entered into a stock purchase agreement (the “SPA”) with Breg Acquisition Corp. (“Buyer”), a newly formed affiliate of Water Street Healthcare Partners II, L.P., pursuant to which Buyer agreed to acquire from Orthofix Holdings all the outstanding shares of Breg, subject to the terms and conditions contained therein (the “Transaction”). Under the terms of the SPA, upon closing of the sale, Orthofix Holdings and the Company agreed to indemnify Buyer with respect to certain specified matters, including the government investigation and product liability matters regarding a previously owned infusion pump product line, and pre-closing sales of cold therapy units and certain post-closing sales of cold therapy units. (See “Matters Related to the Company’s former Breg Subsidiary and Possible Indemnification Obligations under Note 17.) On May 24, 2012 (the “Closing Date”), Orthofix Holdings completed the sale of all of the outstanding shares of Breg for $157.5 million in cash. After adjustments for working capital and indebtedness in accordance with the terms of the SPA, Orthofix Holdings used $145 million of the net proceeds to prepay outstanding Company indebtedness, as required by a lender consent received in connection with the Company’s existing Credit Agreement. As a result of the closing of this Transaction, Breg ceased to be a subsidiary of the Company and, therefore, Breg was released as a credit party under the Credit Agreement. The Company also agreed to enter into certain transition arrangements at the closing, including a transition services agreement pursuant to which the Company agreed to continue to provide administrative operational support for a period of up to twelve months. As a result of the sale of Breg, the Company completed its exit from the Sports Medicine SBU, of which Breg was a significant component.
	The portion of indemnification related to post closing claims related to post-closing sales of cold therapy has created a guarantee under ASC 460—Guarantees and the fair value of the liability has been recorded under the initial recognition criteria in the amount of $2 million at the Closing Date of the transaction. The Company amortizes the fair value of the noncontingent liability ratably over the period of indemnification which is three years. The Company’s obligations under this guarantee were approximately $0.9 million and $1.6 million as of December 31, 2013 and December 31, 2012, respectively.
	Gain on Sale of Discontinued Operations
	The following table presents the value of the asset disposition, proceeds received, net of various working capital adjustments and indebtedness and net gain on sale of Breg as shown in the condensed consolidated statement of operations for the year ended December 31, 2012.
	(U.S. Dollars in thousands)		Total
	Cash proceeds		$	157,500
	Less:
	Working Capital			(7,093	)
	Transaction related expenses			(4,276	)
	Fair value of indemnification			(2,000	)
	Tangible assets			(8,309	)
	Intangible assets			(28,164	)
	Goodwill			(106,200	)
	Gain on sale of Breg			1,458
	Income tax expense			(113	)
	Gain on sale of Breg, net of taxes		$	1,345
	The Sports Medicine SBU contributed $44 million and $108.9 million of net sales in the years ended December 31, 2012 and 2011, respectively. The Sports Medicine SBU had $2.9 million of operating losses and $1.2 million of operating income in the years ended December 31, 2012 and 2011, respectively. The financial information above includes the financial results of Breg operations up to the date of sale.
	The Company’s consolidated financial statements and related footnote disclosures reflect the Sports Medicine SBU as discontinued operations. Income (loss) associated with the Sports Medicine SBU, net of applicable income taxes is shown as income (loss) from discontinued operations for all periods presented.

Contingencies

Contingencies	12 Months Ended
	Dec. 31, 2013
Commitments And Contingencies Disclosure [Abstract]	'
Contingencies	'
	17	Contingencies
	The Company is party to outstanding legal proceedings, investigations and claims as described below. The Company believes that it is unlikely that the outcome of each of these matters, including the matters discussed below, will have a material adverse effect on it and its subsidiaries as a whole, notwithstanding that the unfavorable resolution of any matter may have a material effect on the Company’s net earnings (if any) in any particular quarter. However, the Company cannot predict with any certainty the final outcome of any legal proceedings, investigations (including any settlement discussions with the government seeking to resolve such investigations) or claims made against it as described in the paragraphs below, and there can be no assurance that the ultimate resolution of any such matter will not have a material adverse impact on the Company’s consolidated financial position, results of operations, or cash flows.
	The Company records accruals for certain outstanding legal proceedings, investigations or claims when it is probable that a liability will be incurred and the amount of the loss can be reasonably estimated. The Company evaluates, on a quarterly basis, developments in legal proceedings, investigations and claims that could affect the amount of any accrual, as well as any developments that would make a loss contingency both probable and reasonably estimable. When a loss contingency is not both probable and reasonably estimable, the Company does not accrue the loss. However, if the loss (or an additional loss in excess of the accrual) is at least a reasonable possibility and material, then the Company discloses a reasonable estimate of the possible loss or range of loss, if such reasonable estimate can be made. If the Company cannot make a reasonable estimate of the possible loss, or range of loss, then that is disclosed.
	The assessments of whether a loss is probable or a reasonable possibility, and whether the loss or range of loss is reasonably estimable, often involve a series of complex judgments about future events. Among the factors that the Company considers in this assessment are the nature of existing legal proceedings, investigations and claims, the asserted or possible damages or loss contingency (if reasonably estimable), the progress of the matter, existing law and precedent, the opinions or views of legal counsel and other advisers, the involvement of the U.S. Government and its agencies in such proceedings, the Company’s experience in similar matters and the experience of other companies, the facts available to the Company at the time of assessment, and how the Company intends to respond, or has responded, to the proceeding, investigation or claim. The Company’s assessment of these factors may change over time as individual proceedings, investigations or claims progress. For matters where the Company is not currently able to reasonably estimate the range of reasonably possible loss, the factors that have contributed to this determination include the following: (i) the damages sought are indeterminate, or an investigation has not manifested itself in a filed civil or criminal complaint, (ii) the matters are in the early stages, (iii) the matters involve novel or unsettled legal theories or a large or uncertain number of actual or potential cases or parties, and/or (iv) discussions with the government or other parties in matters that may be expected ultimately to be resolved through negotiation and settlement have not reached the point where the Company believes a reasonable estimate of loss, or range of loss, can be made. In such instances, the Company believes that there is considerable uncertainty regarding the timing or ultimate resolution of such matters, including a possible eventual loss, fine, penalty or business impact, if any.
	In addition to the matters described in the paragraphs below, in the normal course of its business, the Company is involved in various lawsuits from time to time and may be subject to certain other contingencies. To the extent losses related to these contingencies are both probable and reasonably estimable, the Company accrues appropriate amounts in the accompanying financial statements and provides disclosures as to the possible range of loss in excess of the amount accrued, if such range is reasonably estimable. The Company believes losses are individually and collectively immaterial as to a possible loss and range of loss.
	Matters Related to the Audit Committee’s Review and the Restatement of Certain of the Company’s Consolidated Financial Statements
	Audit Committee Review
	In July 2013, the Audit Committee began conducting an independent review, with the assistance of outside professionals, of certain accounting matters. This review resulted in the decision to restate certain of the Company’s previously filed consolidated financial statements. As a result of this review and the restatement of certain of the Company’s previously filed consolidated financial statements, the filing of the Company’s Quarterly Reports on Form 10-Q for the quarterly periods ended June 30, 2013 and September 30, 2013, and the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2013, were not timely. The Company filed its Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2013 on March 24, 2014, and filed its Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2013 on March 25, 2014. The Company also has filed its Annual Report on Form 10-K for the fiscal year ended December 31, 2013 on the date hereof.
	SEC Enforcement Staff Review
	In connection with the initiation of the Audit Committee’s independent review, the Company initiated contact with the staff of the Division of Enforcement of the Securities and Exchange Commission (the “SEC Enforcement Staff”) in July 2013 to advise them of these matters. The Audit Committee, through its counsel, has been in direct communication with the SEC Enforcement Staff regarding these matters, and both the Company and the Audit Committee are cooperating fully with the SEC Enforcement Staff’s review of these matters. The Company has received requests from the SEC Enforcement Staff for documents and other information concerning various accounting practices, internal controls and business practices. Such requests cover the years ended December 31, 2011 and 2012, and in some instances, prior periods. It is anticipated that the Company may receive additional requests from the SEC Enforcement Staff in the future. The Company has further provided notice concerning these matters to the Office of Inspector General of the U.S. Department of Health and Human Services (“HHS-OIG”) pursuant to the Company’s corporate integrity agreement with HHS-OIG (which agreement is described below in this Note 17).
	The Company cannot predict if, when or how this matter will be resolved or what, if any, actions it may be required to take as part of any resolution of these matters. Any action by the SEC, HHS-OIG or other governmental agency could result in civil or criminal sanctions against the Company and/or certain of its current and former officers, directors and employees. The matter is at an early stage and, at this time, the Company cannot reasonably estimate the possible loss, or range of loss, in connection with it.
	Securities Class Action Complaint
	On August 14, 2013, a securities class action complaint against the Company, currently styled Tejinder Singh v. Orthofix International N.V., et al. (No.:1:13-cv-05696-JGK), was filed in the United States District Court for the Southern District of New York arising out of the then anticipated restatement of our prior financial statements and the matters described above. In addition to the Company, Alan W. Milinazzo, the Company’s former President and Chief Executive Officer, Robert S. Vaters, the Company’s former President and Chief Executive Officer, Brian McCollum, the Company’s former Chief Financial Officer, Bradley R. Mason, the Company’s current President and Chief Executive Officer, and Emily Buxton, the Company’s current Chief Financial Officer, are named as defendants. The operative complaint has not yet been filed in the action following the appointment by the court of a lead plaintiff. Accordingly, the allegations that the lead plaintiff ultimately intends to make in this action are unknown. The matter is at an early stage and, at this time, the Company cannot reasonably estimate the possible loss, or range of loss, in connection with it.
	Matters Related to Promeca
	On July 10, 2012, the Company entered into definitive agreements with the DOJ and the SEC agreeing to settle its self-initiated and self-reported internal investigation of our Mexican subsidiary, Promeca S.A. de C.V. (“Promeca”), regarding non-compliance by Promeca with the Foreign Corrupt Practices Act (the “FCPA”). Under the terms of these agreements, the Company voluntarily disgorged profits to the United States government in an amount of $5.2 million, inclusive of pre-judgment interest, and agreed to pay a fine of $2.2 million. The Company paid $2.2 million in July 2012 and $5.2 million in September 2012. As part of the settlement, the Company entered into a three-year deferred prosecution agreement (“DPA”) with the DOJ and a consent to final judgment (the “Consent”) with the SEC.
	The DOJ has agreed not to pursue any criminal charges against the Company in connection with this matter if the Company complied with the terms of the DPA. The DPA takes note of the Company’s self-reporting of this matter to DOJ and the SEC, and of remedial measures, including the implementation of an enhanced compliance program, previously undertaken by the Company. The DPA and the Consent collectively require, among other things, that with respect to anti-bribery compliance matters the Company shall continue to cooperate fully with the government in any future matters related to corrupt payments, false books and records or inadequate internal controls. In that regard, the Company has represented that it has implemented and will continue to implement a compliance and ethics program designed to prevent and detect violations of the FCPA and other applicable anti-corruption laws. The Company will periodically report to the government during the term of the DPA regarding such remediation and implementation of compliance measures. As part of the settlement, the Company also agreed pursuant to the Consent to certain reporting obligations to the SEC regarding the status of the Company’s remediation and implementation of compliance measures. In the event that the Company fails to comply with these obligations, it could be subject to criminal prosecution by the DOJ for the FCPA-related matters we self-reported.
	Review of Potential Improper Payments Involving Brazil Subsidiary
	In August 2013, the Company’s internal legal department was notified of certain allegations involving potential improper payments with respect to its Brazilian subsidiary, Orthofix do Brasil. The Company engaged outside counsel to assist in the review of these matters, focusing on compliance with applicable anti-bribery laws, including the FCPA. This review remains ongoing. The FCPA and related provisions of law provide for potential criminal and civil sanctions in connection with anti-bribery violations, including criminal fines, civil penalties, disgorgement of past profits and other kinds of remedies. The Company currently cannot reasonably estimate a possible loss, or range of loss, in connection with this review.
	Consistent with the provisions of the DPA and the Consent described above, the Company contacted the DOJ and the SEC in August 2013 to voluntarily self-report the Brazil-related allegations, and the Company and its counsel remain in contact with both agencies regarding the status of the review. In the event that the DOJ and the SEC find that the matters related to the Company’s Brazilian subsidiary could give rise to a review of the Company’s obligations under the terms of the DPA and/or the Consent, the Company currently cannot reasonably estimate a possible loss, or range of loss, in connection with that review, including any effects it may have with respect to the DPA and the Consent.
	Corporate Integrity Agreement with HHS-OIG
	As previously disclosed, on June 6, 2012, the Company entered into a definitive settlement agreement with the United States of America, acting through the DOJ and on behalf of HHS-OIG; the TRICARE Management Activity, through its General Counsel; the Office of Personnel Management, in its capacity as administrator of the Federal Employees Health Benefits Program; the United States Department of Veteran Affairs; and the qui tam relator, pursuant to which the Company agreed to pay $34.2 million (plus interest at a rate of 3% from May 5, 2011 through the day before payment was made) to settle criminal and civil matters related to the promotion and marketing of the Company’s regenerative stimulator devices (which the Company has also described in the past as its “bone growth stimulator devices”). In connection with such settlement agreement, Orthofix Inc., the Company’s wholly owned subsidiary, also pled guilty to one felony count of obstruction of a June 2008 federal audit (§18 U.S.C. 1516) and paid a criminal fine of $7.8 million and a mandatory special assessment of $400. Also as previously disclosed, on October 29, 2012, the Company, through Blackstone, entered into a definitive settlement agreement with the U.S. government and the qui tam relator, pursuant to which the Company paid $32 million to settle claims (covering a period prior to Blackstone’s acquisition by the Company) concerning the compensation of physician consultants and related matters. All of the $32 million we paid pursuant to such settlement was funded by proceeds the Company received from an escrow fund established in connection with its acquisition of Blackstone in 2006.
	On June 6, 2012, in connection with these settlements, the Company also entered into a five-year corporate integrity agreement with HHS-OIG (the “CIA”). The CIA acknowledges the existence of the Company’s current compliance program and requires that the Company continues to maintain during the term of the CIA a compliance program designed to promote compliance with federal healthcare and FDA requirements. The Company also is required to maintain several elements of its previously existing program during the term of the CIA, including maintaining a Chief Compliance Officer, a Compliance Committee, and a Code of Conduct. The CIA requires that we conduct certain additional compliance-related activities during the term of the CIA, including various training and monitoring procedures, and maintaining a disciplinary process for compliance obligations.
	Pursuant to the CIA, the Company is required to notify the HHS-OIG in writing, among other things, of: (i) any ongoing government investigation or legal proceeding involving an allegation that the Company has committed a crime or has engaged in fraudulent activities; (ii) any other matter that a reasonable person would consider a probable violation of applicable criminal, civil, or administrative laws related to compliance with federal healthcare programs or FDA requirements; and (iii) any change in location, sale, closing, purchase, or establishment of a new business unit or location related to items or services that may be reimbursed by federal healthcare programs. The Company is also subject to periodic reporting and certification requirements attesting that the provisions of the CIA are being implemented and followed, as well as certain document and record retention mandates. The CIA provides that in the event of an uncured material breach of the CIA, the Company could be excluded from participation in federal healthcare programs and/or subject to monetary penalties.
	Matters Related to the Company’s Former Breg Subsidiary and Possible Indemnification Obligations
	On May 24, 2012, the Company sold Breg to an affiliate of Water Street Healthcare Partners II, L.P. (“Water Street”) pursuant to a stock purchase agreement (the “Breg SPA”). Under the terms of the Breg SPA, upon closing of the sale, the Company and its subsidiary, Orthofix Holdings, Inc., agreed to indemnify Water Street and Breg with respect to certain specified matters, including (i) the government investigation and product liability matters regarding the previously owned infusion pump product line described below, and (ii) pre-closing sales of cold therapy units and certain post-closing sales of cold therapy units. The Company has established an accrual of $4.2 million for its indemnification obligations in connection with the July 2012 verdict described in the third paragraph below; however, actual liability in this case could be higher or lower than the amount accrued. The Company has not established any accrual in connection with its other indemnification obligations under the Breg SPA, and currently cannot reasonably estimate the possible loss, or range of loss, in connection with certain of such obligations (including with respect to the matters described in the three paragraphs below).
	Breg was engaged in the manufacturing and sale of local infusion pumps for pain management from 1999 to 2008. Since 2008, numerous product liability cases have been filed in the United States alleging that the local anesthetic, when dispensed by such infusion pumps inside a joint, causes a rare arthritic condition called “chondrolysis.” The Company incurred losses for settlements and judgments in connection with these matters during 2011, 2012 and 2013 for $1.8 million, $6.8 million and $6.7 million, respectively. In addition, several cases remain outstanding for which the Company currently cannot reasonably estimate the possible loss, or range of loss.
	On or about August 2, 2010, Breg received a HIPAA subpoena issued by the DOJ. The subpoena seeks documents from the Company and its subsidiaries for the period of January 1, 2000 through the date of the subpoena. The Company believes that document production in response to the subpoena was completed as of July 2012. It believes that this subpoena relates to an investigation by the DOJ into whether Breg’s sale, marketing and labeling of local infusion pumps for pain management, prior to Breg’s divestiture of this product line in 2008, complied with FDA regulations and federal law. The Company is currently cooperating with the U.S. government in connection with this matter.
	At the time of its divestiture by the Company, Breg was currently and had been engaged in the manufacturing and sales of motorized cold therapy units used to reduce pain and swelling. Several domestic product liability cases have been filed in recent years, mostly in California state court, alleging that the use of cold therapy causes skin and/or nerve injury and seeking damages on behalf of individual plaintiffs who were allegedly injured by such units. The majority of these cases are at an early stage and no conclusion can be drawn at the present time regarding their potential outcome. However, the Company believes that meritorious defenses exist to these claims. In July 2012, a jury in one case related to a motorized cold therapy unit previously sold by Breg returned a verdict providing for approximately $2.1 million in compensatory damages to the plaintiff against Breg and $7 million in exemplary damages. The case remains subject to appeal. The Company believes that the damages are without merit; however, the ultimate outcome is uncertain. The Company previously established an accrual and related charge to discontinued operations of $4.2 million for both compensatory damages and exemplary damages for its indemnification obligations in connection with this July 2012 verdict; however, actual liability in this case could be higher or lower than the amount accrued.

Pensions_and_deferred_compensa

Pensions and deferred compensation	12 Months Ended
	Dec. 31, 2013
Compensation And Retirement Disclosure [Abstract]	'
Pensions and deferred compensation	'
	18	Pensions and deferred compensation
	Orthofix Inc. sponsors a defined contribution plan (the “Orthofix Inc. 401(k) Plan”) covering substantially all full time US employees. The Orthofix Inc. 401(k) Plan allows for participants to contribute up to 15% of their pre-tax compensation, subject to certain limitations, with the Company matching 100% of the first 2% of the employee’s base compensation and 50% of the next 4% of the employee’s base compensation if contributed to the Orthofix Inc. 401(k) Plan. During the years ended December 31, 2013, 2012 and 2011, expenses incurred relating to 401(k) Plans, including matching contributions, were approximately $2.4 million, $2.5 million and $2.5 million, respectively.
	The Company operates defined contribution pension plans for its other International employees not described above meeting minimum service requirements. The Company’s expenses for such pension contributions during 2013, 2012 and 2011 were $0.7 million, $0.7 million and $0.8 million, respectively.
	Under Italian Law, Orthofix S.r.l. accrues, on behalf of its employees, deferred compensation, which is paid on termination of employment. Each year’s provision for deferred compensation is based on a percentage of the employee’s current annual remuneration plus an annual charge. Deferred compensation is also accrued for the leaving indemnity payable to agents in case of dismissal which is regulated by a national contract and is equal to approximately 3.5% of total commissions earned from the Company.
	The Orthofix Deferred Compensation Plan (the “Plan”), administered by the Board of Directors of the Company, effective January 1, 2007, and as amended and restated effective January 1, 2009, is a plan intended to allow a select group of key management and highly compensated employees of the Company to defer the receipt of compensation that would otherwise be payable to them. The terms of this plan are intended to comply in all respects with the provisions of Code Section 409A and Code Section 457A. As of January 1, 2011 the Company disallowed further contributions into the plan and any new plan participants. Distributions are made in accordance with the requirements of Code Section 409A.
	The Company’s expense for deferred compensation during 2013, 2012 and 2011 was approximately $0.3 million, $0.4 million and $0.1 million, respectively. Deferred compensation payments of $0.1 million and $0.8 million were made in 2013 and 2012, respectively, and no deferred compensation payments were made in 2011. The balance as of December 31, 2013 and 2012 was $2.5 and $2.3 million that represents the amount which would be payable if all the employees and agents had terminated employment at that date and is included in other long-term liabilities.

Sharebased_compensation_plans

Share-based compensation plans	12 Months Ended
	Dec. 31, 2013
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]	'
Share-based compensation plans	'
	19	Share-based compensation plans
	At December 31, 2013, the Company had stock option and award plans, and an employee stock purchase plan which are described below.
	2012 Long Term Incentive Plan
	The Board of Directors adopted the Orthofix International N.V. 2012 Long-Term Incentive Plan (the “2012 LTIP”) on April 13, 2012, subject to shareholder approval which was subsequently provided by shareholder ratification. The 2012 LTIP provides for the grant of options to purchase shares of the Company’s common stock, stock awards (including restricted stock, unrestricted stock, and stock units), stock appreciation rights, performance-based awards and other equity-based awards. All of the Company’s employees and the employees of the Company’s subsidiaries and affiliates are eligible to receive awards under the 2012 LTIP. In addition, the Company’s non-employee directors and consultants and advisors who perform services for the Company and the Company’s subsidiaries and affiliates may receive awards under the 2012 LTIP. Incentive share options, however, are only available to the Company’s employees. The Company reserves a total of 1,600,000 shares of common stock for issuance pursuant to the 2012 LTIP, subject to certain adjustments set forth in the 2012 LTIP. At December 31, 2013, there were 515,917 options outstanding under the 2012 LTIP Plan, of which 22,668 were exercisable; in addition, there were 279,039 shares of restricted stock outstanding, none of which were vested.
	2004 Long Term Incentive Plan
	The 2004 Long Term Incentive Plan (the “2004 LTIP Plan”) reserves 3.1 million shares for issuance (in addition to shares (i) available for future awards as of June 29, 2004 under prior plans or (ii) that become available for future issuance upon the expiration or forfeiture after June 29, 2004 of awards upon prior plans). Awards generally vest on years of service with all awards fully vesting within three years from the date of grant for employees and either three or five years from the date of grant for non-employee directors. Awards can be in the form of a stock option, restricted stock, restricted share unit, performance share unit, or other award form determined by the Board of Directors. Awards granted under the 2004 LTIP Plan expire no later than ten years after the date of the grant. The 2004 LTIP Plan provides an annual grant to non-employee directors of 5,000 shares and limits the future the number of shares that may be awarded under the plan as full value awards to 100,000 shares. At December 31, 2013, there were 1,243,262 options outstanding under the 2004 LTIP Plan, of which 1,179,601 were exercisable; in addition, there were 7,665 shares of restricted stock outstanding, none of which were vested.
	Staff Share Option Plan
	The Staff Share Stock Option Plan (the “Staff Share Plan”) is a fixed stock option plan which was adopted in April 1992. Under the Staff Share Plan, the Company granted options to its employees at the estimated fair market value of such options at the date of grant. Options generally vest based on years of service with all options to be fully vested within five years from date of grant. Options granted under the Staff Share Plan expire ten years after the date of grant. There are no options left to be granted under the Staff Plan. At December 31, 2013, there were 15,000 options outstanding and exercisable under the Staff Share Plan.
	Stock Purchase Plan
	The Orthofix International N.V. Amended and Restated Stock Purchase Plan (the “Stock Purchase Plan”) provides for the issuance of shares of the Company’s common stock to eligible employees and directors of the Company and its subsidiaries that elect to participate in the plan and acquire shares of common stock through payroll deductions (including executive officers).
	During each purchase period, eligible employees may designate between 1% and 25% of their compensation to be deducted for the purchase of common stock under the plan (up to 25% for employees working in North America, South America and Asia, and up to 15% for employees working in Europe). For eligible directors, the designated percentage will be an amount equal to his or her annual or other director compensation paid in cash for the current plan year. The purchase price of the shares under the plan is equal to 85% of the fair market value on the first day of the plan year (which is a calendar year, running from January 1 to December 31) or, if lower, on the last day of the plan year.
	Due to the compensatory nature of such plan, the Company has recorded the related share based compensation in the consolidated statement of operations. The aggregate number of shares reserved for issuance under the Employee Stock Purchase Plan is 1,850,000 shares. As of December 31, 2013, 1,437,519 shares had been issued under the Stock Purchase Plan.
	Share-Based Compensation:
	As of December 31, 2013, the unamortized compensation expense relating to options granted and expected to be recognized was $2.8 million. This amount is expected to be recognized through January 2018. The following table shows the detail of share-based compensation by line item in the consolidated statements of operations for the years ended December 31, 2013, 2012 and 2011 and the assumptions for each of these years in which grants were awarded:
	(U.S. Dollars in thousands, except assumptions)		Year Ended			Year Ended			Year Ended
			December 31,			December 31,			December 31,
			2013			2012			2011
	Cost of sales		$	104		$	592		$	153
	Sales and marketing			1,444			1,550			2,031
	General and administrative			4,483			4,023			4,322
	Research and development			236			138			142
	Total		$	6,267		$	6,303		$	6,648
	Assumptions:
	Expected term			5.00 years			4.50 years			4.58 years
	Expected volatility			32.1% – 50.8	%		50.9% – 51.8	%		49.6% – 49.9	%
	Risk free interest rate			0.58% – 1.52	%		0.76% – 0.84	%		.90% – 2.26	%
	Dividend rate			—			—			—
	Weighted average fair value of options granted during the year		$	10.83		$	16.99		$	14.21
	Stock Option Activity:
	Summaries of the status of the Company’s stock option plans as of December 31, 2013 and 2012 and changes during the year ended December 31, 2013 are presented below:
			Options			Weighted Average			Weighted
						Exercise Price			Average
									Remaining
									Contractual
									Term
	Outstanding at December 31, 2012			1,945,955		$	34.5
	Granted			466,250		$	28.51
	Exercised			(79,949	)	$	23.25
	Forfeited			(408,077	)	$	36.33
	Outstanding at December 31, 2013			1,924,179		$	33.12			4.41
	Vested and expected to vest at December 31, 2013			1,839,383		$	33.5			4.17
	Options exercisable at December 31, 2013			1,367,269		$	34.35			2.89
	Outstanding and exercisable by price range as of December 31, 2013
			Options Outstanding									Options Exercisable
	Range of Exercise Prices		Number			Weighted			Weighted			Number		Weighted
			Outstanding			Average			Average			Exercisable		Average
						Remaining			Exercise					Exercise
						Contractual			Price					Price
						Life
	$10.42 – $21.78			232,250			9.31		$	20.79			16,000	$	13.31
	$22.75 – $25.05			326,166			4.1		$	24.73			306,166	$	24.84
	$26.79 – $28.95			230,000			4.79		$	28.45			170,000	$	28.65
	$29.23 – $37.36			225,168			5.1		$	33.14			169,839	$	32.41
	$37.76 – $38.11			230,975			1.69		$	37.99			230,975	$	37.99
	$38.40 – $40.27			351,354			3.17		$	39.76			174,355	$	39.77
	$41.33 – $43.04			178,633			2.84		$	41.66			150,301	$	41.72
	$44.87 – $45.84			140,133			3.05		$	45.02			140,133	$	45.02
	$50.50 – $50.50			2,000			3.01		$	50.5			2,000	$	50.5
	$50.99 – $50.99			7,500			3.04		$	50.99			7,500	$	50.99
	$10.42 – $50.99			1,924,179			4.41		$	33.12			1,367,269	$	34.35
	The weighted average remaining contractual life of exercisable options was 2.89 years at December 31, 2013. The total intrinsic value of options exercised was $0.4 million, $7.2 million and $4.2 million for the years ended December 31, 2013, 2012 and 2011, respectively. The aggregate intrinsic value of options outstanding and options exercisable as of December 31, 2013 is calculated as the difference between the exercise price of the underlying options and the market price of the Company’s common stock for the shares that had exercise prices that were lower than the $22.82 closing price of the Company’s stock on December 31, 2013. The aggregate intrinsic value of options outstanding was $0.5 million, $11.2 million and $10.8 million for the years ended December 31, 2013, 2012, and 2011, respectively. The aggregate intrinsic value of options exercisable was $0.2 million, $9.8 million and $8.4 million for the years ended December 31, 2013, 2012 and 2011, respectively.
	Restricted Stock:
	During the year ended December 31, 2013, the Company granted to employees and non-employee directors 269,791 shares of restricted stock, which vest at various dates through October 2017. During the year ended December 31, 2012, the Company granted to employees and non-employee directors 149,500 shares of restricted stock, which vest at various dates through November 2015. The compensation expense, which represents the fair value of the stock measured at the market price at the date of grant, less estimated forfeitures, is recognized on a straight-line basis over the vesting period. Unamortized compensation expense related to restricted stock amounted to $6.7 million at December 31, 2013.
A summary of the status of our restricted stock as of December 31, 2013 and 2012 and changes during the year ended December 31, 2013 are presented below:
		Shares			Weighted
					Average Grant
					Date Fair Value
Non-vested as of December 31, 2012			160,831		$	38.34
Granted			269,791		$	27.09
Vested			(62,948	)	$	36.58
Cancelled			(80,970	)	$	38.8
Non-vested as of December 31, 2013			286,704		$	28.01

Earnings_per_share

Earnings per share	12 Months Ended
	Dec. 31, 2013
Earnings Per Share [Abstract]	'
Earnings per share	'
	20	Earnings per share
	For each of the three years ended December 31, 2013, there were no adjustments to net income (loss) for purposes of calculating basic and diluted net income (loss) available to common shareholders. The following is a reconciliation of the weighted average shares used in the basic and diluted net income (loss) per common share computations.
			Year Ended December 31,
			2013		2012		2011
	Weighted average common shares-basic			18,697,228		18,977,263		18,219,343
	Effect of diluted securities:
	Unexercised stock options net of treasury share repurchase			—		413,150		—
	Weighted average common shares-diluted			18,697,228		19,390,413		18,219,343
	No adjustment has been made in 2013 or 2011 for any common stock equivalents because their effects would be anti-dilutive. For 2013 and 2011, potentially dilutive shares totaled 101,672 and 344,168, respectively.
	Options to purchase shares of common stock with exercise prices in excess of the average market price of common shares are not included in the computation of diluted earnings per share. There were 1,186,259 and 789,650 outstanding options not included in the diluted earnings per share computation for the fiscal year ended December 31, 2013 and 2012, respectively, because the inclusion of these options was anti-dilutive.

Stock_Repurchase_Program

Stock Repurchase Program	12 Months Ended
	Dec. 31, 2013
Text Block [Abstract]	'
Stock Repurchase Program	'
	21	Stock Repurchase Program
	On May 8, 2013, the Company announced that the Board of Directors had authorized a share repurchase program in an amount up to $50 million. Repurchases began on May 10, 2013 consisting primarily of open market transactions at prevailing market prices in accordance with the guidelines specified under Rule 10b-18 of the Securities Exchange Act of 1934, as amended. Repurchases are being made from cash on hand, cash generated from operations and additional borrowings. The timing of the transactions and the aggregate number of shares of common stock that will be ultimately repurchased under the repurchase program will depend on a variety of factors, including market conditions and the prices at which the securities are repurchased. The Company may discontinue repurchases without prior notice at any time if the Company determines additional repurchases are not warranted. The Company made total repurchases in 2013 of $39.5 million.

Quarterly_financial_data_unaud

Quarterly financial data (unaudited)	12 Months Ended
	Dec. 31, 2013
Quarterly Financial Information Disclosure [Abstract]	'
Quarterly financial data (unaudited)	'
	22	Quarterly financial data (unaudited)
	We have restated all quarterly periods of 2012 as well as the first quarter of 2013, to reflect the restatement described herein. See “Note 2—Restatement of the Consolidated Financial Statements.” The following tables summarize the impacts of the restatement on our previously reported condensed consolidated statements of operations and balance sheets included in our Quarterly Reports on Form 10-Q for each respective period.
	Condensed Consolidated Statement of Operations
	As Restated or Currently Reported
	(U.S. Dollars, in thousands, except per share data)
			1st			2nd			3rd			4th			Year
			Quarter			Quarter			Quarter			Quarter
			(Restated)
	2013
	Net sales		$	103,373		$	98,280		$	92,738		$	106,143		$	400,534
	Cost of sales			25,617			20,246			23,920			32,517			102,300
	Gross profit			77,756			78,034			68,818			73,626			298,234
	Operating Expense			69,669			69,230			84,418			80,004			303,321
	Operating Income (loss)			8,087			8,804			(15,600	)		(6,378	)		(5,087	)
	Net income (loss) from continuing operations			7,610			4,130			(18,084	)		(8,564	)		(14,908	)
	Net income (loss)		$	4,500		$	(2,317	)	$	(19,822	)	$	(7,876	)	$	(25,515	)
	Net income (loss) per common share:
	Basic:
	Net income (loss) from continuing operations		$	0.39		$	0.22		$	(1.00	)	$	(0.47	)	$	(0.80	)
	Net income (loss)		$	0.23		$	(0.12	)	$	(1.10	)	$	(0.43	)	$	(1.37	)
	Diluted:
	Net income (loss) from continuing operations		$	0.39		$	0.21		$	(1.00	)	$	(0.47	)	$	(0.80	)
	Net income (loss)		$	0.23		$	(0.12	)	$	(1.10	)	$	(0.43	)	$	(1.37	)
			(Restated)			(Restated)			(Restated)			(Restated)			(Restated)
	2012
	Net sales		$	108,936		$	113,423		$	107,857		$	117,365		$	447,581
	Cost of sales			21,378			27,547			24,384			24,944			98,253
	Gross profit			87,558			85,876			83,473			92,421			349,328
	Operating Expense			69,638			71,578			64,668			66,808			272,692
	Operating Income			17,920			14,298			18,805			25,613			76,636
	Net income from continuing operations			8,597			9,870			10,574			16,009			45,050
	Net income		$	9,407		$	7,254		$	5,016		$	21,161		$	42,838
	Net income (loss) per common share:
	Basic:
	Net income from continuing operations		$	0.46		$	0.52		$	0.55		$	0.83		$	2.37
	Net income		$	0.5		$	0.38		$	0.26		$	1.1		$	2.25
	Diluted:
	Net income from continuing operations		$	0.45		$	0.51		$	0.54		$	0.81		$	2.32
	Net income		$	0.49		$	0.37		$	0.25		$	1.07		$	2.21
	Condensed Consolidated Statement of Operations
	As Previously Reported
	(U.S. Dollars, in thousands, except per share data)
			1st			2nd			3rd			4th			Year
			Quarter			Quarter			Quarter			Quarter
	2013 (1)
	Net sales		$	100,254
	Cost of sales			22,699
	Gross profit			77,555
	Operating Expense			73,531
	Operating Income			4,024
	Net income from continuing operations			4,908
	Net income		$	2,116
	Net income (loss) per common share:
	Basic:
	Net income from continuing operations		$	0.25
	Net income		$	0.11
	Diluted:
	Net income from continuing operations		$	0.25
	Net income		$	0.11
	2012
	Net sales		$	116,041		$	119,492		$	114,752		$	112,035		$	462,320
	Cost of sales			21,939			23,676			22,373			18,504			86,492
	Gross profit			94,102			95,816			92,379			93,531			375,828
Operating Expense			71,671			75,251			70,846			69,050			286,818
Operating Income			22,431			20,565			21,533			24,481			89,010
Net income from continuing operations			12,215			13,967			13,118			14,636			53,936
Net income		$	12,016		$	11,205		$	7,560		$	20,514		$	51,295
Net income (loss) per common share:
Basic:
Net income from continuing operations		$	0.65		$	0.74		$	0.69		$	0.76		$	2.84
Net income		$	0.64		$	0.59		$	0.4		$	1.06		$	2.7
Diluted:
Net income from continuing operations		$	0.64		$	0.73		$	0.67		$	0.74		$	2.78
Net income		$	0.63		$	0.58		$	0.39		$	1.04		$	2.64
-1	Q2-Q4 2013 was not previously reported.
Condensed Consolidated Statement of Operations
Restatement Adjustments
(U.S. Dollars, in thousands, except per share data)
		1st			2nd			3rd			4th			Year
		Quarter			Quarter			Quarter			Quarter
2013 (1)
Net sales		$	3,119
Cost of sales			2,918
Gross profit			201
Operating Expense			(3,862	)
Operating Income			4,063
Net income from continuing operations			2,702
Net income		$	2,384
Net income (loss) per common share:
Basic:
Net income from continuing operations		$	0.14
Net income		$	0.12
Diluted:
Net income from continuing operations		$	0.14
Net income		$	0.12
2012
Net sales		$	(7,105	)	$	(6,069	)	$	(6,895	)	$	5,330		$	(14,739	)
Cost of sales			(561	)		3,871			2,011			6,440			11,761
Gross profit			(6,544	)		(9,940	)		(8,906	)		(1,110	)		(26,500	)
Operating Expense			(2,033	)		(3,673	)		(6,178	)		(2,242	)		(14,126	)
Operating Income			(4,511	)		(6,267	)		(2,728	)		1,132			(12,374	)
Net income (loss) from continuing operations			(3,618	)		(4,097	)		(2,544	)		1,373			(8,886	)
Net (loss) income		$	(2,609	)	$	(3,951	)	$	(2,544	)	$	647		$	(8,457	)
Net income (loss) per common share:
Basic:
Net income (loss) from continuing operations		$	(0.19	)	$	(0.22	)	$	(0.14	)	$	0.07		$	(0.47	)
Net income (loss)		$	(0.14	)	$	(0.21	)	$	(0.14	)	$	0.04		$	(0.45	)
Diluted:
Net income (loss) from continuing operations		$	(0.19	)	$	(0.22	)	$	(0.13	)	$	0.07		$	(0.46	)
Net income (loss)		$	(0.14	)	$	(0.21	)	$	(0.14	)	$	0.03		$	(0.43	)
-1	Q2-Q4 2013 was not previously reported and therefore does not have restatement adjustments.
Condensed Consolidated Balance Sheets
As Restated or Currently Reported
(U.S. Dollars, in thousands, except share and per share data)		1st			2nd			3rd			4th
		Quarter			Quarter			Quarter			Quarter
		(Restated)
2013
Total assets		$	475,758		$	459,450		$	430,058		$	423,182
Total liabilities			102,366			114,223			111,001			115,919
Total shareholders’ equity			373,392			345,227			319,057			310,494
Total liabilities and shareholders’ equity		$	475,758		$	459,450		$	430,058		$	423,182
2012		(Restated)			(Restated)			(Restated)			(Restated)
Total assets		$	694,106		$	530,395		$	539,566		$	472,897
Total liabilities			381,734			205,196			193,599			105,065
Total shareholders’ equity			312,372			325,199			345,967			367,832
Total liabilities and shareholders’ equity		$	694,106		$	530,395		$	539,566		$	472,897
Condensed Consolidated Balance Sheets
As Previously Reported
(U.S. Dollars, in thousands, except share and per share data)		1st			2nd			3rd			4th
		Quarter			Quarter			Quarter			Quarter
2013 (1)
Total assets		$	503,380
Total liabilities			101,212
Total shareholders’ equity			402,168
Total liabilities and shareholders’ equity		$	503,380
2012
Total assets		$	707,586		$	553,320		$	565,073		$	504,281
Total liabilities			369,178			199,104			187,463			105,183
Total shareholders’ equity			338,408			354,216			377,610			399,098
Total liabilities and shareholders’ equity		$	707,586		$	553,320		$	565,073		$	504,281
(1) Q2-Q4 2013 was not previously reported.
Condensed Consolidated Balance Sheets
Restatement Adjustments
(U.S. Dollars, in thousands, except share and per share data)		1st			2nd			3rd			4th
		Quarter			Quarter			Quarter			Quarter
2013 (1)
Total assets		$	(27,622	)
Total liabilities			1,154
Total shareholders’ equity			(28,776	)
Total liabilities and shareholders’ equity		$	(27,622	)
2012
Total assets		$	(13,480	)	$	(22,925	)	$	(25,507	)	$	(31,384	)
Total liabilities			12,556			6,092			6,136			(118	)
Total shareholders’ equity			(26,036	)		(29,017	)		(31,643	)		(31,266	)
Total liabilities and shareholders’ equity		$	(13,480	)	$	(22,925	)	$	(25,507	)	$	(31,384	)
-1	Q2-Q4 2013 was not previously reported and therefore does not have restatement adjustments.

Schedule_1Condensed_Financial_

Schedule 1-Condensed Financial Information of Registrant Orthofix International N.V.	12 Months Ended
	Dec. 31, 2013
Condensed Financial Information Of Parent Company Only Disclosure [Abstract]	'
Schedule 1-Condensed Financial Information of Registrant Orthofix International N.V.	'
	Schedule 1—Condensed Financial Information of Registrant Orthofix International N.V.
	Condensed Balance Sheets (unaudited)
	(U.S. Dollars in thousands)		December 31,			December 31,
			2013			2012
						(Restated)
	Assets
	Current assets:
	Cash and cash equivalents		$	1,426		$	7,392
	Prepaid expenses and other current assets			670			534
	Total current assets			2,096			7,926
	Other long term assets			—			15
	Investments in and amounts due from subsidiaries and affiliates			322,804			369,204
	Total assets		$	324,900		$	377,145
	Liabilities and shareholder’s equity
	Current liabilities		$	6,295		$	1,202
	Long-term liabilities			8,111			8,111
	Shareholder’s equity:
	Common stock			1,810			1,934
	Additional paid in capital			216,653			246,306
	Accumulated earnings			89,332			114,847
	Accumulated other comprehensive income			2,699			4,745
				310,494			367,832
	Total liabilities and shareholder’s equity		$	324,900		$	377,145
	See accompanying notes to condensed financial statements.
	Orthofix International N.V.
	Schedule 1—Condensed Financial Information of Registrant Orthofix International N.V.
	Condensed Statements of Operations (unaudited)
	(U.S. Dollars in thousands)		Year Ended			Year Ended			Year Ended
			December 31,			December 31,			December 31,
			2013			2012			2011
						(Restated)			(Restated)
	(Expenses) income:
	General and administrative		$	(16,641	)	$	(7,700	)	$	(11,134	)
	Equity in earnings of investments in subsidiaries and affiliates			(9,197	)		50,317			(6,296	)
	Other, net			323			24			7
	(Loss) income before income taxes			(25,515	)		42,641			(17,423	)
	Income tax benefit (expense)			—			197			(687	)
	Net (loss) income		$	(25,515	)	$	42,838		$	(18,110	)
	See accompanying notes to condensed financial statements.
	Orthofix International N.V.
	Schedule 1—Condensed Financial Information of Registrant Orthofix International N.V.
	Condensed Statement of Cash Flows (unaudited)
	(U.S. Dollars in thousands)		Year Ended			Year Ended			Year Ended
			December 31,			December 31,			December 31,
			2013			2012			2011
						(Restated)			(Restated)
	Net income (loss)		$	(25,515	)	$	42,838		$	(18,110	)
	Equity in earnings of (loss) investments in subsidiaries and affiliates			9,197			(50,317	)		6,296
	Cash used in provided by other operating activities			468			(6,811	)		3,429
	Net cash used in operating activities			(15,850	)		(14,290	)		(8,385	)
	Cash flows from investing activities:
	Distributions and amounts received from subsidiaries			53,389			12,564			5,875
	Capital expenditures			—			—			—
	Net cash used in provided by investing activities			53,389			12,564			5,875
	Cash flows from financing activities:
	Net proceeds from issuance of common stock			3,450			25,586			20,113
	Repurchase of treasury shares			(39,494	)		—			—
	Contributions to subsidiaries and affiliates			(7,543	)		(36,921	)		(2,789	)
	Tax benefit on exercise of stock options			82			1,020			1,737
	Net cash provided by financing activities			(43,505	)		(10,315	)		19,061
	Net increase (decrease) in cash and cash equivalents			(5,966	)		(12,041	)		16,551
	Cash and cash equivalents at the beginning of the year			7,392			19,433			2,882
	Cash and cash equivalents at the end of the year		$	1,426		$	7,392		$	19,433
See accompanying notes to condensed financial statements.
Orthofix International N.V.
Schedule 1—Condensed Financial Information of Registrant Orthofix International N.V.
Notes to Condensed Financial Statements (unaudited)
1	Background and basis of presentation
These condensed parent company financial statements have been prepared in accordance with Rule 12-04, Schedule 1 of Regulation S-X, as the restricted net assets of Orthofix Holdings, Inc. and its subsidiaries exceed 25% of the consolidated net assets of Orthofix International N.V. and its subsidiaries (the “Company”). This information should be read in conjunction with the Company’s consolidated financial statements included elsewhere in this filing.
2	Restricted net assets of subsidiaries
Certain of the Company’s subsidiaries have restrictions on their ability to pay dividends or make intercompany loans and advances pursuant to their financing arrangements. The amount of restricted net assets the Company’s subsidiaries held at December 31, 2013 and 2012 was approximately $192.0 million and $213.4 million, respectively. Such restrictions are on net assets of Orthofix Holdings, Inc. and its subsidiaries.
3	Commitments, contingencies and long-term obligations
For a discussion of the Company’s commitments, contingencies and long term obligations under its senior secured credit facility, see Note 9, Note 12 and Note 17 of the Company’s consolidated financial statements.
4	Dividends from subsidiaries
Orthofix International N.V. did not receive cash dividends in 2013 or 2012.

Schedule_2Valuation_and_Qualif

Schedule 2-Valuation and Qualifying Accounts	12 Months Ended
	Dec. 31, 2013
Valuation And Qualifying Accounts [Abstract]	'
Schedule 2-Valuation and Qualifying Accounts	'
	Schedule 2—Valuation and Qualifying Accounts
	For the years ended December 31, 2013, 2012 and 2011:
				Additions
	(U.S. Dollars in thousands)	Balance at		Charged to			Charged			Deductions/			Balance at
		beginning		cost and			(credited)			Other			end of year
	Provisions from assets to which they apply:	of year		expenses			to other
							accounts
	2013
	Allowance for doubtful accounts receivable	$	13,543	$	6,003			—		$	(7,577	)	$	11,969
	Deferred tax valuation allowance		26,361		5,111			—			—			31,472
	2012 (Restated)
	Allowance for doubtful accounts receivable	$	9,341	$	10,387		$	(13	)	$	(6,172	)	$	13,543
	Deferred tax valuation allowance		19,124		7,237			—			—			26,361
	2011 (Restated)
	Allowance for doubtful accounts receivable	$	6,542	$	12,879		$	(501	)	$	(9,579	)	$	9,341
	Deferred tax valuation allowance		21,023		(1,899	)		—			—			19,124

Summary_of_significant_account1

Summary of significant accounting policies (Policies)	12 Months Ended
	Dec. 31, 2013
Accounting Policies [Abstract]	'
Basis of consolidation	'
		(a)	Basis of consolidation
	The consolidated financial statements include the financial statements of the Company and its wholly owned and majority-owned subsidiaries and entities over which the Company has control.
	All intercompany accounts, transactions and profits are eliminated in the consolidated financial statements on a continuing operations basis unless otherwise noted.
Reclassifications	'
		(b)	Reclassifications
	The Company has reclassified certain line items to conform to the current year presentation. The reclassifications have no effect on previously reported net earnings or shareholders’ equity.
Use of estimates in preparation of financial statements	'
		(c)	Use of estimates in preparation of financial statements
	The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. On an ongoing basis, we evaluate our estimates, including those related to the recoverability and useful lives of long-lived assets and the adequacy of the allowance for doubtful accounts and inventory obsolescence, and income taxes. We base our estimates on historical experience, future expectations and on other relevant assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates.
Foreign currency translation	'
		(d)	Foreign currency translation
	The financial statements for operations outside the United States are generally maintained in their local currency. All foreign currency denominated balance sheet accounts, except shareholders’ equity, are translated to U.S. dollars at year end exchange rates and revenue and expense items are translated at weighted average rates of exchange prevailing during the year. Gains and losses resulting from the translation of foreign currency are recorded in the accumulated other comprehensive income component of shareholders’ equity. Transactional foreign currency gains and (losses), including those generated from intercompany operations, are included in other expense, net and were $0.7 million loss, $0.5 million loss and $1.6 million loss for the years ended December 31, 2013, 2012 and 2011, respectively.
Cash and cash equivalents	'
		(e)	Cash and cash equivalents
	The Company considers all highly liquid investments with an original maturity of three months or less at the date of purchase to be cash equivalents.
Restricted cash	'
		(f)	Restricted cash
	Restricted cash consists of cash held at certain subsidiaries, the distribution or transfer of which to Orthofix International N.V. (the “Parent”) or other subsidiaries that are not parties to the credit facility described in Note 9 is restricted. The senior secured credit facility restricts the Parent and subsidiaries that are not parties to the facility from access to cash held by Orthofix Holdings, Inc. and its subsidiaries. All credit party subsidiaries have access to this cash for operational and debt repayment purposes.
Market risk	'
		(g)	Market risk
	In the ordinary course of business, the Company is exposed to the impact of changes in interest rates and foreign currency fluctuations. The Company’s objective is to limit the impact of such movements on earnings and cash flows. In order to achieve this objective, the Company seeks to balance its non-U.S. dollar denominated income and expenditures. During 2013, 2012 and 2011, the Company made use of a foreign currency swap agreement to manage cash flow exposure generated from foreign currency fluctuations.
	The Company generally does not require collateral on trade receivables.
Inventories	'
		(h)	Inventories
	Inventories are valued at the lower of cost or estimated net realizable value, after provision for excess, obsolete or impaired items which is reviewed and updated on a periodic basis by management. For inventory procured or produced, whether internally or through contract manufacturing arrangements, at our manufacturing facility in Italy, cost is determined on a weighted-average basis, which approximates the first-in, first-out (“FIFO”) method, due to the high turn-over rate of inventory at this location. For inventory procured or produced, whether internally or through contract manufacturing arrangements, at our manufacturing facility in Texas, standard costs, which approximates actual cost on the FIFO method, is used to value inventory. Standard costs are reviewed annually by management, or more often in the event circumstances indicate a change in cost has occurred. The valuation of work-in-process, finished products, field inventory and consignment inventory includes the cost of materials, labor and other production costs. Field inventory represents immediately saleable finished products inventory that is in the possession of the Company’s direct sales representatives. Consignment inventory represents immediately saleable finished products located at third party customers, such as distributors and hospitals.
Long-lived assets, including intangibles	'
		(i)	Long-lived assets, including intangibles
	Property, plant and equipment is stated at cost less accumulated depreciation. Costs include all expenditures necessary to place the asset in service, including freight and sales and use taxes. Plant and equipment also includes instrumentation held by customers and is generally used to facilitate the implantation of the Company’s products, the associated cost and accumulated depreciation as of December 31, 2013 was $54.9 million and ($33.7 million), respectively. Depreciation is computed on a straight-line basis over the useful lives of the assets. Depreciation of leasehold improvements is computed over the shorter of the lease term or the useful life of the asset. The useful lives are as follows:
			Years
	Buildings			25 to 33
	Plant equipment and instrumentation			2 to 10
	Furniture and fixtures			4 to 8
	Expenditures for maintenance and repairs and minor renewals and improvements, which do not extend the lives of the respective assets, are expensed as incurred. All other expenditures for renewals and improvements are capitalized. The assets and related accumulated depreciation are adjusted for property retirements and disposals, with the resulting gain or loss included in operations. Fully depreciated assets remain in the accounts until retired from service.
	Patents and other intangible assets are recorded at cost, or when acquired as a part of a business combination at estimated fair value. These assets primarily include patents and other technology agreements (“developed technologies”) and trademarks. Identifiable intangible assets which are considered definite lived are amortized over their useful lives using a method of amortization that reflects the pattern in which the economic benefit of the intangible assets is consumed. The Company’s weighted average amortization period for developed technologies is 11 years.
	Intangible and long-lived assets with definite lives, such as developed technologies, are tested for impairment if any adverse conditions exist or change in circumstances have occurred that would indicate impairment or a change in the remaining useful life. If an impairment indicator exists, the Company tests the intangible asset for recoverability. For purposes of the recoverability test, the Company groups its intangible assets with other assets and liabilities at the lowest level of identifiable cash flows if the intangible asset does not generate cash flows independent of other assets and liabilities. If the carrying value of the intangible asset (asset group) exceeds the undiscounted cash flows expected to result from the use and eventual disposition of the intangible asset (asset group), the Company will write the carrying value down to the fair value in the period identified.
	The Company generally calculates fair value of indefinite-lived intangible assets as the present value of estimated future cash flows. In determining the estimated future cash flows associated with intangible assets, the Company uses estimates and assumptions about future revenue contributions, cost structures and remaining useful lives of the asset (asset group). The use of alternative assumptions, including estimated cash flows, discount rates, and alternative estimated remaining useful lives could result in different calculations of impairment.
Goodwill	'
	(j)	Goodwill
	The Company tests goodwill at least annually for impairment. The Company tests more frequently if indicators are present or changes in circumstances suggest that impairment may exist. These indicators include, among others, declines in sales, earnings or cash flows, or the development of a material adverse change in the business climate. The Company assesses goodwill for impairment at the reporting unit level, which is defined as an operating segment or one level below an operating segment, referred to as a component. The Company has identified four reporting units, which are consistent with the Company’s reporting segments; BioStim, Biologics, Extremity Fixation, and Spine Fixation.
	In order to calculate the respective carrying values, the Company initially recorded goodwill based on the purchase price allocation performed at the time of acquisition. Corporate assets and liabilities that directly relate to a reporting unit’s operations are ascribed directly to that reporting unit. Corporate assets and liabilities that are not directly related to a specific reporting unit, but from which the reporting unit benefits, are allocated based on the respective contribution measure of each reporting unit. Effective July 1, 2013, the Company re-aligned its reporting units and consequently reallocated the carrying value of goodwill from its previous reporting units to its new reporting units based on the relative fair value of each new reporting unit to total enterprise value at July 1, 2013.
	As a result of the Company’s change in reportable segments, the Company allocated goodwill to each reportable segment, and subsequently evaluated each reportable segment for possible impairment of goodwill, as there were indicators of impairment when completing a qualitative analysis. The result of this analysis was a full impairment of the goodwill allocated to our Extremity Fixation and our Spine Fixation reportable units, totaling $19.2 million.
	The Company’s annual goodwill impairment analysis, which was performed qualitatively during the fourth quarter of 2013, did not result in any additional impairment charge.
Derivative instruments	'
		(k)	Derivative instruments
	The Company manages its exposure to fluctuating cash flows resulting from changes in interest rates and foreign exchange within the consolidated financial statements according to its hedging policy. Under the policy, the Company may engage in non-leveraged transactions involving various financial derivative instruments to manage exposed positions. The policy requires the Company to formally document the relationship between the hedging instrument and hedged item, as well as its risk-management objective and strategy for undertaking the hedge transaction. For instruments designated as a cash flow hedge, the Company formally assesses (both at the hedge’s inception and on an ongoing basis) whether the derivative that is used in the hedging transaction has been effective in offsetting changes in the cash flows of the hedged item and whether such derivative may be expected to remain effective in future periods. If it is determined that a derivative is not (or has ceased to be) effective as a hedge, the Company will discontinue the related hedge accounting prospectively. Such a determination would be made when (1) the derivative is no longer effective in offsetting changes in the cash flows of the hedged item; (2) the derivative expires or is sold, terminated or exercised; or (3) management determines that designating the derivative as a hedging instrument is no longer appropriate. Ineffective portions of changes in the fair value of cash flow hedges are recognized in earnings.
	The Company records all derivatives as either assets or liabilities on the balance sheet at their respective fair values. For a cash flow hedge, the effective portion of the derivative’s change in fair value (i.e. gains or losses) is initially reported as a component of other comprehensive income, net of related taxes, and subsequently reclassified into net earnings when the hedged exposure is no longer effective.
	The Company utilizes a cross currency swap to manage its foreign currency exposure related to a portion of the Company’s intercompany receivable of a U.S. dollar functional currency subsidiary that is denominated in Euro. The cross currency swap has been accounted for as a cash flow hedge in accordance with ASC Topic 815, Derivatives and Hedging.
Accumulated other comprehensive income	'
	(l)	Accumulated other comprehensive income
	Accumulated other comprehensive income is comprised of foreign currency translation adjustments and the effective portion of the gain (loss) on the Company’s cross-currency swap, which is designated and accounted for as a cash flow hedge (see Note 10). The components of and changes in accumulated other comprehensive income are as follows:
	(U.S. Dollars in thousands)		Foreign Currency			Fair Value of			Accumulated Other
			Translation			Cross-			Comprehensive
			Adjustments			Currency Swaps			Income
	Balance at December 31, 2011 (Restated)		$	3,846		$	(132	)	$	3,714
	Unrealized gain on cross-currency swaps, net of taxes of $153			—			263			263
	Foreign currency translation adjustment (1)			768			—			768
	Balance at December 31, 2012 (Restated)			4,614			131			4,745
	Unrealized loss on cross-currency swaps, net of tax benefit of $164			—			(278	)		(278	)
	Foreign currency translation adjustment (1)			(1,768	)		—			(1,768	)
	Balance at December 31, 2013		$	2,846		$	(147	)	$	2,699
	-1	As the cash generally remains permanently invested in the non U.S. dollar denominated foreign subsidiaries, no deferred taxes are recognized on the related foreign currency translation adjustment.
Revenue recognition and accounts receivable	'
	(m)	Revenue recognition and accounts receivable
	Commercial revenue is related to the sale of the Company’s implant products, generally representing hospital customers. Revenues are recognized when these products have been utilized and a confirming purchase order has been received from the hospital.
	Revenue is derived from third-party payors, including commercial insurance carriers, health maintenance organizations, preferred provider organizations and governmental payors such as Medicare, in connection with the sale of our stimulation products. Revenue is recognized when the stimulation product is placed on or implanted in and accepted by the patient. Amounts paid by these third-party payors are generally based on fixed or allowable reimbursement rates. These revenues are recorded at the expected or pre-authorized reimbursement rates, net of any contractual allowances or adjustments. Certain billings are subject to review by the third-party payors and may be subject to adjustment.
	For distributor revenue, which is related primarily to implant products, the Company recognizes revenue either on a sell-in or sell-through basis depending on the specific circumstances of the distributor. In some cases the Company recognizes distributor revenue as title and risk of loss passes at either shipment from the Company’s facilities or receipt at the distributor’s facility, assuming all other revenue recognition criteria has been achieved (the “sell-in method”). Based on the results of the Independent Review, the Company determined in some cases the revenue recognition criteria for distributor sales were not satisfied at the time of shipment or receipt; specifically, the existence of extra-contractual terms or arrangements caused the Company not to meet the fixed or determinable criteria for revenue recognition in some cases, and in others collectability had not been established. In situations where we are unable to satisfy the requirements to recognize revenue on the sell-in method, we recognize revenue relating to distributor arrangements once the product is delivered to the end customer (the “sell-through method”). Because the Company does not have reliable information about when its distributors sell the product through to end customers, the Company uses cash collection from distributors as a basis for revenue recognition under the sell-through method. Although in many cases the Company is legally entitled to the accounts receivable at the time of shipment, the Company has not recognized accounts receivables or any corresponding deferred revenues associated with distributor transactions for which revenue is recognized on the sell-through method. Effective April 1, 2013, all distributor revenue is recognized on the sell-through basis.
	For distributors on the sell-in method prior to April 1, 2013, cost of sales is recognized upon shipment. For sell-through distributors, whose revenue is recognized upon cash receipt, the Company considers whether to match the related cost of sales expense with revenue or to recognize expense upon shipment. In making this assessment, the Company considers the financially viability of its distributors based on their creditworthiness to determine if collectability of amounts sufficient to realize the costs of the products shipped is reasonably assured at the time of shipment to these distributors. In instances where the distributor is determined to be financially viable, the Company defers the costs of sales until the revenue is recognized.
	Biologics revenue is primarily related to a collaborative arrangement with MTF. In 2008, the Company entered into a collaborative arrangement with MTF to develop and commercialize Trinity Evolution ®, a stem cell-based bone growth biologic matrix. With the development process completed in 2009, the Company and MTF operated under the terms of a separate commercialization agreement. Under the terms of the 10-year agreement, MTF sourced the tissue, processed it to create the bone growth matrix, packaged and delivered it to the customer in accordance with orders received from the Company. The Company has exclusive global marketing rights for Trinity Evolution ® and receives marketing fees from MTF based on total sales. These marketing fees are recorded on a net basis within net sales and were $47.7 million, $46.5 million and $36.8 million in 2013, 2012 and 2011, respectively. On January 10, 2012, the Company announced that it had reached an agreement with MTF to both co-develop and commercialize a new technology for use in bone grafting applications and to expand MTF’s Trinity Evolution ® processing capacity. The amendment amends the term of the existing agreement until the later of (i) 15 years after the date that certain development milestones were achieved under the existing agreement (which occurred during 2010) or (ii) the date that certain licensing arrangements between the Company and NuVasive, Inc. expire. MTF is considered the primary obligor in these arrangements and therefore the Company recognizes these marketing service fees on a net basis upon shipment of the product to the customer.
	Revenues exclude any value added or other local taxes, intercompany sales and trade discounts. Shipping and handling costs are included in cost of sales.
	The process for estimating the ultimate collection of accounts receivable involves significant assumptions and judgments. Historical collection and payor reimbursement experience is an integral part of the estimation process related to reserves for doubtful accounts and the establishment of contractual allowances. Accounts receivable are analyzed on a quarterly basis to assess the adequacy of both reserves for doubtful accounts and contractual allowances. Revisions in allowances for doubtful accounts estimates are recorded as an adjustment to bad debt expense within sales and marketing expenses, and contractual allowances are recorded as an adjustment to revenue. These estimates are periodically tested against actual collection experience.
Sale of accounts receivable	'
		(n)	Sale of accounts receivable
	The Company will generally sell receivables from certain Italian hospitals each year. The estimated related fee for 2013 and 2012 was $0.8 million and $0.6 million, respectively, which is recorded as interest expense. Trade accounts receivables sold without recourse are removed from the balance sheet at the time of sale.
Share-based compensation	'
		(o)	Share-based compensation
	The fair value of service-based stock options are determined using the Black-Scholes valuation model. Such value is recognized as expense over the service period net of estimated forfeitures.
	The fair value of market-based stock options are determined at the date of the grant using the Monte Carlo valuation methodology. Such value is recognized as expense over the requisite service period adjusted for estimated forfeitures for each separately vesting tranche of the award. The Monte Carlo methodology that we use to estimate the fair value of market-based options incorporates into the valuation the possibility that the market condition may not be satisfied.
	The expected term of options granted is estimated based on a number of factors, including the vesting and expiration terms of the award, historical employee exercise behavior for both options that are currently outstanding and options that have been exercised or are expired, the historical volatility of the Company’s common stock and an employee’s average length of service. The risk-free interest rate is determined based upon a constant U.S. Treasury security rate with a contractual life that approximates the expected term of the option award. Management estimates expected volatility based on the historical volatility of the Company’s stock. The compensation expense recognized for all equity-based awards is net of estimated forfeitures. Forfeitures are estimated based on an analysis of actual option forfeitures.
Advertising costs	'
		(p)	Advertising costs
	The Company expenses all advertising costs as incurred. Advertising expense included in sales and marketing expense for the years ended December 31, 2013, 2012 and 2011 was $0.2 million, $0.3 million and $0.5 million, respectively.
Research and development costs	'
	(q)	Research and development costs
	Expenditures related to the collaborative arrangement with MTF are expensed based on the terms of the related agreement. Milestone payments made to MTF in 2013 and 2012 totaled $2.5 million and $3.0 million, respectively. There were no milestone payments made to MTF in 2011. Expenditures for other research and development are expensed as incurred.
Income taxes	'
		(r)	Income taxes
	The Company is subject to income taxes in both the U.S. and foreign jurisdictions, and uses estimates in determining the provision for income taxes. The Company accounts for income taxes using the asset and liability method for accounting and reporting for income taxes. Under this method, deferred tax assets and liabilities are recognized based on temporary differences between the financial reporting and income tax basis of assets and liabilities using statutory rates. This process requires that the Company project the current tax liability and estimate the deferred tax assets and liabilities, including net operating loss and tax credit carry forwards. In assessing the need for a valuation allowance, the Company has considered the recent operating results, future taxable income projections and all prudent and feasible tax planning strategies.
	The Company accounts for uncertain tax positions in accordance with ASC 740, Income Taxes, which contains a two-step approach to recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position taken or expected to be taken in a tax return by determining if the weight of available evidence indicates that it is more likely than not that, on an evaluation of the technical merits, the tax position will be sustained on audit, including resolution of any related appeals or litigation processes. The second step is to measure the tax benefit as the largest amount that is more than 50% likely to be realized upon ultimate settlement. The Company reevaluates income tax positions periodically to consider factors such as changes in facts or circumstances, changes in or interpretations of tax law, effectively settled issues under audit, and new audit activity. Such a change in recognition or measurement would result in recognition of a tax benefit or an additional charge to the tax provision.
	The Company includes imputed interest and any applicable penalties related to tax issues as part of income tax expense in our consolidated financial statements.
Net income (loss) per common share	'
		(s)	Net income (loss) per common share
	Net income (loss) per common share—basic is computed using the weighted average number of common shares outstanding during each of the respective years. Net income (loss) per common share—diluted is computed using the weighted average number of common and common equivalent shares outstanding during each of the respective years using the “treasury stock” method, if dilutive. Common equivalent shares represent the dilutive effect of the assumed exercise of outstanding share options (see Note 20). The only differences between basic and diluted shares result from the assumed exercise of certain outstanding share options.
Financial instruments and concentration of credit risk	'
	(t)	Financial instruments and concentration of credit risk
	Financial instruments that could subject the Company to a concentration of credit risk consist primarily of cash and cash equivalents and accounts receivable. Generally, the cash is held at large financial institutions and our cash equivalents consist of highly liquid money market funds. The Company performs ongoing credit evaluations of the customers, generally does not require collateral and maintain a reserve for potential credit losses. The Company believes that a concentration of credit risk related to the accounts receivable is limited because the customers are geographically dispersed and the end users are diversified across several industries.
	Net sales to our customers and distributors based in Europe were approximately $52 million in 2013 which results in a substantial portion of our trade accounts receivable balance as of December 31, 2013. It is at least reasonably possible that changes in global economic conditions and/or local operating and economic conditions in the regions these distributors operate, or other factors, could affect the future realization of these accounts receivable balances.
Recently issued accounting standards	'
	(u)	Recently issued accounting standards
	In July 2013, the Financial Accounting Standards Board (“FASB”), issued Accounting Standards Update (“ASU”) No. 2013-11, Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, A Similar Tax Loss, or a Tax Credit Carryforward Exists. The authoritative guidance concludes that, under certain circumstances, unrecognized tax benefits should be presented in the financial statements as a reduction to a deferred tax asset for a net operating loss carryforward, a similar tax loss, or a tax credit carryforward. We adopted this guidance early, as permitted, for the fiscal year ended December 31, 2013. The adoption of this guidance did not have a material effect on our consolidated financial statements.
	In February 2013, the FASB issued ASU No. 2013-02, Comprehensive Income (Topic 220): Reporting of Amounts Reclassified Out of Accumulated Other Comprehensive Income. The standard requires presentation (either in a single note or parenthetically on the face of the financial statements) of the effect of significant amounts reclassified from each component of accumulated other comprehensive income based on its source and the income statement line items affected by the reclassification. If a component is not required to be reclassified to net income in its entirety, a cross reference to the related footnote for additional information is required. The amendments are effective prospectively for reporting periods beginning after December 15, 2013. The adoption of this guidance did not have a material effect on our consolidated financial statements.
	On June 16, 2011, the FASB issued ASU No. 2011-05, Presentation of Comprehensive Income. This ASU eliminates the current option to present other comprehensive income and its components in the statement of changes in shareholders’ equity and increases the prominence of other comprehensive income in the statements by providing an alternative to present the components of net income and comprehensive income as either one continuous or two separate but consecutive financial statements. Companies are also required to present reclassification adjustments for items that are reclassified from other comprehensive income to net income within these statements. This standard is to be applied retrospectively and is effective for fiscal years beginning after December 15, 2011 with early adoption permitted. The Company adopted this ASU as of March 31, 2012 and it did not have a material impact on the Company’s consolidated financial statements.

Summary_of_significant_account2

Summary of significant accounting policies (Tables)	12 Months Ended
	Dec. 31, 2013
Accounting Policies [Abstract]	'
Schedule of Useful Lives	'
	The useful lives are as follows:
			Years
	Buildings			25 to 33
	Plant equipment and instrumentation			2 to 10
	Furniture and fixtures			4 to 8
Components of Changes in Accumulated Other Comprehensive Income	'
	The components of and changes in accumulated other comprehensive income are as follows:
	(U.S. Dollars in thousands)		Foreign Currency			Fair Value of			Accumulated Other
			Translation			Cross-			Comprehensive
			Adjustments			Currency Swaps			Income
	Balance at December 31, 2011 (Restated)		$	3,846		$	(132	)	$	3,714
	Unrealized gain on cross-currency swaps, net of taxes of $153			—			263			263
	Foreign currency translation adjustment (1)			768			—			768
	Balance at December 31, 2012 (Restated)			4,614			131			4,745
	Unrealized loss on cross-currency swaps, net of tax benefit of $164			—			(278	)		(278	)
	Foreign currency translation adjustment (1)			(1,768	)		—			(1,768	)
	Balance at December 31, 2013		$	2,846		$	(147	)	$	2,699
	-1	As the cash generally remains permanently invested in the non U.S. dollar denominated foreign subsidiaries, no deferred taxes are recognized on the related foreign currency translation adjustment.

Restatement_of_the_Consolidate1

Restatement of the Consolidated Financial Statements (Tables)	12 Months Ended
	Dec. 31, 2013
Text Block [Abstract]	'
Adjustments to Previously Filed Consolidated Income Statements	'
	The results of the adjustments to the Company’s previously filed consolidated statements of operations detailed above are summarized in the tables below. The tax effect of the adjustments is estimated based on the Company’s effective tax rate.
		Year Ended December 31, 2012
					Adjustments by Category
	(U.S. Dollars, in thousands)	Previously			Distributor			Inventory			Royalties			Other			Total			Restated
		Reported			Revenue			Reserves									Adjustments
	Net sales	$	462,320		$	(14,777	)	$	—		$	—		$	38		$	(14,739	)	$	447,581
	Cost of sales		86,492			(2,032	)		5,647			8,190			(44	)		11,761			98,253
	Gross profit		375,828			(12,745	)		(5,647	)		(8,190	)		82			(26,500	)		349,328
	Operating expenses
	Sales and marketing		200,343			(6,629	)		—			(8,190	)		1,607			(13,212	)		187,131
	General and administrative		53,827			(2	)		—			—			(434	)		(436	)		53,391
	Research and development		28,577			—			—			—			—			—			28,577
	Amortization of intangible assets		2,098			—			—			—			200			200			2,298
	Charges related to U.S. Government resolutions		1,973			—			—			—			(678	)		(678	)		1,295
			286,818			(6,631	)		—			(8,190	)		695			(14,126	)		272,692
	Operating income		89,010			(6,114	)		(5,647	)		—			(613	)		(12,374	)		76,636
	Other income and (expense)		(6,282	)		—			—			—			(166	)		(166	)		(6,448	)
	Income before income taxes		82,728			(6,114	)		(5,647	)		—			(779	)		(12,540	)		70,188
	Income tax expense		(28,792	)		1,782			1,645			—			227			3,654			(25,138	)
	Net income from continuing operations	$	53,936		$	(4,332	)	$	(4,002	)	$	—		$	(552	)	$	(8,886	)	$	45,050
		Year Ended December 31, 2011
					Adjustments by Category
	(U.S. Dollars, in thousands)	Previously			Distributor			Inventory			Royalties			Other			Total			Restated
		Reported			Revenue			Reserves									Adjustments
	Net sales	$	470,121		$	(29,135	)	$	—		$	—		$	985		$	(28,150	)	$	441,971
	Cost of sales		92,619			(8,289	)		3,377			7,713			107			2,908			95,527
	Gross profit		377,502			(20,846	)		(3,377	)		(7,713	)		878			(31,058	)		346,444
	Operating expenses
	Sales and marketing		200,145			(1,216	)		—			(7,713	)		2,295			(6,634	)		193,511
	General and administrative		64,374			—			—			—			107			107			64,481
	Research and development		22,861			—			—			—			—			—			22,861
	Amortization of intangible assets		2,350			—			—			—			200			200			2,550
	Charges related to U.S. Government resolutions		56,463			—			—			—			678			678			57,141
			346,193			(1,216	)		—			(7,713	)		3,280			(5,649	)		340,544
	Operating income		31,309			(19,630	)		(3,377	)		—			(2,402	)		(25,409	)		5,900
	Other income and (expense)		(11,868	)		—			—			—			3,915			3,915			(7,953	)
	Income (loss) before income taxes		19,441			(19,630	)		(3,377	)		—			1,513			(21,494	)		(2,053	)
	Income tax expense		(21,181	)		6,408			1,102			—			(494	)		7,016			(14,165	)
	Net loss from continuing operations	$	(1,740	)	$	(13,222	)	$	(2,275	)	$	—		$	1,019		$	(14,478	)	$	(16,218	)
Effects of Restatements on Consolidated Balance Sheet	'
	The effects of the restatements on the Company’s consolidated balance sheet as of December 31, 2012 are as follows:
		As of December 31, 2012
	(U.S. Dollars, in thousands except share and per share data)	Previously			Adjustments			Restated
		Reported
	Assets
	Current assets:
	Cash and cash equivalents	$	31,055		$	—		$	31,055
	Restricted cash		21,314			—			21,314
	Trade accounts receivable, less allowances of $13,543		150,316			(43,004	)		107,312
	Inventories		88,744			(5,371	)		83,373
	Deferred income taxes		16,959			16,491			33,450
	Prepaid expenses and other current assets		32,056			2,023			34,079
	Total current assets		340,444			(29,861	)		310,583
	Property, plant and equipment, net		51,362			2,473			53,835
	Patents and other intangible assets, net		6,880			410			7,290
	Goodwill		74,388			—			74,388
	Deferred income taxes		19,904			(1,023	)		18,881
	Other long-term assets		11,303			(3,383	)		7,920
	Total assets	$	504,281		$	(31,384	)	$	472,897
	Liabilities and shareholders’ equity
	Current liabilities:
	Bank borrowings	$	16		$	—		$	16
	Trade accounts payable		21,812			763			22,575
	Other current liabilities		46,969			(7,375	)		39,594
	Total current liabilities		68,797			(6,612	)		62,185
	Long-term debt		20,000			—			20,000
	Deferred income taxes		11,456			—			11,456
	Other long-term liabilities		4,930			6,494			11,424
	Total liabilities		105,183			(118	)		105,065
	Contingencies (Note 17)
	Shareholders’ equity
	Common shares $0.10 par value; 50,000,000 shares authorized; 19,339,329 issued and outstanding		1,934			—			1,934
	Additional paid-in capital		246,111			195			246,306
	Retained earnings		148,549			(33,702	)		114,847
	Accumulated other comprehensive income		2,504			2,241			4,745
	Total shareholders’ equity		399,098			(31,266	)		367,832
	Total liabilities and shareholders’ equity	$	504,281		$	(31,384	)	$	472,897
Effects of Restatements of Consolidated Statement of Operations and Comprehensive Income (Loss)	'
	The effects of the restatements on the Company’s consolidated statement of operations and comprehensive income for the year ended December 31, 2012 are as follows:
		Year Ended December 31, 2012
	(U.S. Dollars, in thousands, except share and per share data)	Previously			Adjustments			Restated
		Reported
	Product sales	$	415,850			(14,811	)	$	401,039
	Marketing service fees		46,470			72			46,542
	Net sales		462,320			(14,739	)		447,581
	Cost of sales		86,492			11,761			98,253
	Gross profit		375,828			(26,500	)		349,328
	Operating expenses
	Sales and marketing		200,343			(13,212	)		187,131
	General and administrative		53,827			(436	)		53,391
	Research and development		28,577			—			28,577
	Amortization of intangible assets		2,098			200			2,298
	Charges related to U.S. Government resolutions (Note 17)		1,973			(678	)		1,295
			286,818			(14,126	)		272,692
	Operating income		89,010			(12,374	)		76,636
	Other income and (expense)
	Interest expense, net		(4,577	)		(166	)		(4,743	)
	Other expense		(1,705	)		—			(1,705	)
			(6,282	)		(166	)		(6,448	)
	Income before income taxes		82,728			(12,540	)		70,188
	Income tax expense		(28,792	)		3,654			(25,138	)
	Net income from continuing operations		53,936			(8,886	)		45,050
	Discontinued operations (Note 16)
	Gain on sale of Breg, Inc.,		1,345			—			1,345
	Loss from discontinued operations		(4,012	)		1,018			(2,994	)
	Income tax benefit (expense)		26			(589	)		(563	)
	Net loss from discontinued operations		(2,641	)		429			(2,212	)
	Net income	$	51,295			(8,457	)	$	42,838
	Net income (loss) per common share—basic:
	Net income from continuing operations	$	2.84			(0.47	)	$	2.37
	Net loss from discontinued operations		(0.14	)		0.02			(0.12	)
	Net income per common share—basic	$	2.7			(0.45	)	$	2.25
	Net income (loss) per common share—diluted:
	Net income from continuing operations	$	2.78			(0.46	)	$	2.32
	Net loss from discontinued operations		(0.14	)		0.03			(0.11	)
	Net income per common share—diluted:	$	2.64			(0.43	)	$	2.21
	Weighted average number of common shares:
	Basic		18,977,263			—			18,977,263
	Diluted		19,390,413			—			19,390,413
	Other comprehensive income, before tax:
	Translation adjustment	$	480			288		$	768
	Unrealized gain on derivative instrument		416			—			416
	Other comprehensive income, before tax		896			288			1,184
	Income tax expense related to components of other comprehensive income		(153	)		—			(153	)
	Other comprehensive income, net of tax		743			288			1,031
	Comprehensive income	$	52,038			(8,169	)	$	43,869
	The effects of the restatements on the Company’s consolidated statement of operations and comprehensive loss for the year ended December 31, 2011 are as follows:
		Year Ended December 31, 2011
	(U.S. Dollars, in thousands, except share and per share data)	Previously			Adjustments			Restated
		Reported
	Product sales	$	432,975			(27,828	)	$	405,147
	Marketing service fees		37,146			(322	)		36,824
	Net sales		470,121			(28,150	)		441,971
	Cost of sales		92,619			2,908			95,527
	Gross profit		377,502			(31,058	)		346,444
	Operating expenses
	Sales and marketing		200,145			(6,634	)		193,511
	General and administrative		64,374			107			64,481
	Research and development		22,861			—			22,861
	Amortization of intangible assets		2,350			200			2,550
	Charges related to U.S. Government resolutions (Note 17)		56,463			678			57,141
		346,193			(5,649	)		340,544
Operating income		31,309			(25,409	)		5,900
Other income and (expense)
Interest expense, net		(9,456	)		3,915			(5,541	)
Other expense		(2,412	)		—			(2,412	)
		(11,868	)		3,915			(7,953	)
Income (loss) before income taxes		19,441			(21,494	)		(2,053	)
Income tax expense		(21,181	)		7,016			(14,165	)
Net loss from continuing operations		(1,740	)		(14,478	)		(16,218	)
Discontinued operations (Note 16)
Gain on sale of Breg, Inc.		—			—			—
Income (loss) from discontinued operations		1,263			(3,968	)		(2,705	)
Income tax (expense) benefit		(596	)		1,409			813
Net income (loss) from discontinued operations		667			(2,559	)		(1,892	)
Net loss	$	(1,073	)		(17,037	)	$	(18,110	)
Net income (loss) per common share—basic:
Net loss from continuing operations	$	(0.10	)		(0.79	)	$	(0.89	)
Net income (loss) from discontinued operations		0.04			(0.14	)		(0.10	)
Net loss per common share—basic	$	(0.06	)		(0.93	)	$	(0.99	)
Net income (loss) per common share—diluted:
Net loss from continuing operations	$	(0.10	)		(0.79	)	$	(0.89	)
Net income (loss) from discontinued operations		0.04			(0.14	)		(0.10	)
Net loss per common share—diluted:	$	(0.06	)		(0.93	)	$	(0.99	)
Weighted average number of common shares:
Basic		18,219,343			—			18,219,343
Diluted		18,219,343			—			18,219,343
Other comprehensive loss, before tax:
Translation adjustment	$	(3,192	)		913		$	(2,279	)
Unrealized loss on derivative instrument		(693	)		—			(693	)
Other comprehensive loss, before tax		(3,885	)		913			(2,972	)
Income tax benefit related to components of other comprehensive income		256			—			256
Other comprehensive loss, net of tax		(3,629	)		913			(2,716	)
Comprehensive loss	$	(4,702	)		(16,124	)	$	(20,826	)

Inventories_Tables

Inventories (Tables)	12 Months Ended
	Dec. 31, 2013
Inventory Disclosure [Abstract]	'
Schedule of Inventories	'
		December 31,
	(U.S. Dollars in thousands)		2013		2012
					(Restated)
	Raw materials		$	6,499	$	7,623
	Work-in-process			6,606		7,886
	Finished products			31,342		28,308
	Field inventory			34,932		22,629
	Consignment inventory			3,916		6,155
	Deferred cost of sales			7,282		10,772
			$	90,577	$	83,373

Property_plant_and_equipment_T

Property, plant and equipment (Tables)	12 Months Ended
	Dec. 31, 2013
Property Plant And Equipment [Abstract]	'
Schedule of Property Plant and Equipment	'
		December 31,
	(U.S. Dollars in thousands)	2013			2012
					(Restated)
	Cost
	Buildings	$	4,075		$	3,911
	Plant, equipment and instrumentation		131,572			120,982
	Furniture and fixtures		5,872			5,567
			141,519			130,460
	Accumulated depreciation		(86,913	)		(76,625	)
		$	54,606		$	53,835

Patents_and_other_intangible_a1

Patents and other intangible assets (Tables)	12 Months Ended
	Dec. 31, 2013
Goodwill And Intangible Assets Disclosure [Abstract]	'
Schedule of Patents and Other Intangible Assets	'
		December 31,
	(U.S. Dollars in thousands)	2013			2012
					(Restated)
	Cost
	Patents	$	42,568		$	38,905
	Trademarks—definite lived		620			657
			43,188			39,562
	Accumulated amortization
	Patents		(33,688	)		(31,845	)
	Trademarks—definite lived		(454	)		(427	)
			(34,142	)		(32,272	)
	Patents and other intangible assets, net	$	9,046		$	7,290

Goodwill_Tables

Goodwill (Tables)	12 Months Ended
	Dec. 31, 2013
Goodwill And Intangible Assets Disclosure [Abstract]	'
Schedule of Changes in Net Carrying Amount of Goodwill	'
	The following table presents the changes in the net carrying value of goodwill by reportable segment as well as the reallocation as of July 1, 2013 in conjunction with our change in reportable segments. (See Note 1 “Summary of significant accounting policies”):
	(U.S. Dollars in thousands)	Spine			Orthopedics			BioStim		Biologics		Extremity			Spine Fixation			Total
												Fixation
	At December 31, 2011	$	41,419		$	31,675		$	—	$	—	$	—		$	—		$	73,094
	Foreign currency		145			1,149			—		—		—			—			1,294
	At December 31, 2012		41,564			32,824			—		—		—			—			74,388
	Foreign currency		(163	)		(1,467	)		—		—		—			—			(1,630	)
	At June 30, 2013		41,401			31,357			—		—		—			—			72,758
	Reallocation at July 1, 2013		(41,401	)		(31,357	)		42,678		10,887		9,825			9,368			—
	Impairment		—			—			—		—		(9,825	)		(9,368	)		(19,193	)
	At December 31, 2013	$	—		$	—		$	42,678	$	10,887	$	—		$	—		$	53,565

Other_current_liabilities_Tabl

Other current liabilities (Tables)	12 Months Ended
	Dec. 31, 2013
Payables And Accruals [Abstract]	'
Summary of Other Current Liabilities	'
		December 31,
	(U.S. Dollars in thousands)	2013		2012
				(Restated)
	Accrued expenses	$	16,016	$	9,089
	Salaries, bonuses, commissions and related taxes payable		16,598		17,915
	Accrued legal expenses		10,292		8,496
	Other payables		3,240		4,094
		$	46,146	$	39,594

Derivative_instruments_Tables

Derivative instruments (Tables)	12 Months Ended
	Dec. 31, 2013
Derivative Instruments And Hedging Activities Disclosure [Abstract]	'
Schedule of Fair Values of Derivative Instruments	'
	The tables below disclose the types of derivative instruments the Company owns, the classifications and fair values of these instruments within the balance sheet, and the amount of gain (loss) recognized in other comprehensive income (loss) (“OCI”) or net income (loss).
	(U.S. Dollars in thousands)	Fair value: favorable			Balance sheet location
		(unfavorable)
	As of December 31, 2013
	Cross-currency swap	$	(1,036	)	Other long-term liabilities
	As of December 31, 2012
	Cross-currency swap	$	305		Other long-term assets
Schedule of Gain (Loss) Recognized on Derivative Instruments	'
	For the year ended
	December 31,
	(U.S. Dollars in thousands)	2013			2012		2011
	Cross-currency swap gain (loss) recorded in other comprehensive income (loss), net of taxes	$	(278	)	$	263	$	(437	)

Fair_value_measurements_Tables

Fair value measurements (Tables)	12 Months Ended
	Dec. 31, 2013
Fair Value Disclosures [Abstract]	'
Schedule of Financial Assets and Liabilities Recorded at Fair Value on Recurring Basis	'
	The fair value of the Company’s financial assets and liabilities on a recurring basis were as follows:
	(U.S. Dollars in thousands)	Balance			Level 1			Level 2			Level 3
		December 31,
		2013
	Assets
	Deferred compensation plan	$	3,361		$	3,361		$	—		$	—
	Total	$	3,361		$	3,361		$	—		$	—
	Liabilities
	Deferred compensation plan	$	(2,506	)	$	(2,506	)	$	—		$	—
	Cash Flow Hedges
	Cross-currency hedge		(1,036	)		—			(1,036	)		—
	Total	$	(3,542	)	$	(2,506	)	$	(1,036	)	$	—
	(U.S. Dollars in thousands)	Balance			Level 1			Level 2			Level 3
		December 31,
		2012
	Assets
	Deferred compensation plan	$	3,305		$	3,305		$	—		$	—
	Cash flow hedges
	Cross-currency hedge		305			—			305			—
	Total	$	3,610		$	3,305		$	305		$	—
	Liabilities
	Deferred compensation plan	$	(2,320	)	$	(2,320	)	$	—		$	—
	Cash flow hedges
	Cross-currency hedge		—			—			—			—
	Total	$	(2,320	)	$	(2,320	)	$	—		$	—

Commitments_Tables

Commitments (Tables)	12 Months Ended
	Dec. 31, 2013
Commitments And Contingencies Disclosure [Abstract]	'
Schedule of Future Minimum Lease Payments Under Operating Leases, Net of Amount to be Received Under Sub Leases	'
	Future minimum lease payments under operating leases, net of amounts to be received under sub-leases, as of December 31, 2013 are as follows:
	(U.S. Dollars in thousands)
	2014	$	4,342
	2015		4,107
	2016		3,713
	2017		2,974
	2018		2,846
	Thereafter		3,049
	Total	$	21,031

Business_segment_information_T

Business segment information (Tables)	12 Months Ended
	Dec. 31, 2013
Segment Reporting [Abstract]	'
Schedule of External Net Sales by GBU Reporting Segment	'
	External Net Sales by SBU:
	The table below presents external net sales for continuing operations by SBU reporting segment. Net sales include product sales and marketing service fees.
		External Net Sales by SBU
		Year ended December 31,
	(U.S. Dollars in thousands)	2013						2012						2011
		Net Sales			Percent of			Net Sales			Percent of			Net Sales		Percent of
					Total Net						Total Net					Total Net
					Sales						Sales					Sales
								(Restated)			(Restated)			(Restated)		(Restated)
	BioStim	$	147,910			37	%	$	181,959			41	%	$	188,136		43	%
	Biologics		53,769			13	%		53,730			12	%		42,919		10	%
	Extremity Fixation		103,385			26	%		112,009			25	%		119,521		27	%
	Spine Fixation		95,470			24	%		99,883			22	%		91,395		20	%
	Total Net Sales	$	400,534			100	%	$	447,581			100	%	$	441,971		100	%
Summary of Net Margin, Defined as Gross Profit Less Sales And Marketing Expenses from Continuing Operations by SBU Reporting Segment	'
	The table below presents net margin, defined as gross profit less sales and marketing expenses from continuing operations by SBU reporting segment:
	Net Margin by SBU	Year Ended December 31,
	(U.S. Dollars in thousands)	2013			2012			2011
					(Restated)			(Restated)
	Net Margin
	BioStim	$	64,930		$	86,654		$	93,056
	Biologics		24,532			23,559			18,979
	Extremity Fixation		26,389			34,337			29,530
	Spine Fixation		7,245			19,142			13,068
	Corporate		(1,443	)		(1,495	)		(1,700	)
	Total net margin	$	121,653		$	162,197		$	152,933
	General & administrative		65,147			53,391			64,481
	Research and development		26,768			28,577			22,861
	Amortization of intangible assets		2,687			2,298			2,550
	Costs related to the accounting review and restatement		12,945			—			—
	Impairment of goodwill		19,193			—			—
	Charges related to U.S. Government resolutions		—			1,295			57,141
	Operating (loss) income	$	(5,087	)	$	76,636		$	5,900
Schedule of Depreciation and Amortization by GBU Reporting Segment	'
	The following table presents depreciation and amortization for continuing operations by SBU reporting segment:
		Depreciation and amortization by SBU
		Year Ended December 31,
	(U.S. Dollars in thousands)	2013			2012			2011
					(Restated)			(Restated)
	BioStim	$	1,946		$	1,584		$	2,033
	Biologics		628			543			415
	Extremity Fixation		7,195			5,196			5,148
	Spine Fixation		12,794			10,752			9,211
	Corporate		96			70			53
	Total	$	22,659		$	18,145		$	16,860
Summary of Net Sales by Geographic Destination	'
	The following geographic data includes net sales by geographic destination:
	(U.S. Dollars in thousands)	2013			2012			2011
					(Restated)			(Restated)
	U.S.	$	295,857		$	334,624		$	328,585
	International:
	U.K.		10,002			8,431			8,206
	Italy		16,755			18,742			17,447
	Brazil		26,786			31,166			34,424
	Other		51,134			54,618			53,309
	Total international		104,677			112,957			113,386
	Total net sales	$	400,534		$	447,581		$	441,971
Analysis of Property, Plant and Equipment of Reporting Segments by Geographic Area	'
	Analysis of property, plant and equipment by geographic area:
	(U.S. Dollars in thousands)	2013			2012
					(Restated)
	U.S.	$	39,858		$	39,554
	Italy		7,813			7,617
	U.K.		1,871			1,402
	Brazil		3,210			3,421
	Others		1,854			1,841
	Total	$	54,606		$	53,835

Income_taxes_Tables

Income taxes (Tables)	12 Months Ended
	Dec. 31, 2013
Income Tax Disclosure [Abstract]	'
Schedule of Provision for (Benefit from) Income Taxes on Continuing Operations	'
	The provision for (benefit from) income taxes on continuing operations in the accompanying consolidated statements of operations consists of the following:
		Year Ended
		December 31,
	(US$ in thousands)	2013			2012			2011
					(Restated)			(Restated)
	U.S.
	Current	$	2,914		$	17,897		$	25,148
	Deferred		5,716			1,788			(12,657	)
	Total U.S		8,630			19,685			12,491
	Non-U.S.
	Current		2,355			4,609			2,735
	Deferred		(869	)		844			(1,061	)
			1,486			5,453			1,674
	Total tax expense	$	10,116		$	25,138		$	14,165
Schedule of Tax Effects of Significant Temporary Differences Comprising Deferred Tax Assets and Liabilities	'
	The tax effects of the significant temporary differences, which comprise the deferred tax assets and liabilities and assets, are as follows:
	(US$ in thousands)	2013			2012
					(Restated)
	Intangible assets and goodwill	$	4,978		$	5,346
	Inventories and related reserves		14,678			14,020
	Deferred revenue and cost of sales		9,669			11,682
	Other accruals and reserves		3,200			3,868
	Accrued compensation		3,880			3,817
	Allowance for doubtful accounts		4,429			3,718
	Accrued interest		17,775			18,229
	Net operating loss carryforwards		34,215			27,231
	Other, net		621			539
			93,445			88,450
	Valuation allowance		(31,472	)		(26,361	)
	Deferred tax asset	$	61,973		$	62,089
	Withholding taxes		(13,132	)		(11,456	)
	Property, plant and equipment		(9,690	)		(9,758	)
	Deferred tax liability		(22,822	)		(21,214	)
	Net deferred tax assets	$	39,151		$	40,875
Schedule of Effective Income Tax Rate Reconciliation for Continuing Operations	'
	The rate reconciliation for continuing operations presented below is based on the U.S. federal income tax rate, rather than the parent company’s country of domicile tax rate. Management believes, given the large proportion of taxable income earned in the United States, such disclosure is more meaningful.
	(U.S. Dollars in thousands, except percentages)	2013						2012						2011
		Amount			Percent			Amount			Percent			Amount			Percent
								(Restated)			(Restated)			(Restated)			(Restated)
	Statutory U.S. federal income tax rate	$	(1,677	)		35	%	$	24,565			35	%	$	(719	)		35	%
	State taxes, net		2,744			(57.3	)		1,708			2.4			1,896			(92.4	)
	Foreign rate differential		(626	)		13.1			(3,115	)		(4.4	)		1,585			(77.2	)
	Valuation allowance—foreign losses		3,913			(81.7	)		6,183			8.8			4,882			(237.8	)
	SRL intangible		(2,288	)		47.8			(2,214	)		(3.2	)		(2,421	)		117.9
	Goodwill impairment		6,452			(134.7	)		—			—			—			—
	Domestic manufacturing deduction		(233	)		4.9			(1,694	)		(2.4	)		(1,703	)		82.9
	Withholding taxes		1,679			(35.0	)		1,679			2.4			1,676			(81.6	)
	Settlement of U.S. Government resolutions		—			—			(1,260	)		(1.8	)		9,520			(463.7	)
	Other items, net		152			(3.2	)		(714	)		(1.0	)		(551	)		26.9
	Income tax expense/effective rate	$	10,116			(211.1	)%	$	25,138			35.8	%	$	14,165			(690.0	)%
Schedule of Gross Unrecognized Tax Benefits (Excluding Interest and Penalties)	'
	A reconciliation of the gross unrecognized tax benefits (excluding interest and penalties) for the years ended December 31, 2013 and December 31, 2012 follows:
	(US$ in thousands)	2013			2012
					(Restated)
	Balance as of January 1,	$	1,189		$	610
	Additions for current year tax positions		183			793
	Decreases for prior year tax positions		(12	)		(106	)
	Settlements of prior year tax positions		(560	)		—
	Expiration of statutes		(77	)		(108	)
	Balance as of December 31,	$	723		$	1,189

Sale_of_Breg_and_Disposition_o1

Sale of Breg and Disposition of Sports Medicine SBU (Tables)	12 Months Ended
	Dec. 31, 2013
Discontinued Operations And Disposal Groups [Abstract]	'
Schedule of Information Related to Sale of Breg	'
	The following table presents the value of the asset disposition, proceeds received, net of various working capital adjustments and indebtedness and net gain on sale of Breg as shown in the condensed consolidated statement of operations for the year ended December 31, 2012.
	(U.S. Dollars in thousands)	Total
	Cash proceeds	$	157,500
	Less:
	Working Capital		(7,093	)
	Transaction related expenses		(4,276	)
	Fair value of indemnification		(2,000	)
	Tangible assets		(8,309	)
	Intangible assets		(28,164	)
	Goodwill		(106,200	)
	Gain on sale of Breg		1,458
	Income tax expense		(113	)
	Gain on sale of Breg, net of taxes	$	1,345

Sharebased_compensation_plans_

Share-based compensation plans (Tables)	12 Months Ended
	Dec. 31, 2013
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]	'
Schedule of Share-Based Compensation by Line Item in Consolidated Statements of Operations	'
	The following table shows the detail of share-based compensation by line item in the consolidated statements of operations for the years ended December 31, 2013, 2012 and 2011 and the assumptions for each of these years in which grants were awarded:
	(U.S. Dollars in thousands, except assumptions)	Year Ended			Year Ended			Year Ended
		December 31,			December 31,			December 31,
		2013			2012			2011
	Cost of sales	$	104		$	592		$	153
	Sales and marketing		1,444			1,550			2,031
	General and administrative		4,483			4,023			4,322
	Research and development		236			138			142
	Total	$	6,267		$	6,303		$	6,648
Schedule of Share-based Payment Award, Valuation Assumptions	'
	Assumptions:
	Expected term		5.00 years			4.50 years			4.58 years
	Expected volatility		32.1% – 50.8	%		50.9% – 51.8	%		49.6% – 49.9	%
	Risk free interest rate		0.58% – 1.52	%		0.76% – 0.84	%		.90% – 2.26	%
	Dividend rate		0			—			—
	Weighted average fair value of options granted during the year	$	10.83		$	16.99		$	14.21
Schedule of Stock Option Activity	'
	Summaries of the status of the Company’s stock option plans as of December 31, 2013 and 2012 and changes during the year ended December 31, 2013 are presented below:
		Options			Weighted Average			Weighted
					Exercise Price			Average
								Remaining
								Contractual
								Term
	Outstanding at December 31, 2012		1,945,955		$	34.5
	Granted		466,250		$	28.51
	Exercised		(79,949	)	$	23.25
	Forfeited		(408,077	)	$	36.33
	Outstanding at December 31, 2013		1,924,179		$	33.12			4.41
	Vested and expected to vest at December 31, 2013		1,839,383		$	33.5			4.17
	Options exercisable at December 31, 2013		1,367,269		$	34.35			2.89
Schedule of Stock Options Outstanding and Exercisable by Price Range	'
	Outstanding and exercisable by price range as of December 31, 2013
		Options Outstanding									Options Exercisable
	Range of Exercise Prices	Number			Weighted			Weighted			Number		Weighted
		Outstanding			Average			Average			Exercisable		Average
					Remaining			Exercise					Exercise
					Contractual			Price					Price
					Life
	$10.42 – $21.78		232,250			9.31		$	20.79			16,000	$	13.31
	$22.75 – $25.05		326,166			4.1		$	24.73			306,166	$	24.84
	$26.79 – $28.95		230,000			4.79		$	28.45			170,000	$	28.65
	$29.23 – $37.36		225,168			5.1		$	33.14			169,839	$	32.41
	$37.76 – $38.11		230,975			1.69		$	37.99			230,975	$	37.99
	$38.40 – $40.27		351,354			3.17		$	39.76			174,355	$	39.77
	$41.33 – $43.04		178,633			2.84		$	41.66			150,301	$	41.72
	$44.87 – $45.84		140,133			3.05		$	45.02			140,133	$	45.02
	$50.50 – $50.50		2,000			3.01		$	50.5			2,000	$	50.5
	$50.99 – $50.99		7,500			3.04		$	50.99			7,500	$	50.99
	$10.42 – $50.99		1,924,179			4.41		$	33.12			1,367,269	$	34.35
Schedule of Changes in Restricted Stock	'
	A summary of the status of our restricted stock as of December 31, 2013 and 2012 and changes during the year ended December 31, 2013 are presented below:
		Shares			Weighted
					Average Grant
					Date Fair Value
	Non-vested as of December 31, 2012		160,831		$	38.34
	Granted		269,791		$	27.09
	Vested		(62,948	)	$	36.58
	Cancelled		(80,970	)	$	38.8
	Non-vested as of December 31, 2013		286,704		$	28.01

Earnings_per_share_Tables

Earnings per share (Tables)	12 Months Ended
	Dec. 31, 2013
Earnings Per Share [Abstract]	'
Schedule of Reconciliation of Weighted Average Shares Used in Calculation of Basic and Diluted Earnings Per Share	'
	The following is a reconciliation of the weighted average shares used in the basic and diluted net income (loss) per common share computations.
		Year Ended December 31,
		2013		2012		2011
	Weighted average common shares-basic		18,697,228		18,977,263		18,219,343
	Effect of diluted securities:
	Unexercised stock options net of treasury share repurchase		—		413,150		—
	Weighted average common shares-diluted		18,697,228		19,390,413		18,219,343

Quarterly_financial_data_unaud1

Quarterly financial data (unaudited) (Tables)	12 Months Ended
	Dec. 31, 2013
Quarterly Financial Information Disclosure [Abstract]	'
Condensed Consolidated Statement of Operations	'
	Condensed Consolidated Statement of Operations
	As Restated or Currently Reported
	(U.S. Dollars, in thousands, except per share data)
			1st			2nd			3rd			4th			Year
			Quarter			Quarter			Quarter			Quarter
			(Restated)
	2013
	Net sales		$	103,373		$	98,280		$	92,738		$	106,143		$	400,534
	Cost of sales			25,617			20,246			23,920			32,517			102,300
	Gross profit			77,756			78,034			68,818			73,626			298,234
	Operating Expense			69,669			69,230			84,418			80,004			303,321
	Operating Income (loss)			8,087			8,804			(15,600	)		(6,378	)		(5,087	)
	Net income (loss) from continuing operations			7,610			4,130			(18,084	)		(8,564	)		(14,908	)
	Net income (loss)		$	4,500		$	(2,317	)	$	(19,822	)	$	(7,876	)	$	(25,515	)
	Net income (loss) per common share:
	Basic:
	Net income (loss) from continuing operations		$	0.39		$	0.22		$	(1.00	)	$	(0.47	)	$	(0.80	)
	Net income (loss)		$	0.23		$	(0.12	)	$	(1.10	)	$	(0.43	)	$	(1.37	)
	Diluted:
	Net income (loss) from continuing operations		$	0.39		$	0.21		$	(1.00	)	$	(0.47	)	$	(0.80	)
	Net income (loss)		$	0.23		$	(0.12	)	$	(1.10	)	$	(0.43	)	$	(1.37	)
			(Restated)			(Restated)			(Restated)			(Restated)			(Restated)
	2012
	Net sales		$	108,936		$	113,423		$	107,857		$	117,365		$	447,581
	Cost of sales			21,378			27,547			24,384			24,944			98,253
	Gross profit			87,558			85,876			83,473			92,421			349,328
	Operating Expense			69,638			71,578			64,668			66,808			272,692
	Operating Income			17,920			14,298			18,805			25,613			76,636
	Net income from continuing operations			8,597			9,870			10,574			16,009			45,050
	Net income		$	9,407		$	7,254		$	5,016		$	21,161		$	42,838
	Net income (loss) per common share:
	Basic:
	Net income from continuing operations		$	0.46		$	0.52		$	0.55		$	0.83		$	2.37
	Net income		$	0.5		$	0.38		$	0.26		$	1.1		$	2.25
	Diluted:
	Net income from continuing operations		$	0.45		$	0.51		$	0.54		$	0.81		$	2.32
	Net income		$	0.49		$	0.37		$	0.25		$	1.07		$	2.21
	Condensed Consolidated Statement of Operations
	As Previously Reported
	(U.S. Dollars, in thousands, except per share data)
			1st			2nd			3rd			4th			Year
			Quarter			Quarter			Quarter			Quarter
	2013 (1)
	Net sales		$	100,254
	Cost of sales			22,699
	Gross profit			77,555
	Operating Expense			73,531
	Operating Income			4,024
	Net income from continuing operations			4,908
	Net income		$	2,116
	Net income (loss) per common share:
	Basic:
	Net income from continuing operations		$	0.25
	Net income		$	0.11
	Diluted:
	Net income from continuing operations		$	0.25
	Net income		$	0.11
	2012
	Net sales		$	116,041		$	119,492		$	114,752		$	112,035		$	462,320
	Cost of sales			21,939			23,676			22,373			18,504			86,492
	Gross profit			94,102			95,816			92,379			93,531			375,828
	Operating Expense			71,671			75,251			70,846			69,050			286,818
	Operating Income			22,431			20,565			21,533			24,481			89,010
Net income from continuing operations			12,215			13,967			13,118			14,636			53,936
Net income		$	12,016		$	11,205		$	7,560		$	20,514		$	51,295
Net income (loss) per common share:
Basic:
Net income from continuing operations		$	0.65		$	0.74		$	0.69		$	0.76		$	2.84
Net income		$	0.64		$	0.59		$	0.4		$	1.06		$	2.7
Diluted:
Net income from continuing operations		$	0.64		$	0.73		$	0.67		$	0.74		$	2.78
Net income		$	0.63		$	0.58		$	0.39		$	1.04		$	2.64
-1	Q2-Q4 2013 was not previously reported.
Condensed Consolidated Statement of Operations
Restatement Adjustments
(U.S. Dollars, in thousands, except per share data)
		1st			2nd			3rd			4th			Year
		Quarter			Quarter			Quarter			Quarter
2013 (1)
Net sales		$	3,119
Cost of sales			2,918
Gross profit			201
Operating Expense			(3,862	)
Operating Income			4,063
Net income from continuing operations			2,702
Net income		$	2,384
Net income (loss) per common share:
Basic:
Net income from continuing operations		$	0.14
Net income		$	0.12
Diluted:
Net income from continuing operations		$	0.14
Net income		$	0.12
2012
Net sales		$	(7,105	)	$	(6,069	)	$	(6,895	)	$	5,330		$	(14,739	)
Cost of sales			(561	)		3,871			2,011			6,440			11,761
Gross profit			(6,544	)		(9,940	)		(8,906	)		(1,110	)		(26,500	)
Operating Expense			(2,033	)		(3,673	)		(6,178	)		(2,242	)		(14,126	)
Operating Income			(4,511	)		(6,267	)		(2,728	)		1,132			(12,374	)
Net income (loss) from continuing operations			(3,618	)		(4,097	)		(2,544	)		1,373			(8,886	)
Net (loss) income		$	(2,609	)	$	(3,951	)	$	(2,544	)	$	647		$	(8,457	)
Net income (loss) per common share:
Basic:
Net income (loss) from continuing operations		$	(0.19	)	$	(0.22	)	$	(0.14	)	$	0.07		$	(0.47	)
Net income (loss)		$	(0.14	)	$	(0.21	)	$	(0.14	)	$	0.04		$	(0.45	)
Diluted:
Net income (loss) from continuing operations		$	(0.19	)	$	(0.22	)	$	(0.13	)	$	0.07		$	(0.46	)
Net income (loss)		$	(0.14	)	$	(0.21	)	$	(0.14	)	$	0.03		$	(0.43	)
-1	Q2-Q4 2013 was not previously reported and therefore does not have restatement adjustments.
Condensed Consolidated Balance Sheets	'
	Condensed Consolidated Balance Sheets
	As Restated or Currently Reported
	(U.S. Dollars, in thousands, except share and per share data)		1st			2nd			3rd			4th
			Quarter			Quarter			Quarter			Quarter
			(Restated)
	2013
	Total assets		$	475,758		$	459,450		$	430,058		$	423,182
	Total liabilities			102,366			114,223			111,001			115,919
	Total shareholders’ equity			373,392			345,227			319,057			310,494
	Total liabilities and shareholders’ equity		$	475,758		$	459,450		$	430,058		$	423,182
	2012		(Restated)			(Restated)			(Restated)			(Restated)
	Total assets		$	694,106		$	530,395		$	539,566		$	472,897
	Total liabilities			381,734			205,196			193,599			105,065
	Total shareholders’ equity			312,372			325,199			345,967			367,832
	Total liabilities and shareholders’ equity		$	694,106		$	530,395		$	539,566		$	472,897
	Condensed Consolidated Balance Sheets
	As Previously Reported
	(U.S. Dollars, in thousands, except share and per share data)		1st			2nd			3rd			4th
			Quarter			Quarter			Quarter			Quarter
	2013 (1)
	Total assets		$	503,380
	Total liabilities			101,212
	Total shareholders’ equity			402,168
	Total liabilities and shareholders’ equity		$	503,380
	2012
	Total assets		$	707,586		$	553,320		$	565,073		$	504,281
	Total liabilities			369,178			199,104			187,463			105,183
	Total shareholders’ equity			338,408			354,216			377,610			399,098
	Total liabilities and shareholders’ equity		$	707,586		$	553,320		$	565,073		$	504,281
	(1) Q2-Q4 2013 was not previously reported.
	Condensed Consolidated Balance Sheets
	Restatement Adjustments
	(U.S. Dollars, in thousands, except share and per share data)		1st			2nd			3rd			4th
			Quarter			Quarter			Quarter			Quarter
	2013 (1)
	Total assets		$	(27,622	)
	Total liabilities			1,154
	Total shareholders’ equity			(28,776	)
	Total liabilities and shareholders’ equity		$	(27,622	)
	2012
	Total assets		$	(13,480	)	$	(22,925	)	$	(25,507	)	$	(31,384	)
	Total liabilities			12,556			6,092			6,136			(118	)
	Total shareholders’ equity			(26,036	)		(29,017	)		(31,643	)		(31,266	)
	Total liabilities and shareholders’ equity		$	(13,480	)	$	(22,925	)	$	(25,507	)	$	(31,384	)
	-1	Q2-Q4 2013 was not previously reported and therefore does not have restatement adjustments.

Recovered_Sheet1

Summary of Significant Accounting Policies - Additional Information (Detail) (USD $)

3 Months Ended

6 Months Ended

12 Months Ended

3 Months Ended

12 Months Ended

Dec. 31, 2013

Sep. 30, 2013

Jun. 30, 2013

Mar. 31, 2013

Dec. 31, 2012

Sep. 30, 2012

Jun. 30, 2012

Mar. 31, 2012

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Sep. 30, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2009

Dec. 31, 2013

Unit

Customers and Distributors Based in Europe [Member]

Musculoskeletal Transplant Foundation ("MTF") [Member]

Musculoskeletal Transplant Foundation ("MTF") [Member]

Musculoskeletal Transplant Foundation ("MTF") [Member]

Spine Fixation and our Extremity Fixation reportable units [Member]

Spine Fixation and our Extremity Fixation reportable units [Member]

Collaborative Arrangement [Member]

Collaborative Arrangement [Member]

Collaborative Arrangement [Member]

Collaborative Arrangement [Member]

Developed Technology [Member]

Musculoskeletal Transplant Foundation ("MTF") [Member]

Musculoskeletal Transplant Foundation ("MTF") [Member]

Musculoskeletal Transplant Foundation ("MTF") [Member]

Musculoskeletal Transplant Foundation ("MTF") [Member]

Foreign Currency Translation [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Transactional foreign currency gains and (losses), including those generated from intercompany operations

'

'

'

'

'

'

'

'

'

($700,000)

($500,000)

($1,600,000)

'

'

'

'

'

'

'

'

'

'

'

Property plant and equipment, gross

141,519,000

'

'

'

130,460,000

'

'

'

141,519,000

141,519,000

130,460,000

'

'

'

'

'

'

'

'

'

'

'

'

Property plant and equipment, accumulated depreciation

33,700,000

'

'

'

'

'

'

'

33,700,000

33,700,000

'

'

'

'

'

'

'

'

'

'

'

'

'

Weighted average amortization period ( in years)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'11 years

Number of reporting units

'

'

'

'

'

'

'

'

'

4

'

'

'

'

'

'

'

'

'

'

'

'

'

Impairment of goodwill

'

'

'

'

'

'

'

'

19,193,000

19,193,000

'

'

'

'

'

'

19,200,000

19,200,000

'

'

'

'

'

Period of agreement with MTF

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'10 years

'

Extended Period of existing agreement with MTF

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'15 years

'

'

'

'

Marketing fee

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

47,700,000

46,500,000

36,800,000

'

'

Estimated related fee

'

'

'

'

'

'

'

'

'

800,000

600,000

'

'

'

'

'

'

'

'

'

'

'

'

Advertising expense

'

'

'

'

'

'

'

'

'

200,000

300,000

500,000

'

'

'

'

'

'

'

'

'

'

'

Expenditures for other research and development

'

'

'

'

'

'

'

'

'

'

'

'

'

2,500,000

3,000,000

0

'

'

'

'

'

'

'

Net sales

$106,143,000

$92,738,000

$98,280,000

$103,373,000

$117,365,000

$107,857,000

$113,423,000

$108,936,000

'

$400,534,000

$447,581,000

$441,971,000

$52,000,000

'

'

'

'

'

'

'

'

'

'

Recovered_Sheet2

Summary of Significant Accounting Policies - Schedule of Useful Lives (Detail)	12 Months Ended
	Dec. 31, 2013
Minimum [Member] | Buildings [Member]	'
Foreign Currency Translation [Line Items]	'
Useful life, in years	'25 years
Minimum [Member] | Plant equipment and instrumentation [Member]	'
Foreign Currency Translation [Line Items]	'
Useful life, in years	'2 years
Minimum [Member] | Furniture and fixtures [Member]	'
Foreign Currency Translation [Line Items]	'
Useful life, in years	'4 years
Maximum [Member] | Buildings [Member]	'
Foreign Currency Translation [Line Items]	'
Useful life, in years	'33 years
Maximum [Member] | Plant equipment and instrumentation [Member]	'
Foreign Currency Translation [Line Items]	'
Useful life, in years	'10 years
Maximum [Member] | Furniture and fixtures [Member]	'
Foreign Currency Translation [Line Items]	'
Useful life, in years	'8 years

Recovered_Sheet3

Summary of Significant Accounting Policies - Schedule of Components of Changes in Accumulated Other Comprehensive Income (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Accumulated Other Comprehensive Income (Loss) [Line Items]	'	'	'
Beginning Balance	$4,745	'	'
Unrealized gain (loss) on cross-currency swaps, net of tax benefit	-278	263	-437
Foreign currency translation adjustment	-1,768	768	-2,279
Ending Balance	2,699	4,745	'
Foreign Currency Translation Adjustments [Member]	'	'	'
Accumulated Other Comprehensive Income (Loss) [Line Items]	'	'	'
Beginning Balance	4,614	3,846	'
Foreign currency translation adjustment	-1,768	768	'
Ending Balance	2,846	4,614	'
Fair Value of Cross- Currency Swaps [Member]	'	'	'
Accumulated Other Comprehensive Income (Loss) [Line Items]	'	'	'
Beginning Balance	131	-132	'
Unrealized gain (loss) on cross-currency swaps, net of tax benefit	-278	263	'
Ending Balance	-147	131	'
Accumulated Other Comprehensive Income [Member]	'	'	'
Accumulated Other Comprehensive Income (Loss) [Line Items]	'	'	'
Beginning Balance	4,745	3,714	'
Unrealized gain (loss) on cross-currency swaps, net of tax benefit	-278	263	-437
Foreign currency translation adjustment	-1,768	768	-2,279
Ending Balance	$2,699	$4,745	$3,714

Summary_of_Significant_Account3

Summary of Significant Accounting Policies - Schedule of Components of Changes in Accumulated Other Comprehensive Income (Parenthetical) (Detail) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Accumulated Other Comprehensive Income (Loss) [Line Items]	'	'	'
Unrealized loss on cross-currency swaps, taxes (benefit)	($164,000)	$153,000	($256,000)
Deferred taxes recognized on related foreign currency translation adjustment	-869,000	844,000	-1,061,000
Foreign Currency Translation Adjustments [Member]	'	'	'
Accumulated Other Comprehensive Income (Loss) [Line Items]	'	'	'
Deferred taxes recognized on related foreign currency translation adjustment	0	'	'
Fair Value of Cross- Currency Swaps [Member]	'	'	'
Accumulated Other Comprehensive Income (Loss) [Line Items]	'	'	'
Unrealized loss on cross-currency swaps, taxes (benefit)	-164,000	153,000	'
Accumulated Other Comprehensive Income [Member]	'	'	'
Accumulated Other Comprehensive Income (Loss) [Line Items]	'	'	'
Unrealized loss on cross-currency swaps, taxes (benefit)	($164,000)	$153,000	'

Restatement_of_the_Consolidate2

Restatement of the Consolidated Financial Statements - Additional Information (Detail) (USD $)

3 Months Ended

12 Months Ended

3 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

6 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

Dec. 31, 2013

Sep. 30, 2013

Jun. 30, 2013

Mar. 31, 2013

Dec. 31, 2012

Sep. 30, 2012

Jun. 30, 2012

Mar. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Sep. 30, 2013

Jun. 30, 2013

Mar. 31, 2013

Dec. 31, 2012

Sep. 30, 2012

Jun. 30, 2012

Mar. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Sep. 30, 2012

Jun. 30, 2012

31-May-12

Dec. 31, 2013

Jun. 30, 2012

Dec. 31, 2012

31-May-12

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2013

As Previously or Currently Reported [Member]

As Previously or Currently Reported [Member]

As Previously or Currently Reported [Member]

As Previously or Currently Reported [Member]

As Previously or Currently Reported [Member]

As Previously or Currently Reported [Member]

As Previously or Currently Reported [Member]

As Previously or Currently Reported [Member]

As Previously or Currently Reported [Member]

As Previously or Currently Reported [Member]

As Previously or Currently Reported [Member]

Revolving Credit Facility [Member]

Revolving Credit Facility [Member]

Revolving Credit Facility [Member]

Revolving Credit Facility [Member]

Inventory Reserve [Member]

Inventory Reserve [Member]

Term Loan Facility [Member]

Term Loan Facility [Member]

Distributor Revenue [Member]

Distributor Revenue [Member]

Distributor Revenue [Member]

Distributor Revenue [Member]

Distributor Revenue [Member]

Other Adjustment [Member]

Minimum [Member]

Maximum [Member]

Distributor

As Previously or Currently Reported [Member]

As Previously or Currently Reported [Member]

Distributor Revenue [Member]

Distributor Revenue [Member]

Increase (Decrease) in net sales

'

'

'

'

'

'

'

'

'

($14,700,000)

($28,200,000)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Increase (Decrease) in net income from continuing operations

'

'

'

'

'

'

'

'

'

-8,900,000

-14,500,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Net sales

106,143,000

92,738,000

98,280,000

103,373,000

117,365,000

107,857,000

113,423,000

108,936,000

400,534,000

447,581,000

441,971,000

'

'

'

100,254,000

112,035,000

114,752,000

119,492,000

116,041,000

'

462,320,000

470,121,000

'

'

'

'

'

'

'

'

'

'

'

462,000,000

470,000,000

'

'

'

Percentage of net sales

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

11.00%

13.00%

Distributors that did not meet the fixed or determinable or collectability revenue recognition criteria

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

4

'

'

'

'

'

'

'

Number of distributer terminated

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2

'

'

'

'

'

'

'

Sales return

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

3,300,000

4,100,000

'

'

'

'

'

Increase (Decrease) in accounts receivable

'

'

'

'

'

'

'

'

-25,747,000

18,438,000

-293,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-41,300,000

'

'

'

'

'

'

Increase (Decease) in inventory

'

'

'

'

'

'

'

'

6,626,000

2,495,000

12,624,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-14,800,000

'

'

'

11,000,000

'

'

'

'

'

'

Increase (Decrease) in inventory reserve

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,200,000

'

'

'

'

'

'

'

'

'

'

'

Adjustment to reclassify interest expenses

'

'

'

'

'

'

'

'

'

'

3,900,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Repayment of debt obligation

'

'

'

'

'

'

'

'

16,000

188,695,000

7,500,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

87,500,000

87,500,000

'

'

'

'

'

'

'

'

Repayment of debt obligation

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

20,000,000

20,000,000

57,500,000

57,500,000

'

'

'

'

'

'

'

'

'

'

'

'

Increase in cash flow related to operating activities

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$1,000,000

'

'

Restatement_of_the_Consolidate3

Restatement of the Consolidated Financial Statements - Adjustments to Previously Filed Consolidated Income Statements (Detail) (USD $)	3 Months Ended								12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Net sales	$106,143	$92,738	$98,280	$103,373	$117,365	$107,857	$113,423	$108,936	$400,534	$447,581	$441,971
Cost of sales	32,517	23,920	20,246	25,617	24,944	24,384	27,547	21,378	102,300	98,253	95,527
Gross profit	73,626	68,818	78,034	77,756	92,421	83,473	85,876	87,558	298,234	349,328	346,444
Operating expenses	'	'	'	'	'	'	'	'	'	'	'
Sales and marketing	'	'	'	'	'	'	'	'	176,581	187,131	193,511
General and administrative	'	'	'	'	'	'	'	'	65,147	53,391	64,481
Research and development	'	'	'	'	'	'	'	'	26,768	28,577	22,861
Amortization of intangible assets	'	'	'	'	'	'	'	'	2,687	2,298	2,550
Charges related to U.S. Government resolutions	'	'	'	'	'	'	'	'	'	1,295	57,141
Total operation expenses	80,004	84,418	69,230	69,669	66,808	64,668	71,578	69,638	303,321	272,692	340,544
Operating (loss) income	6,378	-15,600	8,804	8,087	25,613	18,805	14,298	17,920	-5,087	76,636	5,900
Other income and (expense)	'	'	'	'	'	'	'	'	295	-6,448	-7,953
Income (loss) before income taxes	'	'	'	'	'	'	'	'	-4,792	70,188	-2,053
Income tax expense	'	'	'	'	'	'	'	'	-10,116	-25,138	-14,165
Net income (loss) from continuing operations	-8,564	-18,084	4,130	7,610	16,009	10,574	9,870	8,597	-14,908	45,050	-16,218
As Previously or Currently Reported [Member]	'	'	'	'	'	'	'	'	'	'	'
Net sales	'	'	'	100,254	112,035	114,752	119,492	116,041	'	462,320	470,121
Cost of sales	'	'	'	22,699	18,504	22,373	23,676	21,939	'	86,492	92,619
Gross profit	'	'	'	77,555	93,531	92,379	95,816	94,102	'	375,828	377,502
Operating expenses	'	'	'	'	'	'	'	'	'	'	'
Sales and marketing	'	'	'	'	'	'	'	'	'	200,343	200,145
General and administrative	'	'	'	'	'	'	'	'	'	53,827	64,374
Research and development	'	'	'	'	'	'	'	'	'	28,577	22,861
Amortization of intangible assets	'	'	'	'	'	'	'	'	'	2,098	2,350
Charges related to U.S. Government resolutions	'	'	'	'	'	'	'	'	'	1,973	56,463
Total operation expenses	'	'	'	73,531	69,050	70,846	75,251	71,671	'	286,818	346,193
Operating (loss) income	'	'	'	4,024	24,481	21,533	20,565	22,431	'	89,010	31,309
Other income and (expense)	'	'	'	'	'	'	'	'	'	-6,282	-11,868
Income (loss) before income taxes	'	'	'	'	'	'	'	'	'	82,728	19,441
Income tax expense	'	'	'	'	'	'	'	'	'	-28,792	-21,181
Net income (loss) from continuing operations	'	'	'	4,908	14,636	13,118	13,967	12,215	'	53,936	-1,740
Total Adjustment [Member]	'	'	'	'	'	'	'	'	'	'	'
Net sales	'	'	'	'	'	'	'	'	'	-14,739	-28,150
Cost of sales	'	'	'	'	'	'	'	'	'	11,761	2,908
Gross profit	'	'	'	'	'	'	'	'	'	-26,500	-31,058
Operating expenses	'	'	'	'	'	'	'	'	'	'	'
Sales and marketing	'	'	'	'	'	'	'	'	'	-13,212	-6,634
General and administrative	'	'	'	'	'	'	'	'	'	-436	107
Research and development	'	'	'	'	'	'	'	'	'	'	'
Amortization of intangible assets	'	'	'	'	'	'	'	'	'	200	200
Charges related to U.S. Government resolutions	'	'	'	'	'	'	'	'	'	-678	678
Total operation expenses	'	'	'	'	'	'	'	'	'	-14,126	-5,649
Operating (loss) income	'	'	'	'	'	'	'	'	'	-12,374	-25,409
Other income and (expense)	'	'	'	'	'	'	'	'	'	-166	3,915
Income (loss) before income taxes	'	'	'	'	'	'	'	'	'	-12,540	-21,494
Income tax expense	'	'	'	'	'	'	'	'	'	3,654	7,016
Net income (loss) from continuing operations	'	'	'	'	'	'	'	'	'	-8,886	-14,478
Distributor Revenue [Member]	'	'	'	'	'	'	'	'	'	'	'
Net sales	'	'	'	'	'	'	'	'	'	-14,777	-29,135
Cost of sales	'	'	'	'	'	'	'	'	'	-2,032	-8,289
Gross profit	'	'	'	'	'	'	'	'	'	-12,745	-20,846
Operating expenses	'	'	'	'	'	'	'	'	'	'	'
Sales and marketing	'	'	'	'	'	'	'	'	'	-6,629	-1,216
General and administrative	'	'	'	'	'	'	'	'	'	-2	'
Research and development	'	'	'	'	'	'	'	'	'	'	'
Amortization of intangible assets	'	'	'	'	'	'	'	'	'	'	'
Charges related to U.S. Government resolutions	'	'	'	'	'	'	'	'	'	'	'
Total operation expenses	'	'	'	'	'	'	'	'	'	-6,631	-1,216
Operating (loss) income	'	'	'	'	'	'	'	'	'	-6,114	-19,630
Other income and (expense)	'	'	'	'	'	'	'	'	'	'	'
Income (loss) before income taxes	'	'	'	'	'	'	'	'	'	-6,114	-19,630
Income tax expense	'	'	'	'	'	'	'	'	'	1,782	6,408
Net income (loss) from continuing operations	'	'	'	'	'	'	'	'	'	-4,332	-13,222
Inventory Reserves [Member]	'	'	'	'	'	'	'	'	'	'	'
Net sales	'	'	'	'	'	'	'	'	'	'	'
Cost of sales	'	'	'	'	'	'	'	'	'	5,647	3,377
Gross profit	'	'	'	'	'	'	'	'	'	-5,647	-3,377
Operating expenses	'	'	'	'	'	'	'	'	'	'	'
Sales and marketing	'	'	'	'	'	'	'	'	'	'	'
General and administrative	'	'	'	'	'	'	'	'	'	'	'
Research and development	'	'	'	'	'	'	'	'	'	'	'
Amortization of intangible assets	'	'	'	'	'	'	'	'	'	'	'
Charges related to U.S. Government resolutions	'	'	'	'	'	'	'	'	'	'	'
Total operation expenses	'	'	'	'	'	'	'	'	'	'	'
Operating (loss) income	'	'	'	'	'	'	'	'	'	-5,647	-3,377
Other income and (expense)	'	'	'	'	'	'	'	'	'	'	'
Income (loss) before income taxes	'	'	'	'	'	'	'	'	'	-5,647	-3,377
Income tax expense	'	'	'	'	'	'	'	'	'	1,645	1,102
Net income (loss) from continuing operations	'	'	'	'	'	'	'	'	'	-4,002	-2,275
Royalties [Member]	'	'	'	'	'	'	'	'	'	'	'
Net sales	'	'	'	'	'	'	'	'	'	'	'
Cost of sales	'	'	'	'	'	'	'	'	'	8,190	7,713
Gross profit	'	'	'	'	'	'	'	'	'	-8,190	-7,713
Operating expenses	'	'	'	'	'	'	'	'	'	'	'
Sales and marketing	'	'	'	'	'	'	'	'	'	-8,190	-7,713
General and administrative	'	'	'	'	'	'	'	'	'	'	'
Research and development	'	'	'	'	'	'	'	'	'	'	'
Amortization of intangible assets	'	'	'	'	'	'	'	'	'	'	'
Charges related to U.S. Government resolutions	'	'	'	'	'	'	'	'	'	'	'
Total operation expenses	'	'	'	'	'	'	'	'	'	-8,190	-7,713
Operating (loss) income	'	'	'	'	'	'	'	'	'	'	'
Other income and (expense)	'	'	'	'	'	'	'	'	'	'	'
Income (loss) before income taxes	'	'	'	'	'	'	'	'	'	'	'
Income tax expense	'	'	'	'	'	'	'	'	'	'	'
Net income (loss) from continuing operations	'	'	'	'	'	'	'	'	'	'	'
Other Adjustment [Member]	'	'	'	'	'	'	'	'	'	'	'
Net sales	'	'	'	'	'	'	'	'	'	38	985
Cost of sales	'	'	'	'	'	'	'	'	'	-44	107
Gross profit	'	'	'	'	'	'	'	'	'	82	878
Operating expenses	'	'	'	'	'	'	'	'	'	'	'
Sales and marketing	'	'	'	'	'	'	'	'	'	1,607	2,295
General and administrative	'	'	'	'	'	'	'	'	'	-434	107
Research and development	'	'	'	'	'	'	'	'	'	'	'
Amortization of intangible assets	'	'	'	'	'	'	'	'	'	200	200
Charges related to U.S. Government resolutions	'	'	'	'	'	'	'	'	'	-678	678
Total operation expenses	'	'	'	'	'	'	'	'	'	695	3,280
Operating (loss) income	'	'	'	'	'	'	'	'	'	-613	-2,402
Other income and (expense)	'	'	'	'	'	'	'	'	'	-166	3,915
Income (loss) before income taxes	'	'	'	'	'	'	'	'	'	-779	1,513
Income tax expense	'	'	'	'	'	'	'	'	'	227	-494
Net income (loss) from continuing operations	'	'	'	'	'	'	'	'	'	($552)	$1,019

Restatement_of_the_Consolidate4

Restatement of the Consolidated Financial Statements - Effects of Restatements on Consolidated Balance Sheet (Detail) (USD $)	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Dec. 31, 2011	Dec. 31, 2010
In Thousands, unless otherwise specified
Current assets:	'	'	'	'	'	'	'	'	'	'
Cash and cash equivalents	$30,486	'	'	'	$31,055	'	'	'	$33,207	$13,561
Restricted cash	23,761	'	'	'	21,314	'	'	'	'	'
Trade accounts receivable, less allowances of $13,543	75,567	'	'	'	107,312	'	'	'	'	'
Inventories	90,577	'	'	'	83,373	'	'	'	'	'
Deferred income taxes	33,947	'	'	'	33,450	'	'	'	'	'
Prepaid expenses and other current assets	25,906	'	'	'	34,079	'	'	'	'	'
Total current assets	280,244	'	'	'	310,583	'	'	'	'	'
Property, plant and equipment, net	54,606	'	'	'	53,835	'	'	'	'	'
Patents and other intangible assets, net	9,046	'	'	'	7,290	'	'	'	'	'
Goodwill	53,565	'	72,758	'	74,388	'	'	'	73,094	'
Deferred income taxes	18,336	'	'	'	18,881	'	'	'	'	'
Other long-term assets	7,385	'	'	'	7,920	'	'	'	'	'
Total assets	423,182	430,058	459,450	475,758	472,897	539,566	530,395	694,106	'	'
Current liabilities:	'	'	'	'	'	'	'	'	'	'
Bank borrowings	'	'	'	'	16	'	'	'	'	'
Trade accounts payable	20,674	'	'	'	22,575	'	'	'	'	'
Other current liabilities	46,146	'	'	'	39,594	'	'	'	'	'
Total current liabilities	66,820	'	'	'	62,185	'	'	'	'	'
Long-term debt	20,000	'	'	'	20,000	'	'	'	'	'
Deferred income taxes	13,132	'	'	'	11,456	'	'	'	'	'
Other long-term liabilities	12,736	'	'	'	11,424	'	'	'	'	'
Total liabilities	112,688	111,001	114,223	102,366	105,065	193,599	205,196	381,734	'	'
Contingencies (Note 17)	'	'	'	'	'	'	'	'	'	'
Shareholders' equity	'	'	'	'	'	'	'	'	'	'
Common shares $0.10 par value; 50,000,000 shares authorized; 19,339,329 issued and outstanding	1,810	'	'	'	1,934	'	'	'	'	'
Additional paid-in capital	216,653	'	'	'	246,306	'	'	'	'	'
Retained earnings	89,332	'	'	'	114,847	'	'	'	'	'
Accumulated other comprehensive income	2,699	'	'	'	4,745	'	'	'	'	'
Total shareholders' equity	310,494	319,057	345,227	373,392	367,832	345,967	325,199	312,372	292,074	'
Total liabilities and shareholders' equity	423,182	430,058	459,450	475,758	472,897	539,566	530,395	694,106	'	'
As Previously or Currently Reported [Member]	'	'	'	'	'	'	'	'	'	'
Current assets:	'	'	'	'	'	'	'	'	'	'
Cash and cash equivalents	'	'	'	'	31,055	'	'	'	'	'
Restricted cash	'	'	'	'	21,314	'	'	'	'	'
Trade accounts receivable, less allowances of $13,543	'	'	'	'	150,316	'	'	'	'	'
Inventories	'	'	'	'	88,744	'	'	'	'	'
Deferred income taxes	'	'	'	'	16,959	'	'	'	'	'
Prepaid expenses and other current assets	'	'	'	'	32,056	'	'	'	'	'
Total current assets	'	'	'	'	340,444	'	'	'	'	'
Property, plant and equipment, net	'	'	'	'	51,362	'	'	'	'	'
Patents and other intangible assets, net	'	'	'	'	6,880	'	'	'	'	'
Goodwill	'	'	'	'	74,388	'	'	'	'	'
Deferred income taxes	'	'	'	'	19,904	'	'	'	'	'
Other long-term assets	'	'	'	'	11,303	'	'	'	'	'
Total assets	'	'	'	503,380	504,281	565,073	553,320	707,586	'	'
Current liabilities:	'	'	'	'	'	'	'	'	'	'
Bank borrowings	'	'	'	'	16	'	'	'	'	'
Trade accounts payable	'	'	'	'	21,812	'	'	'	'	'
Other current liabilities	'	'	'	'	46,969	'	'	'	'	'
Total current liabilities	'	'	'	'	68,797	'	'	'	'	'
Long-term debt	'	'	'	'	20,000	'	'	'	'	'
Deferred income taxes	'	'	'	'	11,456	'	'	'	'	'
Other long-term liabilities	'	'	'	'	4,930	'	'	'	'	'
Total liabilities	'	'	'	101,212	105,183	187,463	199,104	369,178	'	'
Contingencies (Note 17)	'	'	'	'	'	'	'	'	'	'
Shareholders' equity	'	'	'	'	'	'	'	'	'	'
Common shares $0.10 par value; 50,000,000 shares authorized; 19,339,329 issued and outstanding	'	'	'	'	1,934	'	'	'	'	'
Additional paid-in capital	'	'	'	'	246,111	'	'	'	'	'
Retained earnings	'	'	'	'	148,549	'	'	'	'	'
Accumulated other comprehensive income	'	'	'	'	2,504	'	'	'	'	'
Total shareholders' equity	'	'	'	402,168	399,098	377,610	354,216	338,408	'	'
Total liabilities and shareholders' equity	'	'	'	503,380	504,281	565,073	553,320	707,586	'	'
Restatement Adjustments [Member]	'	'	'	'	'	'	'	'	'	'
Current assets:	'	'	'	'	'	'	'	'	'	'
Cash and cash equivalents	'	'	'	'	'	'	'	'	'	'
Restricted cash	'	'	'	'	'	'	'	'	'	'
Trade accounts receivable, less allowances of $13,543	'	'	'	'	-43,004	'	'	'	'	'
Inventories	'	'	'	'	-5,371	'	'	'	'	'
Deferred income taxes	'	'	'	'	16,491	'	'	'	'	'
Prepaid expenses and other current assets	'	'	'	'	2,023	'	'	'	'	'
Total current assets	'	'	'	'	-29,861	'	'	'	'	'
Property, plant and equipment, net	'	'	'	'	2,473	'	'	'	'	'
Patents and other intangible assets, net	'	'	'	'	410	'	'	'	'	'
Goodwill	'	'	'	'	'	'	'	'	'	'
Deferred income taxes	'	'	'	'	-1,023	'	'	'	'	'
Other long-term assets	'	'	'	'	-3,383	'	'	'	'	'
Total assets	'	'	'	-27,622	-31,384	-25,507	-22,925	-13,480	'	'
Current liabilities:	'	'	'	'	'	'	'	'	'	'
Bank borrowings	'	'	'	'	'	'	'	'	'	'
Trade accounts payable	'	'	'	'	763	'	'	'	'	'
Other current liabilities	'	'	'	'	-7,375	'	'	'	'	'
Total current liabilities	'	'	'	'	-6,612	'	'	'	'	'
Long-term debt	'	'	'	'	'	'	'	'	'	'
Deferred income taxes	'	'	'	'	'	'	'	'	'	'
Other long-term liabilities	'	'	'	'	6,494	'	'	'	'	'
Total liabilities	'	'	'	1,154	-118	6,136	6,092	12,556	'	'
Contingencies (Note 17)	'	'	'	'	'	'	'	'	'	'
Shareholders' equity	'	'	'	'	'	'	'	'	'	'
Common shares $0.10 par value; 50,000,000 shares authorized; 19,339,329 issued and outstanding	'	'	'	'	'	'	'	'	'	'
Additional paid-in capital	'	'	'	'	195	'	'	'	'	'
Retained earnings	'	'	'	'	-33,702	'	'	'	'	'
Accumulated other comprehensive income	'	'	'	'	2,241	'	'	'	'	'
Total shareholders' equity	'	'	'	-28,776	-31,266	-31,643	-29,017	-26,036	'	'
Total liabilities and shareholders' equity	'	'	'	($27,622)	($31,384)	($25,507)	($22,925)	($13,480)	'	'

Restatement_of_the_Consolidate5

Restatement of the Consolidated Financial Statements - Effects of Restatements on Consolidated Balance Sheet (Parenthetical) (Detail) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, except Share data, unless otherwise specified
Trade accounts receivable, allowances	$11,969	$13,543
Common shares, par value	$0.10	$0.10
Common shares, authorized	50,000,000	50,000,000
Common shares, issued	18,102,335	19,339,329
Common shares, outstanding	18,102,335	19,339,329
As Previously or Currently Reported [Member]	'	'
Trade accounts receivable, allowances	'	13,543
Common shares, par value	'	$0.10
Common shares, authorized	'	50,000,000
Common shares, issued	'	19,339,329
Common shares, outstanding	'	19,339,329
Restatement Adjustments [Member]	'	'
Trade accounts receivable, allowances	'	$13,543

Restatement_of_the_Consolidate6

Restatement of the Consolidated Financial Statements - Effects of Restatements of Consolidated Statement of Operations and Comprehensive Income (Loss) (Detail) (USD $)	3 Months Ended								12 Months Ended
In Thousands, except Share data, unless otherwise specified	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Product sales	'	'	'	'	'	'	'	'	$352,796	$401,039	$405,147
Marketing service fees	'	'	'	'	'	'	'	'	47,738	46,542	36,824
Net sales	106,143	92,738	98,280	103,373	117,365	107,857	113,423	108,936	400,534	447,581	441,971
Cost of sales	32,517	23,920	20,246	25,617	24,944	24,384	27,547	21,378	102,300	98,253	95,527
Gross profit	73,626	68,818	78,034	77,756	92,421	83,473	85,876	87,558	298,234	349,328	346,444
Operating expenses	'	'	'	'	'	'	'	'	'	'	'
Sales and marketing	'	'	'	'	'	'	'	'	176,581	187,131	193,511
General and administrative	'	'	'	'	'	'	'	'	65,147	53,391	64,481
Research and development	'	'	'	'	'	'	'	'	26,768	28,577	22,861
Amortization of intangible assets	'	'	'	'	'	'	'	'	2,687	2,298	2,550
Charges related to U.S. Government resolutions (Note 17)	'	'	'	'	'	'	'	'	'	1,295	57,141
Total operating expenses	80,004	84,418	69,230	69,669	66,808	64,668	71,578	69,638	303,321	272,692	340,544
Operating (loss) income	6,378	-15,600	8,804	8,087	25,613	18,805	14,298	17,920	-5,087	76,636	5,900
Other income and (expense)	'	'	'	'	'	'	'	'	'	'	'
Interest expense, net	'	'	'	'	'	'	'	'	-1,925	-4,743	-5,541
Other expense	'	'	'	'	'	'	'	'	2,220	-1,705	-2,412
Total other income (expense)	'	'	'	'	'	'	'	'	295	-6,448	-7,953
Income (loss) before income taxes	'	'	'	'	'	'	'	'	-4,792	70,188	-2,053
Income tax (expense) benefit	'	'	'	'	'	'	'	'	-10,116	-25,138	-14,165
Net income (loss) from continuing operations	-8,564	-18,084	4,130	7,610	16,009	10,574	9,870	8,597	-14,908	45,050	-16,218
Discontinued operations (Note 16)	'	'	'	'	'	'	'	'	'	'	'
Gain on sale of Breg, Inc	'	'	'	'	'	'	'	'	'	1,345	'
Income (loss) from discontinued operations	'	'	'	'	'	'	'	'	-15,510	-2,994	-2,705
Income tax (expense) benefit	'	'	'	'	'	'	'	'	4,903	-563	813
Net income (loss) from discontinued operations	'	'	'	'	'	'	'	'	-10,607	-2,212	-1,892
Net income (loss)	'	'	'	'	'	'	'	'	-25,515	42,838	-18,110
Net income (loss) per common share-basic:	'	'	'	'	'	'	'	'	'	'	'
Net income (loss) from continuing operations	($0.47)	($1)	$0.22	$0.39	$0.83	$0.55	$0.52	$0.46	($0.80)	$2.37	($0.89)
Net income (loss) from discontinued operations	'	'	'	'	'	'	'	'	($0.57)	($0.12)	($0.10)
Net income (loss) per common share-basic	($0.43)	($1.10)	($0.12)	$0.23	$1.10	$0.26	$0.38	$0.50	($1.37)	$2.25	($0.99)
Net income (loss) per common share-diluted:	'	'	'	'	'	'	'	'	'	'	'
Net income (loss) from continuing operations	($0.47)	($1)	$0.21	$0.39	$0.81	$0.54	$0.51	$0.45	($0.80)	$2.32	($0.89)
Net income (loss) from discontinued operations	'	'	'	'	'	'	'	'	($0.57)	($0.11)	($0.10)
Net income (loss) per common share-diluted:	($0.43)	($1.10)	($0.12)	$0.23	$1.07	$0.25	$0.37	$0.49	($1.37)	$2.21	($0.99)
Weighted average number of common shares:	'	'	'	'	'	'	'	'	'	'	'
Basic	'	'	'	'	'	'	'	'	18,697,228	18,977,263	18,219,343
Diluted	'	'	'	'	'	'	'	'	18,697,228	19,390,413	18,219,343
Other comprehensive income (loss), before tax:	'	'	'	'	'	'	'	'	'	'	'
Translation adjustment	'	'	'	'	'	'	'	'	-1,768	768	-2,279
Unrealized gain (loss) on derivative instrument	'	'	'	'	'	'	'	'	-442	416	-693
Other comprehensive income (loss), before tax	'	'	'	'	'	'	'	'	-2,210	1,184	-2,972
Income tax (expense) benefit related to components of other comprehensive income	164	'	'	'	-153	'	'	'	164	-153	256
Other comprehensive income (loss), net of tax	'	'	'	'	'	'	'	'	-2,046	1,031	-2,716
Comprehensive income (loss)	'	'	'	'	'	'	'	'	-27,561	43,869	-20,826
As Previously or Currently Reported [Member]	'	'	'	'	'	'	'	'	'	'	'
Product sales	'	'	'	'	'	'	'	'	'	415,850	432,975
Marketing service fees	'	'	'	'	'	'	'	'	'	46,470	37,146
Net sales	'	'	'	100,254	112,035	114,752	119,492	116,041	'	462,320	470,121
Cost of sales	'	'	'	22,699	18,504	22,373	23,676	21,939	'	86,492	92,619
Gross profit	'	'	'	77,555	93,531	92,379	95,816	94,102	'	375,828	377,502
Operating expenses	'	'	'	'	'	'	'	'	'	'	'
Sales and marketing	'	'	'	'	'	'	'	'	'	200,343	200,145
General and administrative	'	'	'	'	'	'	'	'	'	53,827	64,374
Research and development	'	'	'	'	'	'	'	'	'	28,577	22,861
Amortization of intangible assets	'	'	'	'	'	'	'	'	'	2,098	2,350
Charges related to U.S. Government resolutions (Note 17)	'	'	'	'	'	'	'	'	'	1,973	56,463
Total operating expenses	'	'	'	73,531	69,050	70,846	75,251	71,671	'	286,818	346,193
Operating (loss) income	'	'	'	4,024	24,481	21,533	20,565	22,431	'	89,010	31,309
Other income and (expense)	'	'	'	'	'	'	'	'	'	'	'
Interest expense, net	'	'	'	'	'	'	'	'	'	-4,577	-9,456
Other expense	'	'	'	'	'	'	'	'	'	-1,705	-2,412
Total other income (expense)	'	'	'	'	'	'	'	'	'	-6,282	-11,868
Income (loss) before income taxes	'	'	'	'	'	'	'	'	'	82,728	19,441
Income tax (expense) benefit	'	'	'	'	'	'	'	'	'	-28,792	-21,181
Net income (loss) from continuing operations	'	'	'	4,908	14,636	13,118	13,967	12,215	'	53,936	-1,740
Discontinued operations (Note 16)	'	'	'	'	'	'	'	'	'	'	'
Gain on sale of Breg, Inc	'	'	'	'	'	'	'	'	'	1,345	'
Income (loss) from discontinued operations	'	'	'	'	'	'	'	'	'	-4,012	1,263
Income tax (expense) benefit	'	'	'	'	'	'	'	'	'	26	-596
Net income (loss) from discontinued operations	'	'	'	'	'	'	'	'	'	-2,641	667
Net income (loss)	'	'	'	'	'	'	'	'	'	51,295	-1,073
Net income (loss) per common share-basic:	'	'	'	'	'	'	'	'	'	'	'
Net income (loss) from continuing operations	'	'	'	$0.25	$0.76	$0.69	$0.74	$0.65	'	$2.84	($0.10)
Net income (loss) from discontinued operations	'	'	'	'	'	'	'	'	'	($0.14)	$0.04
Net income (loss) per common share-basic	'	'	'	$0.11	$1.06	$0.40	$0.59	$0.64	'	$2.70	($0.06)
Net income (loss) per common share-diluted:	'	'	'	'	'	'	'	'	'	'	'
Net income (loss) from continuing operations	'	'	'	$0.25	$0.74	$0.67	$0.73	$0.64	'	$2.78	($0.10)
Net income (loss) from discontinued operations	'	'	'	'	'	'	'	'	'	($0.14)	$0.04
Net income (loss) per common share-diluted:	'	'	'	$0.11	$1.04	$0.39	$0.58	$0.63	'	$2.64	($0.06)
Weighted average number of common shares:	'	'	'	'	'	'	'	'	'	'	'
Basic	'	'	'	'	'	'	'	'	'	18,977,263	18,219,343
Diluted	'	'	'	'	'	'	'	'	'	19,390,413	18,219,343
Other comprehensive income (loss), before tax:	'	'	'	'	'	'	'	'	'	'	'
Translation adjustment	'	'	'	'	'	'	'	'	'	480	-3,192
Unrealized gain (loss) on derivative instrument	'	'	'	'	'	'	'	'	'	416	-693
Other comprehensive income (loss), before tax	'	'	'	'	'	'	'	'	'	896	-3,885
Income tax (expense) benefit related to components of other comprehensive income	'	'	'	'	-153	'	'	'	'	-153	256
Other comprehensive income (loss), net of tax	'	'	'	'	'	'	'	'	'	743	-3,629
Comprehensive income (loss)	'	'	'	'	'	'	'	'	'	52,038	-4,702
Restatement Adjustments [Member]	'	'	'	'	'	'	'	'	'	'	'
Product sales	'	'	'	'	'	'	'	'	'	-14,811	-27,828
Marketing service fees	'	'	'	'	'	'	'	'	'	72	-322
Net sales	'	'	'	3,119	5,330	-6,895	-6,069	-7,105	'	-14,739	-28,150
Cost of sales	'	'	'	2,918	6,440	2,011	3,871	-561	'	11,761	2,908
Gross profit	'	'	'	201	-1,110	-8,906	-9,940	-6,544	'	-26,500	-31,058
Operating expenses	'	'	'	'	'	'	'	'	'	'	'
Sales and marketing	'	'	'	'	'	'	'	'	'	-13,212	-6,634
General and administrative	'	'	'	'	'	'	'	'	'	-436	107
Amortization of intangible assets	'	'	'	'	'	'	'	'	'	200	200
Charges related to U.S. Government resolutions (Note 17)	'	'	'	'	'	'	'	'	'	-678	678
Total operating expenses	'	'	'	-3,862	-2,242	-6,178	-3,673	-2,033	'	-14,126	-5,649
Operating (loss) income	'	'	'	4,063	1,132	-2,728	-6,267	-4,511	'	-12,374	-25,409
Other income and (expense)	'	'	'	'	'	'	'	'	'	'	'
Interest expense, net	'	'	'	'	'	'	'	'	'	-166	3,915
Total other income (expense)	'	'	'	'	'	'	'	'	'	-166	3,915
Income (loss) before income taxes	'	'	'	'	'	'	'	'	'	-12,540	-21,494
Income tax (expense) benefit	'	'	'	'	'	'	'	'	'	3,654	7,016
Net income (loss) from continuing operations	'	'	'	2,702	1,373	-2,544	-4,097	-3,618	'	-8,886	-14,478
Discontinued operations (Note 16)	'	'	'	'	'	'	'	'	'	'	'
Income (loss) from discontinued operations	'	'	'	'	'	'	'	'	'	1,018	-3,968
Income tax (expense) benefit	'	'	'	'	'	'	'	'	'	-589	1,409
Net income (loss) from discontinued operations	'	'	'	'	'	'	'	'	'	429	-2,559
Net income (loss)	'	'	'	'	'	'	'	'	'	-8,457	-17,037
Net income (loss) per common share-basic:	'	'	'	'	'	'	'	'	'	'	'
Net income (loss) from continuing operations	'	'	'	$0.14	$0.07	($0.14)	($0.22)	($0.19)	'	($0.47)	($0.79)
Net income (loss) from discontinued operations	'	'	'	'	'	'	'	'	'	$0.02	($0.14)
Net income (loss) per common share-basic	'	'	'	$0.12	$0.04	($0.14)	($0.21)	($0.14)	'	($0.45)	($0.93)
Net income (loss) per common share-diluted:	'	'	'	'	'	'	'	'	'	'	'
Net income (loss) from continuing operations	'	'	'	$0.14	$0.07	($0.13)	($0.22)	($0.19)	'	($0.46)	($0.79)
Net income (loss) from discontinued operations	'	'	'	'	'	'	'	'	'	$0.03	($0.14)
Net income (loss) per common share-diluted:	'	'	'	$0.12	$0.03	($0.14)	($0.21)	($0.14)	'	($0.43)	($0.93)
Other comprehensive income (loss), before tax:	'	'	'	'	'	'	'	'	'	'	'
Translation adjustment	'	'	'	'	'	'	'	'	'	288	913
Other comprehensive income (loss), before tax	'	'	'	'	'	'	'	'	'	288	913
Other comprehensive income (loss), net of tax	'	'	'	'	'	'	'	'	'	288	913
Comprehensive income (loss)	'	'	'	'	'	'	'	'	'	($8,169)	($16,124)

Inventories_Schedule_of_Invent

Inventories - Schedule of Inventories (Detail) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Inventory Disclosure [Abstract]	'	'
Raw materials	$6,499	$7,623
Work-in-process	6,606	7,886
Finished products	31,342	28,308
Field inventory	34,932	22,629
Consignment inventory	3,916	6,155
Deferred cost of sales	7,282	10,772
Inventory, net	$90,577	$83,373

Property_Plant_and_Equipment_S

Property, Plant and Equipment - Schedule of Property,Plant and Equipment (Detail) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Property, Plant and Equipment [Line Items]	'	'
Cost	$141,519	$130,460
Accumulated depreciation	-86,913	-76,625
Total	54,606	53,835
Buildings [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Cost	4,075	3,911
Plant equipment and instrumentation [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Cost	131,572	120,982
Furniture and fixtures [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Cost	$5,872	$5,567

Property_Plant_and_Equipment_A

Property, Plant and Equipment - Additional Information (Detail) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Property Plant And Equipment Useful Life And Values [Abstract]	'	'	'
Depreciation expense	$20	$15.80	$14.30

Recovered_Sheet4

Patents and Other Intangible Assets - Schedule of Patents and Other Intangibles Assets (Detail) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Finite And Indefinite Lived Intangible Assets [Line Items]	'	'
Cost	$43,188	$39,562
Accumulated amortization	-34,142	-32,272
Patents and other intangible assets, net	9,046	7,290
Patents [Member]	'	'
Finite And Indefinite Lived Intangible Assets [Line Items]	'	'
Cost	42,568	38,905
Accumulated amortization	-33,688	-31,845
Trademarks-definite lived [Member]	'	'
Finite And Indefinite Lived Intangible Assets [Line Items]	'	'
Cost	620	657
Accumulated amortization	($454)	($427)

Recovered_Sheet5

Patents and Other Intangible Assets - Additional Information (Detail) (USD $)	Dec. 31, 2013
In Millions, unless otherwise specified
Future Amortization expense	'
2014	$2.10
2015	1.8
2016	1.7
2017	1.4
2018	0.5
2019 and thereafter	$1.50

Goodwill_Schedule_of_Changes_i

Goodwill - Schedule of Changes in Net Carrying Amount of Goodwill (Detail) (USD $)	6 Months Ended		12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Jun. 30, 2013	Dec. 31, 2013	Dec. 31, 2012
Goodwill [Line Items]	'	'	'	'
Beginning balance	$72,758	$74,388	$74,388	$73,094
Foreign currency	'	-1,630	'	1,294
Impairment	-19,193	'	-19,193	'
Ending balance	53,565	72,758	53,565	74,388
Spine [Member]	'	'	'	'
Goodwill [Line Items]	'	'	'	'
Beginning balance	41,401	41,564	41,564	41,419
Reallocation	-41,401	'	'	'
Foreign currency	'	-163	'	145
Impairment	'	'	'	'
Ending balance	'	41,401	'	41,564
Orthopedics [Member]	'	'	'	'
Goodwill [Line Items]	'	'	'	'
Beginning balance	31,357	32,824	32,824	31,675
Reallocation	-31,357	'	'	'
Foreign currency	'	-1,467	'	1,149
Impairment	'	'	'	'
Ending balance	'	31,357	'	32,824
BioStim [Member]	'	'	'	'
Goodwill [Line Items]	'	'	'	'
Beginning balance	'	'	'	'
Reallocation	42,678	'	'	'
Foreign currency	'	'	'	'
Impairment	'	'	'	'
Ending balance	42,678	'	42,678	'
Biologics [Member]	'	'	'	'
Goodwill [Line Items]	'	'	'	'
Beginning balance	'	'	'	'
Reallocation	10,887	'	'	'
Foreign currency	'	'	'	'
Impairment	'	'	'	'
Ending balance	10,887	'	10,887	'
Extremity Fixation [Member]	'	'	'	'
Goodwill [Line Items]	'	'	'	'
Beginning balance	'	'	'	'
Reallocation	9,825	'	'	'
Foreign currency	'	'	'	'
Impairment	-9,825	'	'	'
Ending balance	'	'	'	'
Spine Fixation [Member]	'	'	'	'
Goodwill [Line Items]	'	'	'	'
Beginning balance	'	'	'	'
Reallocation	9,368	'	'	'
Foreign currency	'	'	'	'
Impairment	-9,368	'	'	'
Ending balance	'	'	'	'

Goodwill_Additional_Informatio

Goodwill - Additional Information (Detail) (USD $)	6 Months Ended	12 Months Ended	3 Months Ended	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2013	Sep. 30, 2013	Dec. 31, 2013
			Spine Fixation and our Extremity Fixation reportable units [Member]	Spine Fixation and our Extremity Fixation reportable units [Member]
Goodwill [Line Items]	'	'	'	'
Impairment of goodwill	$19,193	$19,193	$19,200	$19,200

Bank_Borrowings_Additional_Inf

Bank Borrowings - Additional Information (Detail)	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2012
In Millions, unless otherwise specified	USD ($)	EUR (€)	USD ($)	EUR (€)
Equity Method Investments And Cost Method Investments [Abstract]	'	'	'	'
Amount outstanding under lines of credit	$0	'	$0.01	'
Weighted average interest rate on borrowings under lines of credit	3.70%	3.70%	3.70%	3.70%
Maximum borrowing capacity	$8	€ 5.80	$7.60	€ 5.80

Other_Current_Liabilities_Summ

Other Current Liabilities - Summary of Other Current Liabilities (Detail) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Payables And Accruals [Abstract]	'	'
Accrued expenses	$16,016	$9,089
Salaries, bonuses, commissions and related taxes payable	16,598	17,915
Accrued legal expenses	10,292	8,496
Other payables	3,240	4,094
Total	$46,146	$39,594

LongTerm_Debt_Additional_Infor

Long-Term Debt - Additional Information (Detail)

12 Months Ended

1 Months Ended

12 Months Ended

12 Months Ended

0 Months Ended

1 Months Ended

12 Months Ended

12 Months Ended

12 Months Ended

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2012

Sep. 30, 2012

Jun. 30, 2012

31-May-12

Dec. 31, 2013

Dec. 31, 2012

Aug. 30, 2010

Dec. 31, 2013

Dec. 31, 2012

Aug. 30, 2010

31-May-12

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Aug. 30, 2010

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

USD ($)

USD ($)

USD ($)

EUR (€)

EUR (€)

Revolving Credit Facility [Member]

Revolving Credit Facility [Member]

Revolving Credit Facility [Member]

Revolving Credit Facility [Member]

Revolving Credit Facility [Member]

Revolving Credit Facility [Member]

Revolving Credit Facility [Member]

Revolving Credit Facility [Member]

Term Loan Facility [Member]

Term Loan Facility [Member]

Term Loan Facility [Member]

Term Loan Facility [Member]

Term Loan Facility [Member]

New Credit Agreement [Member]

New Credit Agreement [Member]

New Credit Agreement [Member]

Prior Credit Agreement [Member]

Prior Credit Agreement [Member]

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

LIBOR [Member]

LIBOR [Member]

USD ($)

USD ($)

USD ($)

USD ($)

Base rate [Member]

USD ($)

LIBOR [Member]

Base rate [Member]

LIBOR [Member]

LIBOR [Member]

Maximum [Member]

Maximum [Member]

Maximum [Member]

Debt Instrument [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt instrument term (in years)

'

'

'

'

'

'

'

'

'5 years

'

'

'

'

'

'

'5 years

'

'

'

'

'

'

'

Maximum borrowing capacity

$8,000,000

$7,600,000

'

€ 5,800,000

€ 5,800,000

'

'

'

'

'

$200,000,000

'

'

'

'

'

'

'

'

'

'

'

'

Maximum borrowing capacity

'

'

'

'

'

'

'

'

'

'

'

'

'

100,000,000

'

'

'

'

'

'

'

'

'

Maximum additional borrowing capacity available

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

50,000,000

'

'

'

'

Repayment of debt obligation

16,000

188,695,000

7,500,000

'

'

'

'

'

'

'

'

'

'

'

87,500,000

87,500,000

'

'

'

'

'

'

'

Repayment of debt obligation

'

'

'

'

'

20,000,000

20,000,000

57,500,000

57,500,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Amount outstanding

0

10,000

'

'

'

'

'

'

20,000,000

20,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

Margin on variable rate

'

'

'

'

'

'

'

'

'

'

'

2.50%

2.50%

'

'

'

'

'

'

3.25%

2.25%

'

'

Variable rate basis

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'LIBOR

'

'

'

'

'

Effective interest rate (as a Percent)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2.70%

2.70%

Revolving credit facility due date

'

'

'

'

'

'

'

'

30-Aug-15

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Amount of restricted net assets

192,000,000

213,400,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Restricted cash

23,761,000

21,314,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt issuance costs incurred

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

5,000,000

'

'

'

'

'

'

'

Write-off of debt issue costs

'

'

'

'

'

'

'

'

'

'

'

'

'

'

800,000

'

'

'

'

'

'

'

'

Deferred debt issuance costs, net

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$1,100,000

$1,800,000

'

'

'

'

'

'

Derivative_Instruments_Schedul

Derivative Instruments - Schedule of Fair Values of Derivative Instruments (Detail) (Cross-currency swap [Member], USD $)	Dec. 31, 2013
In Thousands, unless otherwise specified
Other long-term liabilities [Member]	'
Derivatives, Fair Value [Line Items]	'
Fair value: favorable (unfavorable)	($1,036)
Other long-term assets [Member]	'
Derivatives, Fair Value [Line Items]	'
Fair value: favorable (unfavorable)	$305

Derivative_Instruments_Schedul1

Derivative Instruments - Schedule of Gain (Loss) Recognized on Derivative Instruments (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Derivative Instruments [Line Items]	'	'	'
Cross-currency swap gain (loss) recorded in other comprehensive income (loss), net of taxes	($278)	$263	($437)
Cross-currency swap [Member]	'	'	'
Derivative Instruments [Line Items]	'	'	'
Cross-currency swap gain (loss) recorded in other comprehensive income (loss), net of taxes	($278)	$263	($437)

Derivative_Instruments_Additio

Derivative Instruments - Additional Information (Detail)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2013	Sep. 30, 2010	Sep. 30, 2010
	Swap Agreement [Member]	Cross-currency swap [Member]	Cross-currency swap [Member]
		Designated as Hedging Instrument [Member]	Designated as Hedging Instrument [Member]
		Pay Euros [Member]	Receive U.S. dollars [Member]
		EUR (€)	USD ($)
Derivatives, Fair Value [Line Items]	'	'	'
Notional amount	'	€ 28.70	$39
Fixed rate (as a percent)	'	5.00%	4.64%
Swap agreement expiration date	30-Dec-16	'	'

Fair_Value_Measurements_Additi

Fair Value Measurements - Additional Information (Detail) (Maximum [Member])	12 Months Ended
	Dec. 31, 2013
Maximum [Member]	'
Financial Instruments And Fair Value Measurements [Line Items]	'
Cash equivalents original maturity period	'90 days

Fair_Value_Measurements_Schedu

Fair Value Measurements - Schedule of Financial Assets and Liabilities Recorded at Fair Value on Recurring Basis (Detail) (Fair Value, Measurements, Recurring [Member], USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Deferred compensation plan, Assets	$3,361	$3,305
Cross currency hedge, Assets	'	305
Assets fair value, Total	3,361	3,610
Deferred Compensation Plan, Liabilities	-2,506	-2,320
Cross currency hedge, Liabilities	-1,036	'
Liabilities fair value, Total	-3,542	-2,320
Fair Value, Inputs, Level 1 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Deferred compensation plan, Assets	3,361	3,305
Cross currency hedge, Assets	'	'
Assets fair value, Total	3,361	3,305
Deferred Compensation Plan, Liabilities	-2,506	-2,320
Cross currency hedge, Liabilities	'	'
Liabilities fair value, Total	-2,506	-2,320
Fair Value, Inputs, Level 2 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Deferred compensation plan, Assets	'	'
Cross currency hedge, Assets	'	305
Assets fair value, Total	'	305
Deferred Compensation Plan, Liabilities	'	'
Cross currency hedge, Liabilities	-1,036	'
Liabilities fair value, Total	-1,036	'
Fair Value, Inputs, Level 3 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Deferred compensation plan, Assets	'	'
Cross currency hedge, Assets	'	'
Assets fair value, Total	'	'
Deferred Compensation Plan, Liabilities	'	'
Cross currency hedge, Liabilities	'	'
Liabilities fair value, Total	'	'

Commitments_Additional_Informa

Commitments - Additional Information (Detail) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Commitments And Contingencies Disclosure [Abstract]	'	'	'
Rent expenses	$3.40	$4.10	$4.80

Commitments_Schedule_of_Future

Commitments - Schedule of Future Minimum Lease Payments Under Operating Leases, Net of Amount to be Received Under Sub Leases (Detail) (USD $)	Dec. 31, 2013
In Thousands, unless otherwise specified
Commitments And Contingencies Disclosure [Abstract]	'
2014	$4,342
2015	4,107
2016	3,713
2017	2,974
2018	2,846
Thereafter	3,049
Total	$21,031

Business_Segment_Information_A

Business Segment Information - Additional Information (Detail)	12 Months Ended
	Dec. 31, 2013
	Segment
Segment Reporting [Abstract]	'
Number of strategic business units	4

Business_Segment_Information_S

Business Segment Information - Schedule of External Net Sales by SBU Reporting Segment (Detail) (USD $)	3 Months Ended								12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Sales Information [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Percent of Total Net Sales	'	'	'	'	'	'	'	'	100.00%	100.00%	100.00%
Net sales	$106,143	$92,738	$98,280	$103,373	$117,365	$107,857	$113,423	$108,936	$400,534	$447,581	$441,971
BioStim [Member]	'	'	'	'	'	'	'	'	'	'	'
Sales Information [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Percent of Total Net Sales	'	'	'	'	'	'	'	'	37.00%	41.00%	43.00%
Net sales	'	'	'	'	'	'	'	'	147,910	181,959	188,136
Biologics [Member]	'	'	'	'	'	'	'	'	'	'	'
Sales Information [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Percent of Total Net Sales	'	'	'	'	'	'	'	'	13.00%	12.00%	10.00%
Net sales	'	'	'	'	'	'	'	'	53,769	53,730	42,919
Spine Fixation [Member]	'	'	'	'	'	'	'	'	'	'	'
Sales Information [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Percent of Total Net Sales	'	'	'	'	'	'	'	'	24.00%	22.00%	20.00%
Net sales	'	'	'	'	'	'	'	'	95,470	99,883	91,395
Extremity Fixation [Member]	'	'	'	'	'	'	'	'	'	'	'
Sales Information [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Percent of Total Net Sales	'	'	'	'	'	'	'	'	26.00%	25.00%	27.00%
Net sales	'	'	'	'	'	'	'	'	$103,385	$112,009	$119,521

Business_Segment_Information_S1

Business Segment Information - Summary of Net Margin, Defined as Gross Profit Less Sales and Marketing Expenses from Continuing Operations by SBU Reporting Segment (Detail) (USD $)

3 Months Ended

6 Months Ended

12 Months Ended

In Thousands, unless otherwise specified

Dec. 31, 2013

Sep. 30, 2013

Jun. 30, 2013

Mar. 31, 2013

Dec. 31, 2012

Sep. 30, 2012

Jun. 30, 2012

Mar. 31, 2012

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Sales Information [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

Total net margin

'

'

'

'

'

'

'

'

'

$121,653

$162,197

$152,933

General & administrative

'

'

'

'

'

'

'

'

'

65,147

53,391

64,481

Research and development

'

'

'

'

'

'

'

'

'

26,768

28,577

22,861

Amortization of intangible assets

'

'

'

'

'

'

'

'

'

2,687

2,298

2,550

Costs related to the accounting review and restatement

'

'

'

'

'

'

'

'

'

12,945

'

'

Impairment of goodwill

'

'

'

'

'

'

'

'

19,193

19,193

'

'

Charges related to U.S. Government resolutions

'

'

'

'

'

'

'

'

'

'

1,295

57,141

Operating (loss) income

6,378

-15,600

8,804

8,087

25,613

18,805

14,298

17,920

'

-5,087

76,636

5,900

BioStim [Member]

'

'

'

'

'

'

'

'

'

'

'

'

Sales Information [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

Total net margin

'

'

'

'

'

'

'

'

'

64,930

86,654

93,056

Impairment of goodwill

'

'

'

'

'

'

'

'

'

'

'

'

Biologics [Member]

'

'

'

'

'

'

'

'

'

'

'

'

Sales Information [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

Total net margin

'

'

'

'

'

'

'

'

'

24,532

23,559

18,979

Impairment of goodwill

'

'

'

'

'

'

'

'

'

'

'

'

Extremity Fixation [Member]

'

'

'

'

'

'

'

'

'

'

'

'

Sales Information [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

Total net margin

'

'

'

'

'

'

'

'

'

26,389

34,337

29,530

Impairment of goodwill

'

'

'

'

'

'

'

'

9,825

'

'

'

Spine Fixation [Member]

'

'

'

'

'

'

'

'

'

'

'

'

Sales Information [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

Total net margin

'

'

'

'

'

'

'

'

'

7,245

19,142

13,068

Impairment of goodwill

'

'

'

'

'

'

'

'

9,368

'

'

'

Corporate [Member]

'

'

'

'

'

'

'

'

'

'

'

'

Sales Information [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

Total net margin

'

'

'

'

'

'

'

'

'

($1,443)

($1,495)

($1,700)

Business_Segment_Information_S2

Business Segment Information - Schedule of Depreciation and Amortization by SBU Reporting Segment (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Sales Information [Line Items]	'	'	'
Depreciation and amortization	$22,659	$20,580	$23,017
BioStim [Member]	'	'	'
Sales Information [Line Items]	'	'	'
Depreciation and amortization	1,946	1,584	2,033
Biologics [Member]	'	'	'
Sales Information [Line Items]	'	'	'
Depreciation and amortization	628	543	415
Extremity Fixation [Member]	'	'	'
Sales Information [Line Items]	'	'	'
Depreciation and amortization	7,195	5,196	5,148
Spine Fixation [Member]	'	'	'
Sales Information [Line Items]	'	'	'
Depreciation and amortization	12,794	10,752	9,211
Operating Segments [Member] | Corporate [Member]	'	'	'
Sales Information [Line Items]	'	'	'
Depreciation and amortization	$96	$70	$53

Business_Segment_Information_S3

Business Segment Information - Summary of Net Sales by Geographic Destination (Detail) (USD $)	3 Months Ended								12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Revenues from External Customers and Long-Lived Assets [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Net sales	$106,143	$92,738	$98,280	$103,373	$117,365	$107,857	$113,423	$108,936	$400,534	$447,581	$441,971
Domestic Tax Authority [Member] | U.S. [Member]	'	'	'	'	'	'	'	'	'	'	'
Revenues from External Customers and Long-Lived Assets [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Net sales	'	'	'	'	'	'	'	'	295,857	334,624	328,585
Foreign Tax Authority [Member]	'	'	'	'	'	'	'	'	'	'	'
Revenues from External Customers and Long-Lived Assets [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Net sales	'	'	'	'	'	'	'	'	104,677	112,957	113,386
Foreign Tax Authority [Member] | U.K. [Member]	'	'	'	'	'	'	'	'	'	'	'
Revenues from External Customers and Long-Lived Assets [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Net sales	'	'	'	'	'	'	'	'	10,002	8,431	8,206
Foreign Tax Authority [Member] | Italy [Member]	'	'	'	'	'	'	'	'	'	'	'
Revenues from External Customers and Long-Lived Assets [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Net sales	'	'	'	'	'	'	'	'	16,755	18,742	17,447
Foreign Tax Authority [Member] | Brazil [Member]	'	'	'	'	'	'	'	'	'	'	'
Revenues from External Customers and Long-Lived Assets [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Net sales	'	'	'	'	'	'	'	'	26,786	31,166	34,424
Foreign Tax Authority [Member] | Others [Member]	'	'	'	'	'	'	'	'	'	'	'
Revenues from External Customers and Long-Lived Assets [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Net sales	'	'	'	'	'	'	'	'	$51,134	$54,618	$53,309

Business_Segment_Information_A1

Business Segment Information - Analysis of Property, Plant and Equipment of Reporting Segments by Geographic Area (Detail) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Revenues from External Customers and Long-Lived Assets [Line Items]	'	'
Property plant and equipment net	$54,606	$53,835
U.S. [Member]	'	'
Revenues from External Customers and Long-Lived Assets [Line Items]	'	'
Property plant and equipment net	39,858	39,554
Italy [Member]	'	'
Revenues from External Customers and Long-Lived Assets [Line Items]	'	'
Property plant and equipment net	7,813	7,617
U.K. [Member]	'	'
Revenues from External Customers and Long-Lived Assets [Line Items]	'	'
Property plant and equipment net	1,871	1,402
Brazil [Member]	'	'
Revenues from External Customers and Long-Lived Assets [Line Items]	'	'
Property plant and equipment net	3,210	3,421
Others [Member]	'	'
Revenues from External Customers and Long-Lived Assets [Line Items]	'	'
Property plant and equipment net	$1,854	$1,841

Income_Taxes_Schedule_of_Provi

Income Taxes - Schedule of Provision for (Benefit from) Income Taxes on Continuing Operations (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
U.S.	'	'	'
Current	$2,914	$17,897	$25,148
Deferred	5,716	1,788	-12,657
Total U.S	8,630	19,685	12,491
Non-U.S.	'	'	'
Current	2,355	4,609	2,735
Deferred	-869	844	-1,061
Total Non U.S	1,486	5,453	1,674
Income tax expense/effective rate	$10,116	$25,138	$14,165

Income_Taxes_Schedule_of_Tax_E

Income Taxes - Schedule of Tax Effects of Significant Temporary Differences Comprising Deferred Tax Assets and Liabilities (Detail) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Income Tax Disclosure [Abstract]	'	'
Intangible assets and goodwill	$4,978	$5,346
Inventories and related reserves	14,678	14,020
Deferred revenue and cost of sales	9,669	11,682
Other accruals and reserves	3,200	3,868
Accrued compensation	3,880	3,817
Allowance for doubtful accounts	4,429	3,718
Accrued interest	17,775	18,229
Net operating loss carryforwards	34,215	27,231
Other, net	621	539
Total	93,445	88,450
Valuation allowance	-31,472	-26,361
Deferred tax asset	61,973	62,089
Withholding taxes	-13,132	-11,456
Property, plant and equipment	-9,690	-9,758
Deferred tax liability	-22,822	-21,214
Net deferred tax assets	$39,151	$40,875

Income_Taxes_Additional_Inform

Income Taxes - Additional Information (Detail) (USD $)	6 Months Ended	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010
Components Of Income Tax Expense Benefit [Line Items]	'	'	'	'	'
Valuation allowance	$31,472,000	$31,472,000	$26,361,000	'	'
Net increase in valuation allowance	'	5,100,000	'	'	'
Operating loss carry forwards, state, net of tax	22,800,000	22,800,000	'	'	'
Operating loss carry forwards, foreign, net of tax	121,700,000	121,700,000	'	'	'
Impairment of goodwill	19,193,000	19,193,000	'	'	'
Income tax expense	'	10,116,000	25,138,000	14,165,000	'
Income tax effective rate	'	-211.10%	35.80%	-690.00%	'
Gross unrecognized tax benefit	700,000	700,000	1,200,000	'	'
Accrued interest and penalties related to unrecognized tax benefits	500,000	500,000	800,000	'	'
Recognized tax benefit	'	300,000	'	'	'
Unremitted foreign earnings	345,200,000	345,200,000	292,000,000	'	'
Total cash and cash equivalents	54,200,000	54,200,000	'	'	'
Cash and cash equivalents	30,486,000	30,486,000	31,055,000	33,207,000	13,561,000
U.S. Subsidiary [Member]	'	'	'	'	'
Components Of Income Tax Expense Benefit [Line Items]	'	'	'	'	'
Unremitted foreign earnings	354,800,000	354,800,000	'	'	'
Senior Secured Credit Agreement [Member]	'	'	'	'	'
Components Of Income Tax Expense Benefit [Line Items]	'	'	'	'	'
Restricted cash and cash equivalents	23,700,000	23,700,000	'	'	'
Non-U.S. Subsidiaries [Member]	'	'	'	'	'
Components Of Income Tax Expense Benefit [Line Items]	'	'	'	'	'
Cash and cash equivalents	$30,500,000	$30,500,000	'	'	'

Income_Taxes_Schedule_of_Effec

Income Taxes - Schedule of Effective Income Tax Rate Reconciliation for Continuing Operations (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Income Tax Disclosure [Abstract]	'	'	'
Statutory U.S. federal income tax rate	35.00%	35.00%	35.00%
State taxes, net	-57.30%	2.40%	-92.40%
Foreign rate differential	13.10%	-4.40%	-77.20%
Valuation allowance-foreign losses	-81.70%	8.80%	-237.80%
SRL intangible	47.80%	-3.20%	117.90%
Goodwill impairment	-134.70%	'	'
Domestic manufacturing deduction	4.90%	-2.40%	82.90%
Withholding taxes	-35.00%	2.40%	-81.60%
Settlement of U.S. Government resolutions	'	-1.80%	-463.70%
Other items, net	-3.20%	-1.00%	26.90%
Income tax expense/effective rate	-211.10%	35.80%	-690.00%
Statutory U.S. federal income tax rate	($1,677)	$24,565	($719)
State taxes, net	2,744	1,708	1,896
Foreign rate differential	-626	-3,115	1,585
Valuation allowance-foreign losses	3,913	6,183	4,882
SRL intangible	-2,288	-2,214	-2,421
Goodwill impairment	6,452	'	'
Domestic manufacturing deduction	-233	-1,694	-1,703
Withholding taxes	1,679	1,679	1,676
Settlement of U.S. Government resolutions	'	-1,260	9,520
Other items, net	152	-714	-551
Income tax expense/effective rate	$10,116	$25,138	$14,165

Income_Taxes_Schedule_of_Gross

Income Taxes - Schedule of Gross Unrecognized Tax Benefits (Excluding Interest and Penalties) (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Income Tax Disclosure [Abstract]	'	'
Beginning Balance	$1,189	$610
Additions for current year tax positions	183	793
Decreases for prior year tax positions	-12	-106
Settlements of prior year tax positions	-560	'
Expiration of statutes	-77	-108
Ending Balance	$723	$1,189

Related_parties_Additional_inf

Related parties - Additional information (Detail) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2011
Commitment Contingency And Related Party Transactions [Abstract]	'
Sales	$0.50

Sale_of_Breg_and_Disposition_o2

Sale of Breg and Disposition of Sports Medicine SBU - Additional Information (Detail) (USD $)	12 Months Ended			0 Months Ended	12 Months Ended
	Dec. 31, 2012	Dec. 31, 2012	Dec. 31, 2011	24-May-12	Dec. 31, 2013	Dec. 31, 2012
	Breg [Member]	Sports Medicine [Member]	Sports Medicine [Member]	Orthofix Inc [Member]	Orthofix Inc [Member]	Orthofix Inc [Member]
				Breg [Member]	Breg [Member]	Breg [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]	'	'	'	'	'	'
Proceeds from sale of outstanding shares of Breg	'	'	'	$157,500,000	'	'
Prepayment of outstanding company indebtedness	'	'	'	145,000,000	'	'
Fair value of liability	'	'	'	'	'	2,000,000
Period of indemnification (in years)	'	'	'	'	'3 years	'
Obligations under guarantee	2,000,000	'	'	'	900,000	1,600,000
Net sales	'	44,000,000	108,900,000	'	'	'
Operating income (loss)	'	$2,900,000	$1,200,000	'	'	'

Sale_of_Breg_and_Disposition_o3

Sale of Breg and Disposition of Sports Medicine SBU - Schedule of Information Related to Sale of Breg (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2012
Less:	'
Gain on sale of Breg, net of taxes	$1,345
Breg [Member]	'
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]	'
Cash proceeds	157,500
Less:	'
Working Capital	-7,093
Transaction related expenses	-4,276
Fair value of indemnification	-2,000
Tangible assets	-8,309
Intangible assets	-28,164
Goodwill	-106,200
Gain on sale of Breg	1,458
Income tax expense	-113
Gain on sale of Breg, net of taxes	$1,345

Contingencies_Additional_Infor

Contingencies - Additional Information (Detail) (USD $)	0 Months Ended			12 Months Ended				12 Months Ended	1 Months Ended
	Oct. 29, 2012	Jun. 06, 2012	24-May-12	Dec. 31, 2013	Dec. 31, 2012	Jul. 31, 2012	Dec. 31, 2011	Dec. 31, 2013	Jul. 31, 2012
								Litigation related to Promeca [Member]	Litigation Related to Breg [Member]
Commitment And Contingencies [Line Items]	'	'	'	'	'	'	'	'	'
Imputed Interest settlement against the charge	'	'	'	'	'	'	'	$5,200,000	'
Amount of fine	7,800,000	'	'	'	'	'	'	2,200,000	'
Deferred prosecution agreement term	'	'	'	'3 years	'	'	'	'	'
Amount approved to be paid under the agreement	'	34,200,000	'	'	'	'	'	'	'
Interest rate on settlement amount approved to be paid under the agreement (as a percent)	'	'	'	3.00%	'	'	'	'	'
Settlement agreement description	'	'	'	'The Company agreed to pay $34.2 million (plus interest at a rate of 3% from May 5, 2011 through the day before payment was made)	'	'	'	'	'
Mandatory special assessment	400	'	'	'	'	'	'	'	'
Amount paid to settlement of claims	32,000,000	'	'	'	'	'	'	'	'
Amount used from escrow fund through acquisition of Blackstone for legal settlement	32,000,000	'	'	'	'	'	'	'	'
Charges accrued in connection with litigation	'	'	4,200,000	'	'	'	'	'	'
Judgments and settlement costs	'	'	'	6,700,000	6,800,000	'	1,800,000	'	'
Compensatory damages to plaintiff	'	'	'	'	'	'	'	'	2,100,000
Exemplary damages	'	'	'	'	'	'	'	'	7,000,000
Discontinued operations for compensatory damages and exemplary damages	'	'	'	'	'	$4,200,000	'	'	'

Recovered_Sheet6

Pensions and Deferred Compensation - Additional Information (Detail) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Orthofix Inc 401(k) Plan [Member]	'	'	'
Defined Benefit Plans and Other Postretirement Benefit Plans [Line Items]	'	'	'
Employee contribution limit per calendar year (as a percent of compensation)	15.00%	'	'
Employer match of employee contributions of first level of eligible compensation (as a percent)	100.00%	'	'
Percentage of eligible compensation, matched by employer, level one	2.00%	'	'
Employer match of employee contributions of second level of eligible compensation (as a percent)	50.00%	'	'
Percentage of eligible compensation matched by employer, level two	4.00%	'	'
401 (k) Plans [Member]	'	'	'
Defined Benefit Plans and Other Postretirement Benefit Plans [Line Items]	'	'	'
Expenses incurred for contribution plans	$2.40	$2.50	$2.50
Defined Contribution pension plans for other International employees [Member]	'	'	'
Defined Benefit Plans and Other Postretirement Benefit Plans [Line Items]	'	'	'
Expenses incurred for contribution plans	0.7	0.7	0.8
Deferred Compensation Plan [Member]	'	'	'
Defined Benefit Plans and Other Postretirement Benefit Plans [Line Items]	'	'	'
Annual deferred compensation provision for leaving indemnity, as a percentage of total commissions earned	3.50%	'	'
Expense for deferred compensation	0.3	0.4	0.1
Deferred compensation payments	0.1	0.8	'
Amount of deferred compensation payable	$2.50	$2.30	'

Recovered_Sheet7

Share-based Compensation plans - Additional Information (Detail) (USD $)

12 Months Ended

12 Months Ended

12 Months Ended

12 Months Ended

In Millions, except Share data, unless otherwise specified

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Jun. 29, 2004

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

2004 LTIP Plan [Member]

2004 LTIP Plan [Member]

2004 LTIP Plan [Member]

2004 LTIP Plan [Member]

2004 LTIP Plan [Member]

2004 LTIP Plan [Member]

Stock Purchase Plan [Member]

Stock Purchase Plan [Member]

Stock Purchase Plan [Member]

Stock Purchase Plan [Member]

Stock Purchase Plan [Member]

Staff Share Option Plan [Member]

Staff Share Option Plan [Member]

Restricted Stock [Member]

Restricted Stock [Member]

Employees [Member]

Non-Employees Director [Member]

Minimum [Member]

Maximum [Member]

North America, South America and Asia [Member]

Minimum [Member]

Maximum [Member]

Maximum [Member]

2004 LTIP Plan [Member]

Non-Employees Director [Member]

Non-Employees Director [Member]

Customers and Distributors Based in Europe [Member]

Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Amount of shares reserved for issuance

'

'

'

1,600,000

3,100,000

'

'

'

'

1,850,000

'

'

'

'

'

'

'

'

Options outstanding

1,924,179

1,945,955

'

515,917

'

'

'

'

'

'

'

'

'

'

15,000

1,243,262

'

'

Options exercisable

1,367,269

'

'

22,668

'

'

'

'

'

'

'

'

'

'

15,000

1,179,601

'

'

Restricted stock outstanding

286,704

160,831

'

279,039

'

'

'

'

'

'

'

'

'

'

'

7,665

'

'

Award vesting period

'

'

'

'

'

'3 years

'

'3 years

'5 years

'

'

'

'

'

'5 years

'

'

'

Number of shares approved for annual grant

'

'

'

'

'

'

5,000

'

'

'

'

'

'

'

'

'

'

'

Award Contractual term

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'10 years

'10 years

'

'

Full value award limit

'

'

'

100,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Percentage of compensation eligible employees to be deducted for purchase of common stock

'

'

'

'

'

'

'

'

'

'

25.00%

1.00%

25.00%

15.00%

'

'

'

'

Purchase price of shares equivalent to fair market value

85.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Shares issued under stock purchase plan

1,437,519

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Unamortized compensation expense

$2.80

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$6.70

'

Weighted average remaining contractual life of exercisable options (in years)

'2 years 10 months 21 days

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Total intrinsic value of options exercised

0.4

7.2

4.2

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Closing stock price

$22.82

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Aggregate intrinsic value of options outstanding

0.5

11.2

10.8

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Aggregate intrinsic value of options exercisable

$0.20

$9.80

$8.40

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Non-vested shares

269,791

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

269,791

149,500

Recovered_Sheet8

Share-based Compensation Plans - Schedule of Share-Based Compensation by Line Item in Consolidated Statements of Operations (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'
Allocated share based compensation expense	$6,267	$6,303	$6,648
Cost of sales [Member]	'	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'
Allocated share based compensation expense	104	592	153
Sales and marketing [Member]	'	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'
Allocated share based compensation expense	1,444	1,550	2,031
General and administrative [Member]	'	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'
Allocated share based compensation expense	4,483	4,023	4,322
Research and development [Member]	'	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'
Allocated share based compensation expense	$236	$138	$142

Sharebased_Compensation_Plans_1

Share-based Compensation Plans - Schedule of Share-based Payment Award, Valuation Assumptions (Detail) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'
Expected volatility	32.10%	50.90%	49.60%
Expected volatility	50.80%	51.80%	49.90%
Expected term	'5 years	'4 years 6 months	'4 years 6 months 29 days
Dividend rate	'	'	'
Weighted average fair value of options granted during the year	$10.83	$16.99	$14.21
Minimum [Member]	'	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'
Risk free interest rate	0.58%	0.76%	0.90%
Maximum [Member]	'	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'
Risk free interest rate	1.52%	0.84%	2.26%

Sharebased_Compensation_Plans_2

Share-based Compensation Plans - Schedule of Stock Option Activity (Detail) (USD $)	12 Months Ended
	Dec. 31, 2013
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]	'
Outstanding at the beginning of the period (in shares)	1,945,955
Granted	466,250
Exercised	-79,949
Forfeited	-408,077
Outstanding at the end of the period (in shares)	1,924,179
Vested and expected to vest	1,839,383
Options exercisable (in shares)	1,367,269
Outstanding at the beginning of the period (in dollars per share)	$34.50
Granted	$28.51
Exercised	$23.25
Forfeited	$36.33
Outstanding at the end of the period (in dollars per share)	$33.12
Vested and expected to vest	$33.50
Options exercisable	$34.35
Options outstanding, weighted average remaining contractual term	'4 years 4 months 28 days
Options vested and expected, weighted average remaining contractual term	'4 years 2 months 1 day
Options exercisable, weighted average remaining contractual term	'2 years 10 months 21 days

Sharebased_Compensation_Plans_3

Share-based Compensation Plans - Schedule of Stock Options Outstanding and Exercisable by Price Range (Detail) (USD $)	12 Months Ended
	Dec. 31, 2013
$10.42 - $21.78 [Member]	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'
Exercise price, low end of range (in dollars per share)	$10.42
Exercise price, high end of range (in dollars per share)	$21.78
Number outstanding (in shares)	232,250
Weighted Average Remaining Contractual Life of options outstanding (in years)	'9 years 3 months 22 days
Weighted Average Exercise Price of options outstanding (in dollars per share)	$20.79
Number Exercisable (in shares)	16,000
Weighted Average Exercise Price of options exercisable (in dollars per share)	$13.31
$22.75 - $25.05 [Member]	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'
Exercise price, low end of range (in dollars per share)	$22.75
Exercise price, high end of range (in dollars per share)	$25.05
Number outstanding (in shares)	326,166
Weighted Average Remaining Contractual Life of options outstanding (in years)	'4 years 1 month 6 days
Weighted Average Exercise Price of options outstanding (in dollars per share)	$24.73
Number Exercisable (in shares)	306,166
Weighted Average Exercise Price of options exercisable (in dollars per share)	$24.84
$26.79 - $28.95 [Member]	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'
Exercise price, low end of range (in dollars per share)	$26.79
Exercise price, high end of range (in dollars per share)	$28.95
Number outstanding (in shares)	230,000
Weighted Average Remaining Contractual Life of options outstanding (in years)	'4 years 9 months 15 days
Weighted Average Exercise Price of options outstanding (in dollars per share)	$28.45
Number Exercisable (in shares)	170,000
Weighted Average Exercise Price of options exercisable (in dollars per share)	$28.65
$29.23 - $37.36 [Member]	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'
Exercise price, low end of range (in dollars per share)	$29.23
Exercise price, high end of range (in dollars per share)	$37.36
Number outstanding (in shares)	225,168
Weighted Average Remaining Contractual Life of options outstanding (in years)	'5 years 1 month 6 days
Weighted Average Exercise Price of options outstanding (in dollars per share)	$33.14
Number Exercisable (in shares)	169,839
Weighted Average Exercise Price of options exercisable (in dollars per share)	$32.41
$37.76 - $38.11 [Member]	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'
Exercise price, low end of range (in dollars per share)	$37.76
Exercise price, high end of range (in dollars per share)	$38.11
Number outstanding (in shares)	230,975
Weighted Average Remaining Contractual Life of options outstanding (in years)	'1 year 8 months 9 days
Weighted Average Exercise Price of options outstanding (in dollars per share)	$37.99
Number Exercisable (in shares)	230,975
Weighted Average Exercise Price of options exercisable (in dollars per share)	$37.99
$38.40 - $40.27 [Member]	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'
Exercise price, low end of range (in dollars per share)	$38.40
Exercise price, high end of range (in dollars per share)	$40.27
Number outstanding (in shares)	351,354
Weighted Average Remaining Contractual Life of options outstanding (in years)	'3 years 2 months 1 day
Weighted Average Exercise Price of options outstanding (in dollars per share)	$39.76
Number Exercisable (in shares)	174,355
Weighted Average Exercise Price of options exercisable (in dollars per share)	$39.77
$41.33 - $43.04 [Member]	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'
Exercise price, low end of range (in dollars per share)	$41.33
Exercise price, high end of range (in dollars per share)	$43.04
Number outstanding (in shares)	178,633
Weighted Average Remaining Contractual Life of options outstanding (in years)	'2 years 10 months 2 days
Weighted Average Exercise Price of options outstanding (in dollars per share)	$41.66
Number Exercisable (in shares)	150,301
Weighted Average Exercise Price of options exercisable (in dollars per share)	$41.72
$44.87 - $45.84 [Member]	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'
Exercise price, low end of range (in dollars per share)	$44.87
Exercise price, high end of range (in dollars per share)	$45.84
Number outstanding (in shares)	140,133
Weighted Average Remaining Contractual Life of options outstanding (in years)	'3 years 18 days
Weighted Average Exercise Price of options outstanding (in dollars per share)	$45.02
Number Exercisable (in shares)	140,133
Weighted Average Exercise Price of options exercisable (in dollars per share)	$45.02
$50.50 - $50.50 [Member]	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'
Exercise price, low end of range (in dollars per share)	$50.50
Exercise price, high end of range (in dollars per share)	$50.50
Number outstanding (in shares)	2,000
Weighted Average Remaining Contractual Life of options outstanding (in years)	'3 years 4 days
Weighted Average Exercise Price of options outstanding (in dollars per share)	$50.50
Number Exercisable (in shares)	2,000
Weighted Average Exercise Price of options exercisable (in dollars per share)	$50.50
$50.99 - $50.99 [Member]	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'
Exercise price, low end of range (in dollars per share)	$50.99
Exercise price, high end of range (in dollars per share)	$50.99
Number outstanding (in shares)	7,500
Weighted Average Remaining Contractual Life of options outstanding (in years)	'3 years 15 days
Weighted Average Exercise Price of options outstanding (in dollars per share)	$50.99
Number Exercisable (in shares)	7,500
Weighted Average Exercise Price of options exercisable (in dollars per share)	$50.99
$10.42 - $50.99 [Member]	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'
Exercise price, low end of range (in dollars per share)	$10.42
Exercise price, high end of range (in dollars per share)	$50.99
Number outstanding (in shares)	1,924,179
Weighted Average Remaining Contractual Life of options outstanding (in years)	'4 years 4 months 28 days
Weighted Average Exercise Price of options outstanding (in dollars per share)	$33.12
Number Exercisable (in shares)	1,367,269
Weighted Average Exercise Price of options exercisable (in dollars per share)	$34.35

Sharebased_Compensation_Plans_4

Share-based Compensation Plans - Schedule of Changes in Restricted Stock (Detail) (USD $)	12 Months Ended
	Dec. 31, 2013
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]	'
Non-vested at the beginning of the period (in shares)	160,831
Granted (in shares)	269,791
Vested (in shares)	-62,948
Cancelled (in shares)	-80,970
Non-vested at the end of the period (in shares)	286,704
Non-vested at the beginning of period (in dollars per share)	$38.34
Granted (in dollars per share)	$27.09
Vested (in dollars per share)	$36.58
Cancelled (in dollars per share)	$38.80
Non-vested at the end of period (in dollars per share)	$28.01

Earnings_Per_Share_Schedule_of

Earnings Per Share - Schedule of Reconciliation of Weighted Average Shares Used in Calculation of Basic and Diluted Earnings Per Share (Detail)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Earnings Per Share [Abstract]	'	'	'
Weighted average common shares-basic	18,697,228	18,977,263	18,219,343
Effect of diluted securities:	'	'	'
Unexercised stock options net of treasury share repurchase	'	413,150	'
Weighted average common shares-diluted	18,697,228	19,390,413	18,219,343

Earnings_Per_Share_Additional_

Earnings Per Share - Additional Information (Detail)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Dec. 31, 2011
	Options to Purchase Common Stock [Member]	Options to Purchase Common Stock [Member]	Common Stock Equivalents [Member]	Common Stock Equivalents [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'	'
Outstanding options not included in diluted earnings per share	1,186,259	789,650	101,672	344,168

Stock_Repurchase_Program_Addit

Stock Repurchase Program - Additional Information (Detail) (USD $)	0 Months Ended	12 Months Ended
In Millions, unless otherwise specified	8-May-13	Dec. 31, 2013
Equity [Abstract]	'	'
Share repurchase program, authorized amount	$50	'
Stock repurchased amount	'	$39.50

Quarterly_Financial_Data_Conde

Quarterly Financial Data - Condensed Consolidated Statement of Operations (Detail) (USD $)	3 Months Ended								12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Interim Reporting [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Net sales	$106,143	$92,738	$98,280	$103,373	$117,365	$107,857	$113,423	$108,936	$400,534	$447,581	$441,971
Cost of sales	32,517	23,920	20,246	25,617	24,944	24,384	27,547	21,378	102,300	98,253	95,527
Gross profit	73,626	68,818	78,034	77,756	92,421	83,473	85,876	87,558	298,234	349,328	346,444
Operating Expense	80,004	84,418	69,230	69,669	66,808	64,668	71,578	69,638	303,321	272,692	340,544
Operating (loss) income	6,378	-15,600	8,804	8,087	25,613	18,805	14,298	17,920	-5,087	76,636	5,900
Net income (loss) from continuing operations	-8,564	-18,084	4,130	7,610	16,009	10,574	9,870	8,597	-14,908	45,050	-16,218
Net (loss) income	-7,876	-19,822	-2,317	4,500	21,161	5,016	7,254	9,407	-25,515	42,838	-18,110
Basic:	'	'	'	'	'	'	'	'	'	'	'
Net income (loss) from continuing operations	($0.47)	($1)	$0.22	$0.39	$0.83	$0.55	$0.52	$0.46	($0.80)	$2.37	($0.89)
Net income (loss)	($0.43)	($1.10)	($0.12)	$0.23	$1.10	$0.26	$0.38	$0.50	($1.37)	$2.25	($0.99)
Diluted:	'	'	'	'	'	'	'	'	'	'	'
Net income (loss) from continuing operations	($0.47)	($1)	$0.21	$0.39	$0.81	$0.54	$0.51	$0.45	($0.80)	$2.32	($0.89)
Net income (loss)	($0.43)	($1.10)	($0.12)	$0.23	$1.07	$0.25	$0.37	$0.49	($1.37)	$2.21	($0.99)
As Previously or Currently Reported [Member]	'	'	'	'	'	'	'	'	'	'	'
Interim Reporting [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Net sales	'	'	'	100,254	112,035	114,752	119,492	116,041	'	462,320	470,121
Cost of sales	'	'	'	22,699	18,504	22,373	23,676	21,939	'	86,492	92,619
Gross profit	'	'	'	77,555	93,531	92,379	95,816	94,102	'	375,828	377,502
Operating Expense	'	'	'	73,531	69,050	70,846	75,251	71,671	'	286,818	346,193
Operating (loss) income	'	'	'	4,024	24,481	21,533	20,565	22,431	'	89,010	31,309
Net income (loss) from continuing operations	'	'	'	4,908	14,636	13,118	13,967	12,215	'	53,936	-1,740
Net (loss) income	'	'	'	2,116	20,514	7,560	11,205	12,016	'	51,295	'
Basic:	'	'	'	'	'	'	'	'	'	'	'
Net income (loss) from continuing operations	'	'	'	$0.25	$0.76	$0.69	$0.74	$0.65	'	$2.84	($0.10)
Net income (loss)	'	'	'	$0.11	$1.06	$0.40	$0.59	$0.64	'	$2.70	($0.06)
Diluted:	'	'	'	'	'	'	'	'	'	'	'
Net income (loss) from continuing operations	'	'	'	$0.25	$0.74	$0.67	$0.73	$0.64	'	$2.78	($0.10)
Net income (loss)	'	'	'	$0.11	$1.04	$0.39	$0.58	$0.63	'	$2.64	($0.06)
Restatement Adjustments [Member]	'	'	'	'	'	'	'	'	'	'	'
Interim Reporting [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Net sales	'	'	'	3,119	5,330	-6,895	-6,069	-7,105	'	-14,739	-28,150
Cost of sales	'	'	'	2,918	6,440	2,011	3,871	-561	'	11,761	2,908
Gross profit	'	'	'	201	-1,110	-8,906	-9,940	-6,544	'	-26,500	-31,058
Operating Expense	'	'	'	-3,862	-2,242	-6,178	-3,673	-2,033	'	-14,126	-5,649
Operating (loss) income	'	'	'	4,063	1,132	-2,728	-6,267	-4,511	'	-12,374	-25,409
Net income (loss) from continuing operations	'	'	'	2,702	1,373	-2,544	-4,097	-3,618	'	-8,886	-14,478
Net (loss) income	'	'	'	$2,384	$647	($2,544)	($3,951)	($2,609)	'	($8,457)	'
Basic:	'	'	'	'	'	'	'	'	'	'	'
Net income (loss) from continuing operations	'	'	'	$0.14	$0.07	($0.14)	($0.22)	($0.19)	'	($0.47)	($0.79)
Net income (loss)	'	'	'	$0.12	$0.04	($0.14)	($0.21)	($0.14)	'	($0.45)	($0.93)
Diluted:	'	'	'	'	'	'	'	'	'	'	'
Net income (loss) from continuing operations	'	'	'	$0.14	$0.07	($0.13)	($0.22)	($0.19)	'	($0.46)	($0.79)
Net income (loss)	'	'	'	$0.12	$0.03	($0.14)	($0.21)	($0.14)	'	($0.43)	($0.93)

Quarterly_Financial_Data_Conde1

Quarterly Financial Data - Condensed Consolidated Balance Sheets (Detail) (USD $)	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Dec. 31, 2011
In Thousands, unless otherwise specified
Interim Reporting [Line Items]	'	'	'	'	'	'	'	'	'
Total assets	$423,182	$430,058	$459,450	$475,758	$472,897	$539,566	$530,395	$694,106	'
Total liabilities	112,688	111,001	114,223	102,366	105,065	193,599	205,196	381,734	'
Total shareholders' equity	310,494	319,057	345,227	373,392	367,832	345,967	325,199	312,372	292,074
Total liabilities and shareholders' equity	423,182	430,058	459,450	475,758	472,897	539,566	530,395	694,106	'
As Previously or Currently Reported [Member]	'	'	'	'	'	'	'	'	'
Interim Reporting [Line Items]	'	'	'	'	'	'	'	'	'
Total assets	'	'	'	503,380	504,281	565,073	553,320	707,586	'
Total liabilities	'	'	'	101,212	105,183	187,463	199,104	369,178	'
Total shareholders' equity	'	'	'	402,168	399,098	377,610	354,216	338,408	'
Total liabilities and shareholders' equity	'	'	'	503,380	504,281	565,073	553,320	707,586	'
Restatement Adjustments [Member]	'	'	'	'	'	'	'	'	'
Interim Reporting [Line Items]	'	'	'	'	'	'	'	'	'
Total assets	'	'	'	-27,622	-31,384	-25,507	-22,925	-13,480	'
Total liabilities	'	'	'	1,154	-118	6,136	6,092	12,556	'
Total shareholders' equity	'	'	'	-28,776	-31,266	-31,643	-29,017	-26,036	'
Total liabilities and shareholders' equity	'	'	'	($27,622)	($31,384)	($25,507)	($22,925)	($13,480)	'

Schedule_1_Condensed_Financial

Schedule 1- Condensed Financial Information of Registrant Orthofix International N.V. - Condensed Balance Sheets (unaudited) (Detail) (USD $)	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Dec. 31, 2011	Dec. 31, 2010
In Thousands, unless otherwise specified
Current assets:	'	'	'	'	'	'	'	'	'	'
Cash and cash equivalents	$30,486	'	'	'	$31,055	'	'	'	$33,207	$13,561
Prepaid expenses and other current assets	25,906	'	'	'	34,079	'	'	'	'	'
Total current assets	280,244	'	'	'	310,583	'	'	'	'	'
Other long term assets	7,385	'	'	'	7,920	'	'	'	'	'
Total assets	423,182	430,058	459,450	475,758	472,897	539,566	530,395	694,106	'	'
Liabilities and shareholder's equity	'	'	'	'	'	'	'	'	'	'
Current liabilities	66,820	'	'	'	62,185	'	'	'	'	'
Shareholder's equity:	'	'	'	'	'	'	'	'	'	'
Common stock	1,810	'	'	'	1,934	'	'	'	'	'
Additional paid in capital	216,653	'	'	'	246,306	'	'	'	'	'
Accumulated earnings	89,332	'	'	'	114,847	'	'	'	'	'
Accumulated other comprehensive income	2,699	'	'	'	4,745	'	'	'	'	'
Total shareholders' equity	310,494	319,057	345,227	373,392	367,832	345,967	325,199	312,372	292,074	'
Total liabilities and shareholder's equity	423,182	430,058	459,450	475,758	472,897	539,566	530,395	694,106	'	'
Orthofix International N V [Member]	'	'	'	'	'	'	'	'	'	'
Current assets:	'	'	'	'	'	'	'	'	'	'
Cash and cash equivalents	1,426	'	'	'	7,392	'	'	'	19,433	2,882
Prepaid expenses and other current assets	670	'	'	'	534	'	'	'	'	'
Total current assets	2,096	'	'	'	7,926	'	'	'	'	'
Other long term assets	'	'	'	'	15	'	'	'	'	'
Investments in and amounts due from subsidiaries and affiliates	322,804	'	'	'	369,204	'	'	'	'	'
Total assets	324,900	'	'	'	377,145	'	'	'	'	'
Liabilities and shareholder's equity	'	'	'	'	'	'	'	'	'	'
Current liabilities	6,295	'	'	'	1,202	'	'	'	'	'
Long-term liabilities	8,111	'	'	'	8,111	'	'	'	'	'
Shareholder's equity:	'	'	'	'	'	'	'	'	'	'
Common stock	1,810	'	'	'	1,934	'	'	'	'	'
Additional paid in capital	216,653	'	'	'	246,306	'	'	'	'	'
Accumulated earnings	89,332	'	'	'	114,847	'	'	'	'	'
Accumulated other comprehensive income	2,699	'	'	'	4,745	'	'	'	'	'
Total shareholders' equity	310,494	'	'	'	367,832	'	'	'	'	'
Total liabilities and shareholder's equity	$324,900	'	'	'	$377,145	'	'	'	'	'

Schedule_1_Condensed_Financial1

Schedule 1 - Condensed Financial Information of Registrant Orthofix International NV - Condensed Statements of Operations (unaudited) (Detail) (USD $)	3 Months Ended								12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
(Expenses) income:	'	'	'	'	'	'	'	'	'	'	'
General and administrative	'	'	'	'	'	'	'	'	($65,147)	($53,391)	($64,481)
(Loss) income before income taxes	'	'	'	'	'	'	'	'	-4,792	70,188	-2,053
Income tax (expense) benefit	'	'	'	'	'	'	'	'	-10,116	-25,138	-14,165
Net (loss) income	-7,876	-19,822	-2,317	4,500	21,161	5,016	7,254	9,407	-25,515	42,838	-18,110
Orthofix International N V [Member]	'	'	'	'	'	'	'	'	'	'	'
(Expenses) income:	'	'	'	'	'	'	'	'	'	'	'
General and administrative	'	'	'	'	'	'	'	'	-16,641	-7,700	-11,134
Equity in earnings of investments in subsidiaries and affiliates	'	'	'	'	'	'	'	'	-9,197	50,317	-6,296
Other, net	'	'	'	'	'	'	'	'	323	24	7
(Loss) income before income taxes	'	'	'	'	'	'	'	'	-25,515	42,641	-17,423
Income tax (expense) benefit	'	'	'	'	'	'	'	'	'	197	-687
Net (loss) income	'	'	'	'	'	'	'	'	($25,515)	$42,838	($18,110)

Schedule_1_Condensed_Financial2

Schedule 1 - Condensed Financial Information of Registrant Orthofix International NV - Condensed Statement of Cash Flows (unaudited) (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Condensed Financial Statements, Captions [Line Items]	'	'	'
Net income (loss)	($25,515)	$42,838	($18,110)
Cash flows from investing activities:	'	'	'
Capital expenditures	-24,787	-27,994	-24,965
Cash flows from financing activities:	'	'	'
Net proceeds from issuance of common stock	3,450	25,586	20,113
Contributions to subsidiaries and affiliates	'	'	-517
Tax benefit on exercise of stock options	82	1,020	1,737
Cash and cash equivalents at the beginning of the year	31,055	33,207	13,561
Cash and cash equivalents at the end of the year	30,486	31,055	33,207
Orthofix International N V [Member]	'	'	'
Condensed Financial Statements, Captions [Line Items]	'	'	'
Net income (loss)	-25,515	42,838	-18,110
Equity in earnings of (loss) investments in subsidiaries and affiliates	9,197	-50,317	6,296
Cash used in provided by other operating activities	468	-6,811	3,429
Net cash used in operating activities	-15,850	-14,290	-8,385
Cash flows from investing activities:	'	'	'
Distributions and amounts received from subsidiaries	53,389	12,564	5,875
Capital expenditures	'	'	'
Net cash used in provided by investing activities	53,389	12,564	5,875
Cash flows from financing activities:	'	'	'
Net proceeds from issuance of common stock	3,450	25,586	20,113
Repurchase of treasury shares	-39,494	'	'
Contributions to subsidiaries and affiliates	-7,543	-36,921	-2,789
Tax benefit on exercise of stock options	82	1,020	1,737
Net cash provided by financing activities	-43,505	-10,315	19,061
Net increase (decrease) in cash and cash equivalents	-5,966	-12,041	16,551
Cash and cash equivalents at the beginning of the year	7,392	19,433	2,882
Cash and cash equivalents at the end of the year	$1,426	$7,392	$19,433

Schedule_1_Condensed_Financial3

Schedule 1 - Condensed Financial Information of Registrant Orthofix International NV - Additional information (Detail) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Condensed Financial Statements, Captions [Line Items]	'	'
Restricted net assets of subsidiary of the reporting entity	$192,000,000	$213,400,000
Cash dividends received from consolidated subsidiaries	0	0
Orthofix Inc [Member]	'	'
Condensed Financial Statements, Captions [Line Items]	'	'
Percent of restricted net assets of a Subsidiary to consolidated net assets of the company where condensed parent company financial statement are required	25.00%	'
Restricted net assets of subsidiary of the reporting entity	$192,000,000	$213,400,000

Schedule_2_Valuation_and_Quali

Schedule 2 - Valuation and Qualifying Accounts (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Allowance for doubtful accounts receivable [Member]	'	'	'
Valuation and Qualifying Accounts Disclosure [Line Items]	'	'	'
Balance at beginning of year	$13,543	$9,341	$6,542
Additions Charged to cost and expenses	6,003	10,387	12,879
Additions Charged (credited) to other accounts	'	-13	-501
Deductions/ Other	-7,577	-6,172	-9,579
Balance at end of year	11,969	13,543	9,341
Deferred tax valuation allowance [Member]	'	'	'
Valuation and Qualifying Accounts Disclosure [Line Items]	'	'	'
Balance at beginning of year	26,361	19,124	21,023
Additions Charged to cost and expenses	5,111	7,237	-1,899
Balance at end of year	$31,472	$26,361	$19,124